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Abstract 
Background: Alzheimer’s disease (AD) is a progressive neurodegenerative disease that is 
characterized by two neuropathological hallmarks: neurofibrillary tangles composed of 
hyperphosphorylated tau protein and extracellular plaques composed of amyloid-β peptides 
(Aβ). Recent GWAS have linked PICALM and BIN1 to AD risk, and several studies have 
implicated PICALM and BIN1 in Aβ production and clearance. However, so far their roles in 
modulating Aβ42 toxicity remain unclear. 
 
Aims: This study aimed 1.) to test whether the fly orthologues of PICALM and BIN1, lap and 
Amph, suppress Aβ42 toxicity and to elucidate the molecular mechanisms at work. 2.) to 
identify novel suppressors of Aβ42 toxicity by genetic screens. 
 
Results: 1.) I showed that over-expression of the Drosophila PICALM orthologue, lap, 
ameliorated Aβ42 toxicity in an adult onset AD model without affecting Aβ levels. I then 
performed a small-scale targeted genetic screen of endocytic-exocytic genes and identified 
Rab5 as a suppressor of Aβ42 toxicity. Aβ in flies led to the accumulation of pre-synaptic 
vesicular glutamate transporter (VGlut). Lap directly interacted with VGlut and reduced its 
accumulation back to control levels. Consistent with this, Aβ caused an increase in 
extracellular glutamate levels, while lap expression reduced the Aβ-induced increase in 
extracellular glutamate levels, suggesting lap might play a role in modulating glutamatergic 
transmission. Amph, the homologue of another AD risk factor, BIN1, modulated post-synaptic 
glutamate receptor (GluRII) localization. Amph localisation was disrupted upon Aβ expression 
and restored upon lap over-expression. 2.) The rough eye phenotype (REP) of Drosophila 
allows for high-throughput screening of enhancers and suppressors of therapeutic targets in 
neurodegenerative diseases. Using the REP, my collaborators and I performed a 
genome-wide genetic screen to identify novel modifiers of Aβ toxicity. The primary hits were 
further validated using negative geotaxis and lifespan assays. I found 4 gene-knockdown 
suppressors of Aβ42 toxicity. 3 of these suppressors did not reduce Aβ42 levels. 
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Conclusions: 1.) I propose a model where lap and Amph collaborate to modulate 
glutamatergic transmission and so affect disease development. 2.) I find Rab5, EndoA and 
Snap25 are potential gene-overexpression suppressors of Aβ42 toxicity, and CG15011, Larp, 
Pxn, and Sodh2 are potent gene-knockdown suppressors of Aβ42 toxicity. 
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1. Introduction 
1.1 Pathogenesis of Alzheimer’s disease 
In 1906, the first example of dementia was reported by Alois Alzheimer at the 37
th
 conference 
of south-west German psychiatrists in Tubingen. Subsequently, this disease was named after 
the lecturer and became known as Alzheimer’s disease (AD). AD is characterized by 
progressive memory loss, cognitive impairment and gradual neurodegeneration. In the 
severely impaired stage, AD patients show behavioral symptoms, major language dysfunction, 
difficulties in abstract reasoning, decision making, complete social dependence, and 
commonly die early (Graeber et al., 1997; Maurer et al., 1997). Through detailed examinations, 
Alzheimer described two histopathological characteristics of this disease: first, neuritic plaques 
(military foci), consistent with Redlich’s prior findings (1898); second, neurofibrillary tangles, 
which were first described by Alzheimer. These typical plaques and tangles are extensively 
distributed in the hippocampus, limbic cortex and neocortex of brains and result in progressive 
neuronal lesions. It is now clear that they are the respective results of extracellular deposition 
of amyloid protein and intracellular accumulation of tau proteins.  
 
After Alzheimer’s report on Auguste’s case, doctors subsequently diagnosed more AD cases 
that were significantly different from it. The majority of patients suffered from the disease after 
the age of 65. The predominant view now is that only 1% of AD cases are like Auguste’s, which 
is defined as presenile or familial AD (with an age of onset < 65 years). The vast majority of 
other cases are termed senile or sporadic AD (onset of > 65 years). Sporadic AD is the most 
common, irreversible, progressive type of dementia. It is estimated that only ~13% of people 
aged 65 years suffer from AD but ~45% after the age of 85 (Goedert and Spillantini, 2006; 
Hardy, 2006). 
 
With the development of biochemical and genetic techniques, the understanding of AD has 
steadily advanced. In the 1980s, the component of amyloid deposits, Aβ peptide, was first 
isolated and described by George Glenner (Glenner and Wong, 1984a, b). At the same time, 
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the subunit protein of neurofibrillary tangles, tau, was also identified (Goedert et al., 1989b; 
Goedert et al., 1988). Aβ and tau proteins are regarded as two diagnostic hallmarks of AD that 
induce cytotoxicity. Although both Aβ and tau induce neuronal toxicity, several specific neurons 
are more vulnerable to this toxicity. They are the cortical cholinergic and glutamatergic neurons 
(Bowen et al., 1976; Davies and Maloney, 1976; Perry et al., 1977; Whitehouse et al., 1982; 
Hsieh et al., 2006; Shankar et al., 2007; Snyder et al., 2005; Zhao et al., 2010). As cholinergic 
and glutamatergic transmission are important for memory formation in the cortex, this could 
explain why memory is severely impaired in AD cases (Bartus, 1979; Davis et al., 1978).  
 
Although AD research has been so fruitful since the first description of AD by Alois Alzheimer, 
its treatment is still not effective. The main reason is that we still lack sufficient knowledge on 
the disease aetiology, which emphasizes the necessity of elucidating the molecular 
mechanisms underlying AD pathogenesis and so facilitating the discovery of targets for 
pharmacological intervention. 
1.1.1 Amyloid hypothesis  
In the 1980s, Aβ peptide was first identified from amyloid deposits in brain tissue from AD 
patients (Glenner and Wong, 1984a, b). Based on these findings, an amyloid hypothesis by 
which the neurodegeneration in AD resulted from deposition of Aβ peptide was proposed 
(Hardy, 2006; Hardy and Selkoe, 2002; Selkoe and Podlisny, 2002; Singleton and Hardy, 
2016). This hypothesis was supported by the discovery of APP mutations in FAD patients in 
the following studies. 
 
In the 1990s, the advent of genetic technology has revolutionized AD research. The 
application of linkage analysis and positional cloning has allowed scientists to establish the 
relationships between genes and diseases. This uncovered a number of mutations linked to 
aggressive, early onset forms of familial AD. The first mutant gene in familial AD patients is the 
amyloid precursor protein (APP) gene on chromosome 21 (Goate et al., 1991). Given that APP 
processing give rise to production of Aβ, this finding provides a link between APP mutations, 
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amyloid plaques in brain tissue and AD pathogenesis. The first APP mutation was identified at 
the position 22 of the Aβ sequence in a Dutch family (Levy et al., 1990). This missense 
mutation in APP leads to a several-fold increase in the toxic Aβ species, and lead these 
patients to develop AD earlier than the age of 65 [early-onset AD (EAOD)]. Following the 
discovery of the first APP mutation, another 12 mutations have subsequently been identified, 
including Austrian, Iranian, French, German, London, Swedish and Florida mutations. These 
mutations affect APP processing in different behaviors. For instance, several mutations such 
as the Swedish mutation elevate production of longer Aβ species (Aβ42) (Citron et al., 1992; 
Saito et al., 2014), while others such as the Beyreuther/Iberian mutation increase the 
Aβ42/Aβ40 ratio (Guardia-Laguarta et al., 2010; Lichtenthaler et al., 1999). In addition to this, 
some mutations such as the Arctic mutation facilitate Aβ fibrillogenesis, while others such as 
the Dutch, Flemish and Italian mutations make Aβ resistant to proteolytic degradation 
(Nilsberth et al., 2001; Tsubuki et al., 2003). Until now, all of the known mutations are found at 
or near the α-, β-, γ-secretase cleavage sites or in the middle of the Aβ region and none of 
them are found outside this region. This evidence strongly supports the point that familial AD is 
a genetically inherited disease (Hardy, 2006; Hardy and Selkoe, 2002; Selkoe and Podlisny, 
2002; Singleton and Hardy, 2016). However, further investigations have revealed that such 
familial AD only accounts for 1~2 % of AD cases and that the most are instead sporadic. 
Sporadic AD also shows increased levels of Aβ, which is not ascribed to genetic mutations in 
the APP gene but the disturbance of Aβ clearance (Mawuenyega et al., 2010). 
 
Through research over the past decades, it is becoming increasingly clear how APP 
processing produces Aβ peptides. APP is processed along 2 pathways: the non- 
amyloidogenic and amyloidogenic pathways. Only the amyloidogenic pathway leads to 
production of Aβ. APP is a 695-770 amino acid long transmembrane protein (Koo, 2002) that 
functions in neurite outgrowth, axonal transport and apoptotic cell death (Baumkotter et al., 
2014; Choi et al., 2013; Cousins et al., 2009; Cousins et al., 2013; Deyts et al., 2016; Deyts et 
al., 2012; Hoe et al., 2009; Koo, 2002; Osterhout et al., 2015; Wang et al., 2009b). Knockout of 
APP causes impairment in synaptic function, learning and memory only in aged mice (Corrigan 
et al., 2012; Dawson et al., 1999; Hefter et al., 2016; Lee et al., 2010b; Li et al., 1996; Ring et 
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al., 2007; Seabrook et al., 1999; Steinbach et al., 1998; Zheng et al., 1995; Zou et al., 2016). 
APP is composed of a short intracellular C-terminal domain linked to a longer extracellular 
N-terminal domain by a membrane-spanning domain. Alternative cleavage of APP can 
generate a series of heterogeneous polypeptides (Kang et al., 1987). Several lines of evidence 
have revealed that neurons predominantly express the APP695 isoform (Hick et al., 2015; 
Wang et al., 2014). In the healthy brain, APP fragments are usually released from the cellular 
membrane through α-endoproteolytic cleavages and then enter the nucleus to regulate 
transcription (Cao and Sudhof, 2001; Kimberly et al., 2001). This constitutive scission is most 
frequently mediated by α-secretase and APP is cut at the residue 687 between amino acid 16 
and 17 of the Aβ region. This action enables the APP to secret the large, soluble ectodomain 
(APP-α) into the extracellular matrix and retain the 83-residue C-terminal fragments (CTF) 
(C83) on the cell surface (Sisodia, 1992). APP-α is neuroprotective and limits the activity of 
β-secretase (Kundu et al., 2016; Obregon et al., 2012). 
 
In AD patients, APP proteins are cleaved at residue 671 by β-secretase to create slightly 
truncated APP derivatives (APP-β) and membrane-maintained 99-residue CTFs (C99). APP-β 
is released into the extracellular space (Haass et al., 1992). A recent study confirms that this 
fragment can also trigger neuronal death through binding to death receptor 6 (DR6) and thus 
gives rise to neurodegeneration (Nikolaev et al., 2009). APP on the cell surface prefers 
non-amyloidogenic processing, whereas APP internalization triggers amyloidogenic 
processing. Both C83 and C99 are further cleaved by γ-secretase to release the APP 
intracellular domain (AICD). AICD is a transcription factor to repress WAVE1 transcription. In 
turn, downregulation of WAVE1 activity prevents the APP trafficking and Aβ generation (Ceglia 
et al., 2015). This γ-secretase-mediated cleavage of C83 also produces the nontoxic p3 
peptides (Seubert et al., 1992). C99 undergoes multiple γ-secretase-mediated cleavages. The 
first endopeptidase cleavage yields two products: Aβ49/50-residue AICD and Aβ48/49-residue 
AICD. Aβ49 is sequentially cleaved by γ-secretase through its carboxypeptidase activity to 
remove 6 or 9 C-terminal amino acids to produce Aβ43 or Aβ40 respectively. Aβ48 is also clipped 
by γ-secretase to yield 42 amino acid peptides designated Aβ42 (Fernandez et al., 2014; 
Okochi et al., 2013). APP proteolysis occurs at the trans-Golgi network, endoplasmic reticulum 
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(ER) and early endosome where the β-secretase and γ-secretase are localized (Busciglio et 
al., 1993; Kinoshita et al., 2003; Koo and Squazzo, 1994; Wertkin et al., 1993; Xu et al., 
1995a). The localization of APP is vital for production of different Aβ peptides. For instance, 
Aβ42 is produced in the ER, while Aβ40 is produced in the trans-Golgi network (Cook et al., 
1997; Hartmann et al., 1997; Lee et al., 1998; Skovronsky et al., 1998; Wild-Bode et al., 1997).  
 
Longer Aβ species (e.g. Aβ42 and Aβ43) are prone to self-aggregation to form dimers, oligomers, 
fibrils and plaques (Kim et al., 2007a). The formation of amyloid plaques starts from Aβ 
oligomerization. Then Aβ oligomers convert to nucleus (Lee et al., 2011). Amyloid nucleation 
requires three or four amyloid molecules, which is a stochastic and rare event (Nelson et al., 
2005). Therefore, amyloid nucleation is a slow phase. Once the nucleus is formed or seeded, 
the nucleus grows fast to form fibrils (Eisenberg and Jucker, 2012). Aβ fibrillogenesis is 
stabilized by cross-seeding of Aβ fibrils and formation of cross-β sheets (Kajava et al., 2010). 
This process promotes maturation of amyloid plaques (Knowles et al., 2014). The prevalent 
view suggests that amyloid plaques give rise to neurotoxicity because they are found to be 
deposited in the brains of AD patients. However, this opinion is disputed as amyloid loads do 
not match AD progression. Growing evidence has shown that soluble Aβ42 oligomers are the 
main toxic species whose levels correlate best with disease status (Walsh and Selkoe, 2007; 
Wang et al., 1999).  
 
Recently, APP has been found to undergo a new form of proteolytic processing. This included 
the η-secretase pathway, where η-secretase snips at the 540 residue of APP and produces 
APP-η. The remaining CTFs are subsequently clipped by α- or β-secretases to release Aη-α or 
Aη-β respectively. Aη-α is the main neuronal toxic species (Willem et al., 2015). A potential 
η-secretase is matrix metalloproteinase 5 (MMP5) (Barganer et al., 2015) (Figure 1.1).  
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Figure 1.1 APP proteolysis. The non-amyloidogenic pathway includes APP cleavages by α- and γ-secretases and thus 
the generation of the sAPPα, C-terminal fragments (CTF83/AICD) and p3. α-secretases include ADAM9, ADAM10 
and ADAM17. γ-secretases contain presenilin 1 and 2. The amyloid-β (Aβ) peptides are derived from an 
amyloidogenic pathway, including Aβ40, Aβ42, Aβ43. APP undergoes proteolytic processing by β- and γ-secretases and 
generates the sAPPβ, C-terminal fragments (CTF99/AICD) and Aβ peptides. sAPPβ activates DR6. Aβ peptides 
oligomerise and fibrillise to from amyloid plaques. A typical β-secretase is BACE1. APP is also cleaved by 
η-secretases to release sAPPη (e.g. ADAM5). The remaining CTFs are subsequently cleaved by α- or β-secretases 
resulting in Aη-α or Aη-β respectively. Aη-α causes toxicity. 
1.1.2 Presenilins in amyloidogenic pathway 
As stated earlier, the amyloid hypothesis asserts that production of Aβ in the brain is the 
primary influence driving AD pathogenesis. Therefore, the activation of the amyloidogenic 
pathway might facilitate production of Aβ and affect AD progression. The amyloidogenic 
pathway is mediated by γ-secretase which has several subunits. However, only presenilins are 
found to have mutations linked to familial AD. Mutations in presenilins were first discovered in 
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familial AD (early onset AD, EOAD) patients by genetic linkage analysis and positional cloning. 
After an initial finding, mutations in another highly homologous gene were identified in EOAD. 
These two genes are named presenilin 1 (PS1) and presenilin 2 (PS2) respectively 
(Levy-Lahad et al., 1995a; Levy-Lahad et al., 1995b; Sherrington et al., 1995). Following the 
discovery of the first PSEN mutation, many missense mutations in PSEN are observed in 
EOAD cases. Most of them are speculated to lead to an increase in Aβ42 production (Bentahir 
et al., 2006; Houlden et al., 2001; Kim et al., 2012; Kretner et al., 2011; Piccini et al., 2007; 
Uttner et al., 2010).  
 
Presenilins harbor six to eight transmembrane (TM) segments. In vivo, the active PS protein is 
hard to detect. Usually its N-terminal and C-terminal fragments exist separately because when 
these two fragments are assembled into active PS (Capell et al., 1998; Nishimura et al., 1999; 
Thinakaran et al., 1997; Thinakaran et al., 1998), this PS form is unstable and rapidly 
degraded by proteases (Kim et al., 1997). The missense mutations cause PS to escape the 
proteolytic system (Jacobsen et al., 1999; Steiner et al., 1999a; Steiner et al., 1999b). 
Consequently, the mutated PS cannot be degraded, so its endoproteolytic activity is 
maintained.  
 
Next, an open question is how the PS biological function correlates with the loss-of-function 
toxicity in AD. Recent evidence demonstrates that several missense mutations actually inhibit 
PS activity. For instance, exon 9 in PSEN encodes the TM6 and TM7 domains that contain two 
unusual intramembranous aspartates and form the active regions of PS. Missense mutation in 
exon 9 causes loss of endoproteolytic activity and a reduction in Aβ42 level (Kim et al., 2005; 
Kim et al., 2001; Wolfe et al., 1999a). However, this mutation also leads to an incomplete 
digestion of long Aβ peptides and therefore enhances the Aβ42/Aβ40 ratio (Crook et al., 1998; 
Ishii et al., 1997; Wolfe et al., 1999b).  
 
PS serves as an aspartyl protease and its proteolytic function stimulates APP cleavage. PS1 
mutant mice show normal levels of APP substrates processed by α-and β-secretase but 
accumulate the γ-secretase-mediated APP substrates C83 and C99, suggesting that PS 
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serves as a subunit of γ-secretase (De Strooper et al., 1998). Moreover, PS 
immunoprecipitates with full-length APP protein. PS and APP colocalize to the same 
subcellular region suggesting that PS directly interacts with APP (Xia et al., 2000). However, 
the conflicting evidence argues that PS mediates Aβ42 production through direct cleavage. 
This controversy has arisen from the fact that PS is distributed in the ER and early Golgi 
apparatus (Annaert et al., 1999; De Strooper et al., 1997; Kovacs et al., 1996; Walter et al., 
1996) in contrast that the activity of γ-secretase is restricted to the late Golgi apparatus 
(Hartmann et al., 1997; Koo and Squazzo, 1994). The increasing findings suggest other 
‘nonproteolytic’ functions of PS. Therefore, it is not surprising that PS is widely distributed in 
subcellular components although it is a γ-secretase (Esselens et al., 2004; Nelson et al., 2007; 
Tu et al., 2006). 
1.1.3 Tauopathies 
According to the amyloid hypothesis, formation of neurofibrillary tangles (NFTs) is caused by 
an imbalance between Aβ production and Aβ clearance. Neurofibrillary tangles are composed 
of tau proteins. Compared with amyloid plaques, NFTs correlate well with AD. However, tau 
mutations are never found in AD patients, but in other disorders, such as frontotemporal 
dementia and parkinsonism linked to chromosome 17 (FTDP-17), which are monogenic 
disorders caused by a dominant mutation (Hong et al., 1998). This suggests that tau itself is 
able to cause neurodegeneration.  
 
Tau protein is encoded by the microtubule-associated proteins (MAPT) gene and enriched in 
both CNS and PNS neurons (Binder et al., 1985; Cleveland et al., 1977a, b; Couchie et al., 
1992; LoPresti et al., 1995; Shin et al., 1991a; Shin et al., 1991b). The tau gene is composed 
of 16 exons that have been identified on chromosome 17. Of these, 11 tau exons are 
expressed in the CNS giving six isoforms through alternative mRNA splicing (Andreadis et al., 
1992; Goedert et al., 1988; Neve et al., 1986). The differences between these six isoforms are 
dependent on the presence or absence of carboxy-terminal repeat domain (R2 encoded by 
exon (E) 10) or near-amino-terminal inserts (1N and 2N encoded by E2 and E3 respectively) 
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(Figure 1.2). Tau containing R2 is termed 4R-tau, otherwise it is called 3R-tau (Goedert et al., 
1989a; Goedert et al., 1989b). In a healthy human brain, the ratio of the 3R-tau to the 4R-tau 
isoform is ~1. Tau has a biological function in healthy individuals (Cleveland et al., 1977a, b; 
Weingarten et al., 1975). Tau binds to microtubules (MTs), which is mediated by the MT 
binding sites and regions flanking MT binding sites (Gustke et al., 1994). The MT-binding 
domains comprise a positively charged proline-rich region, while other domains form a 
negatively charged acidic amino-terminal region known as the projection domain (Selkoe, 
2002; Tanzi and Bertram, 2005). Under normal physiological conditions, the MT-binding 
domains are tightly attached to β-tubulin at the inner surface of the MTs, while the projection 
domain binds to the outer surface of the MTs, and so the projection domain is repulsed away 
from the MT-surface (Ballatore et al., 2007). As 4R-tau possesses a unique sequence flanking 
R2 repeats with twice the binding affinity compared with other MT binding regions, 4R-tau 
shows stronger MT binding affinity than 3R-tau (Butner and Kirschner, 1991; Goedert and 
Jakes, 1990). 
 
Figure 1.2 Schematic representation of the expression and splicing of the human tau gene in adult brain. The human 
tau gene consists of 16 exons (E). Among these, only E1, E2, E3, E4, E5, E7, E9, E10, E11, E12 and E13 are 
expressed in adult brain. Notably, E1, E4, E5, E7, E9, E11, E12 and E13 are constitutively spliced, whereas E2 (green), 
E3 (yellow) and E10 (red) are alternatively spliced to give rise to the six tau isoforms. The tau isoforms differ according 
to the presence of 0, 1 or 2 N (yielding 0N, 1N and 2N tau isoforms, respectively) and the presence of repeat R2 
(yielding 3R or 4R tau isoforms, respectively). In the adult human brain, levels of the 3R and 4R isoforms are roughly 
equal, but the expression of 0N, 1N and 2N isoforms are quiet different: the 0N, 1N and 2N tau isoforms 
comprise ~37%, ~54% and ~9% of total tau, respectively. This diagram is adapted from (Wang and Mandelkow, 2016) 
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There are about 79 potential phosphorylation sites that are mostly clustered in the MT binding 
neighbor regions (Billingsley and Kincaid, 1997; Buee et al., 2000). These sites are usually 
hyperphosphorylated at the embryonic stage (Bramblett et al., 1993; Goedert et al., 1993; 
Kanemaru et al., 1992; Watanabe et al., 1993), but their phosphorylation levels decrease with 
age and only half of sites are phosphorylated in the adult healthy brain (Mawal-Dewan et al., 
1994). However, in AD, tau is hyperphosphorylated. Hyperphosphorylated tau detaches from 
MT (Baumann et al., 1993; Bramblett et al., 1993; Drechsel et al., 1992; Yoshida and Ihara, 
1993). This detachment possibly accounts for the compromise of MT-mediated axonal 
transport (Vossel et al., 2010). In addition to the loss-of-function toxicity, tau 
hyperphosphorylation also leads to gain-of-function toxicity of tau. Tau hyperphosphorylation 
accelerates tau assembly and neurofibrillary tangles (NFTs) formation (Alonso et al., 2001; 
Braak et al., 1994). The NFTs eventually give rise to synaptic dysfunction and 
neurodegeneration (DuBoff et al., 2012; Tracy et al., 2016). Although little is known about how 
phosphorylated tau assembles the paired helical filaments (PHFs) and straight filaments that 
are main components of NFT, a growing body of experimental evidence suggests that both 
PHFs and straight filaments are constituted of hyperphosphorylated tau (Lee et al., 2001). By 
stimulating a number of protein kinases, it has been seen that in vitro expressed tau is 
phosphorylated to generate typical pathological filaments (Baumann et al., 1993; Drewes et al., 
1997; Hanger et al., 1992). It is interesting to note that not all phosphorylated sites are 
necessary for regulating tau assembly. Until now, the leading theory suggests that the free tau 
proteins are prone to aggregate and form intracellular NFTs following the extracellular 
accumulation of amyloid-β. This process is divided into five steps. First, as tau is disengaged 
from MTs, the cytosolic concentration of unbound tau rises. Then, unbound tau is prone to 
misfolding, which forms the early deposits lacking typical β-sheet structures. After that, pleated 
β-sheets gradually become visible pretangles and pretangles are transferred to PHFs. Finally, 
PHFs develop to more complex NFTs (Brion et al., 1993; Gotz et al., 1995; Maas et al., 2000; 
Santacruz et al., 2005). More recently, Liu et al. have reported that tau is also modified by 
O-glycosylation, which negatively regulates tau phosphorylation (Liu et al., 2004). It is still 
unknown whether tau dephosphorylation contributes to alleviating AD symptoms. 
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The detrimental role of tau species is a matter of debate. Recent ‘amyloid cascade hypothesis’ 
asserts that soluble oligomers are toxic species. In line with this hypothesis, tau oligomers lead 
to toxicity in cultured neurons (Flach et al., 2012; Tian et al., 2013a). In addition to this, 
switching off tau expression ameliorates memory deficiency in a mouse model of tauopathy 
although NFTs remains. This suggests that NFT formation is not the causative agent of AD 
(Alonso Adel et al., 2006; Santacruz et al., 2005; Sydow et al., 2011; Van der Jeugd et al., 
2012). Remarkably the concept that tau does not propagate is also challenged. Tau 
aggregates are found to be released into the extracellular matrix (ECM) (Kfoury et al., 2012). 
The secreted tau is then taken up by the neighbor neurons (Frost et al., 2009; Wu et al., 2013). 
This neuron-neuron protein transmission is reminiscent of the behavior of amyloid-β. Tau 
seeding and transmission accelerate AD pathology. 
1.1.4 Linking amyloid-β to tau 
Amyloid-β and tau are two hallmark proteins of AD that have been extensively studied. 
However, their links have remained elusive. Based on the fact that enhanced 
hyperphosphorylation of tau is observed in APP transgenic animal models, while there is no 
obvious formation of amyloid-β in tau transgenic models, it seems that tau is a downstream 
target of amyloid-β toxicity (Gotz et al., 2004). This opinion is further supported by in vivo and 
in vitro evidence. In double transgenic mice expressing both APP and tau variants, the 
neurofibrillary tangles pathology, rather than amyloid-β pathology, is exacerbated (Gotz et al., 
2001; Lewis et al., 2001; Oddo et al., 2004; Terwel et al., 2008). In iPSC-derived neurons, 
increased APP gene dosage is found to specifically increase tau protein levels (Moore et al., 
2015; Muratore et al., 2014). Apart from this, the predominant view asserts that tau 
phosphorylation is also increased upon amyloid-β expression possibly by activating kinases 
such as PKA or GSK3 (Terwel et al., 2008). However, in tau
-/-
 cells and tau deficient animals, 
the amyloid-induced toxicity is alleviated but not fully reversed, which suggests that tau may 
not be the unique target of amyloid-β (Rapoport et al., 2002; Vossel et al., 2010). Tau 
hyperphosphorylation is also activated by other amyloidogenic proteins, for example, NFT 
formation is induced by deposits of integral membrane protein 2B in familial British or Danish 
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dementia (Coomaraswamy et al., 2010). Several conflicting studies imply that amyloid-β and 
tau compromise different organelles, which does not support the idea that tau is a secondary 
effector of amyloid-β. For instance, amyloid-β contributes to defects in complex I of 
mitochondria while tau targets complex IV (Rhein et al., 2009) Moreover, tau post-translational 
modification is not altered in APP mice, changeling the idea that tau is a second messenger of 
amyloid-β (Lill et al., 2015). Taken together, an alternative point suggests that tau is a mediator 
of amyloid-β toxicity. For example, the interaction between tau and the tyrosine protein kinase 
(FYN) facilitates the dendritic transport of the NMDAR subunit 2B (NR2B) to postsynaptic sites, 
which gives rises to neuronal dysfunction. This hypothesis explains why knockout of tau 
ameliorates amyloid-β toxicity (Fuhrmann et al., 2010). In addition to this, given that tau 
negatively regulates axonal transport, tau reduction also protects from Aβ-induced defects in 
axonal transport (Vossel et al., 2010).  
1.2 AD risk factors 
Variants in the APP gene are associated with AD. Its discovery relied on unbiased linkage 
analysis and positional cloning. Genetic linkage analysis successfully mapped a number of 
genes underlying monogenic Mendelian diseases such as presenilins in EOAD as described 
earlier, but it cannot be applied to non-mendelian disease. As sporadic AD (late onset AD, 
LOAD) is a non-mendelian disease, traditional genetic linkage analysis is useless to uncover 
genetic risk factors. In 2005, genome-wide association studies (GWAS) were first developed 
and applied to AD research. This provides a method to find common variants of quite small 
effect sizes (Harold et al., 2009; Hollingworth et al., 2011; Lambert et al., 2009; Lambert et al., 
2013; Naj et al., 2011; Seshadri et al., 2010). A variation in a single nucleotide is termed single 
nucleotide polymorphism (SNP). SNPs are used as markers to compare the frequency of 
alleles between disease cases and controls. The latest SNP chip allows for genotyping 
1,000,000 SNPs and capturing > 80% of the variation in 90% the genome. Significant SNPs 
are then aligned to genotypes to identify possible causative genes (Kruglyak, 2008; McCarthy 
et al., 2008; Vilhjalmsson and Nordborg, 2013; Wray et al., 2013). 
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So far, more than 1000 GWAS studies have been published to identify 695 susceptibility genes 
for AD. These genes include APOE4, CR1, BIN1, CD2AP, EPHA1, CLU, MS4A6A, PICALM 
and ABCA7 (Harold et al., 2009; Hollingworth et al., 2011; Lambert et al., 2009; Lambert et al., 
2013; Naj et al., 2011; Seshadri et al., 2010). These genes are mainly categorized into protein 
transport, intracellular signaling pathways and protein clearance. PICALM, BIN1 and CD2AP 
are all involved in clathrin-mediated endocytosis (CME) (Koo et al., 2015; Koo et al., 2011; 
Moreau et al., 2014; Zhao et al., 2015b; Cormont et al., 2003; Leprince et al., 2003; Leprince et 
al., 1997; Lynch et al., 2003; Micheva et al., 1997; Pant et al., 2009; Ramjaun and McPherson, 
1998; Slepnev et al., 2000; Tebar et al., 1999; Wigge et al., 1997). CR1, CLU and ABCA7 are 
responsible for clearance of toxic proteins (Fuhrmann et al., 2010) Bell et al., 2007; (Fu et al., 
2016; Kim et al., 2013b; Li et al., 2016; Sakae et al., 2016; Satoh et al., 2015). APOE4, EPHA1 
and MS4A6A could mediate downstream cascades of amyloid-β (Bell et al., 2012; Deane et al., 
2008). 
 
Although GWAS have provided numerous hit for AD risk, they bear several limitations. Firstly, 
GWAS cannot identify rare variants in a disease, and so a novel approach is required. The 
revolution of whole genome sequencing provided such a method, which discovered that rare 
variants in TREM2 are strongly associated with LOAD (Guerreiro et al., 2013; Jonsson et al., 
2013). Secondly, GWAS cannot elucidate the biological function of GWAS hits in AD pathology. 
As such, the following experiments are required to achieve functional characterization of 
disease linked genetic variability. Thirdly, GWAS cannot detect the influences of protein 
modification on AD progression. Therefore, the functional experiments are still inevitable to 
understanding the molecular mechanisms underlying disease. 
1.2.1 ApoE4 in LOAD 
The first identified risk factor for AD is the allele of apolipoprotein E (ApoE4). It was first 
discovered in a biochemical screen (Strittmatter et al., 1993), confirmed by subsequent GWAS 
(Corder et al., 1993) and remains the strongest AD risk factor to date. ApoE4 is one of three 
isoforms of the ApoE protein, conferring the most susceptibility for LOAD compared with other 
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AD risk genes (Namba et al., 1991; Rebeck et al., 1993; Schmechel et al., 1993). Mutations in 
ApoE4 are estimated to increase the frequency of AD and reduce the age of onset for AD 
(Corder et al., 1993; Farrer et al., 1997). Moreover, ApoE4 carriers show more severe 
cognitive defects and memory impairments compared to non-carriers (Cosentino et al., 2008; 
Dik et al., 2000; Elias-Sonnenschein et al., 2011; Farlow et al., 2004; Fleisher et al., 2007; 
Petersen et al., 1995; Ramakers et al., 2008; Smith et al., 1998; Whitehair et al., 2010). 
 
ApoE is an apolipoprotein that binds to low density lipoprotein receptor (LDLR) (Beisiegel et al., 
1989; Innerarity and Mahley, 1978; Kim et al., 1996; Kowal et al., 1989). It is polymorphic and 
is characterized by three isoforms: ApoE2, ApoE3 and ApoE4. The differences between these 
isoforms come from different amino acid residues at positions 112 and 158 (Rall et al., 1982; 
Weisgraber et al., 1981). These differences lead to ApoE4 having stronger affinity with LDLR, 
including LDLR-related protein 1 (LRP1) (Dong et al., 1994; Hatters et al., 2006). Although the 
molecular mechanism by which apoE4 elevates AD risk remains elusive, there are two 
possible genetic pathways to explain the detrimental effects of ApoE4: the Aβ-dependent and 
the Aβ-independent pathway.  
 
With regard to the Aβ-dependent pathway, first, ApoE4 enhances Aβ aggregation, fibril and 
amyloid plaque formation (Biere et al., 1995; Evans et al., 1995; Ma et al., 1994). Both in vitro 
and in vivo experiments have demonstrated that ApoE4 accelerates Aβ aggregation and 
firbillogenesis (Buttini et al., 1999; Cerf et al., 2011; Hamanaka et al., 2000; Nathan et al., 1994; 
Veinbergs et al., 1999) and ApoE4 mice have more Aβ oligomers and plaques (Bales et al., 
2009; Fryer et al., 2005; Oakley et al., 2006; Youmans et al., 2012). In contrast, the expression 
of ApoE2 and E3 alleles lower the risk for AD. Mice expressing human ApoE2 or E3 have 
significantly reduced Aβ fibrils and deposition (Holtzman et al., 2000; Holtzman et al., 1999). 
More recently, evidence has demonstrated that ApoE4 has a direct effect on Aβ production 
through promoting APP transcription (Huang et al., 2017). In addition to this, ApoE4 interacts 
with LRP1 which slows the Aβ42 uptake by neurons or blood brain barriers (Kanekiyo et al., 
2013) Zhao et al., 2015b). ApoE4 expression also inhibits autophagy which might further 
interfere with Aβ clearance (Parcon et al., 2017). 
 25 
 
With respect to the Aβ-independent pathway, ApoE4 expression suppresses neurite growth 
and mitochondrial function in primary neuronal cultures and confers spatial learning and 
memory deficits in mice, which is rescued by ApoE3 (Mauch et al., 2001; Pfrieger, 2003). This 
is possibly attributed to abnormal glucose and lipid metabolism (Hamanaka et al., 2000; Rapp 
et al., 2006). A recent study reveals that ApoE4 impairs neuronal insulin signaling (Zhao et al., 
2017). Moreover, ApoE4 substantially reduces lipid transports from neurons to glia and 
therefore causes neuronal dysfunction (Liu et al., 2017). Apart from this, ApoE4 is reported to 
reduce anti-inflammatory responses (Lynch et al., 2003). Therefore, it markedly confers 
neuroinflammation and neurodegeneration in a model of tauopathy (Shi et al., 2017) 
1.2.2 BIN1 in LOAD 
The BIN1 gene is the second strongest susceptibility gene for LOAD. At least 11 
single-nucleotide polymorphisms (SNPs) in BIN1 are linked to the AD risk. These include the 
most significant SNPs rs744373 and rs7561528 (Carrasquillo et al., 2011; Kamboh et al., 2012; 
Lambert et al., 2011; Wijsman et al., 2011). These SNPs elevate or lower AD risk, which 
depends on how they mediate the expression of BIN1 (Chapuis et al., 2013; Glennon et al., 
2013). 
 
Since whether the change of BIN1 expression in AD is still controversial (Chapuis et al., 2013; 
Glennon et al., 2013), BIN1’s role in AD pathology remains explored. Given that it binds to 
dynamin and plays a crucial role in endocytosis and endosomal trafficking (Takei et al., 1999), 
BIN1 and PICALM are predicted to act on a common pathway. Lack of BIN1 displays learning 
deficits (Di Paolo et al., 2002).  
 
BIN1 has been implicated in tau pathology, although its role is a matter of debate, with some 
studies suggesting that upregulation blocks the uptake and spread of tau (Calafate et al., 2016) 
while others suggesting that downregulation ameliorates tau hyperphosphorylation (Chapuis 
et al., 2013).  
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BIN1 is also recently reported to contribute to Aβ production. For instance, BIN1 is found to 
regulate vesicular scission, so its depletion decreases BACE1 recycling to the plasma 
membrane and BACE1 lysosomal degradation, therefore increasing Aβ production (Miyagawa 
et al., 2016; Ubelmann et al., 2017). The contribution of BIN1 to Aβ clearance and pathology 
remains unknown. Given that BIN1 functions in apoptosis and inflammation (Chang et al., 
2007; Elliott et al., 2000; Galderisi et al., 1999; Wechsler-Reya et al., 1997), it might have 
many impacts on AD pathology. 
1.2.3 PICALM in LOAD 
The PICALM gene is an important risk locus for LOAD after APOE4 and BIN1. Until now, more 
than ten AD-associated SNPs in PICALM have been identified (Carrasquillo et al., 2015; 
Harold et al., 2009; Hollingworth et al., 2011; Lambert et al., 2013). Among them, several 
SNPs such as rs3851179 are neuroprotective, while the others are associated with a higher 
risk of AD (Harold et al., 2009; Lambert et al., 2013). These SNPs affect AD risk through their 
influence on PICALM expression (Zhao et al., 2015b; (Raj et al., 2012). 
 
PICALM is ubiquitously expressed in neurons, glial and endothelial cells, and is involved in 
clathrin-mediated endocytosis (Tian et al., 2013). It physically binds to soluble NSF attachment 
protein receptors (SNAREs) such as VAMP2, VAMP8 and RAB5, RAB11 and promotes 
vesicular formation (Koo et al., 2015; Koo et al., 2011; Moreau et al., 2014; Zhao et al., 2015b).  
 
The association between PICALM and tau pathology is not fully understood. One potential 
pathway underpinning the role of PICALM in tau pathology is that down-regulation of PICALM 
leads to elevated autophagy and therefore promotes tau degradation (Moreau et al., 2014). 
Apart from this, it is unclear whether lack of PICALM prevents tau transmission.  
 
PICALM expression is decreased in brain samples of AD patients (Ando et al., 2013; Parikh et 
al., 2014). However, the role of PICALM in Alzheimer’s disease remains controversial. On one 
hand, knockdown of PICALM limits APP or γ-secretase internalization and therefore inhibits 
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Aβ42 production (Kanatsu et al., 2014; Moreau et al., 2014; Xiao et al., 2012; Yu et al., 2010). 
On the other hand, PICALM over-expression promotes APP degradation including APP-CTF 
and Aβ42 clearance (Tian et al., 2013b; Zhao et al., 2015b). Although PICALM in endothelial 
cells is implicated in transportation of Aβ42 across the blood-brain barrier and removal of Aβ42 
(Zhao et al., 2015b), little is known about the contribution of PICALM in neurons to modulating 
Aβ pathology: on one hand, uptake of Aβ might enhance Aβ elimination (Kanekiyo et al., 2013); 
on the other hand, abundant Aβ accumulation in neurons might lead to lysosomal dysfunction 
(Hu et al., 2009b). In addition to this, as PICALM is involved in synaptic function and immunity 
(Harel et al., 2008; Scotland et al., 2012), this suggests that PICALM might affect AD 
progression independent of Aβ or tau pathology.  
1.2.4 Ageing as a risk factor for LOAD 
Ageing is characterized by a gradual functional decline of all organ systems, accompanied by 
a wide range of physiological challenge, loss of ability, decline in function and death. It is 
estimated that by 2050, 2 billion people worldwide will be over the age of 60 years (Bloom et 
al., 2011). Increased population ageing raises vulnerability to diseases like cancer, diabetes, 
cardiovascular disorders and neurodegenerative diseases. It is anticipated that human health 
will become society’s big burden in the next ten years (Bloom et al., 2011). In the past decades, 
scientists made great efforts to understand a connection between ageing and 
neurodegenerative disease. Slowly, the genetic basis underlying ageing and 
neurodegenerative disease is becoming clearer.  
 
Ageing and neurodegenerative disease share basic cellular pathways such as DNA repair, 
histone methylation, ubiquitin-proteasome degradation, autophagy and NAD production. 
These pathways are lost with age and impaired with neurodegenerative disease. For example, 
elevation of ubiquitin protein ligases or ATG proteins is able to increase life expectancy as well 
as attenuate neurodegenerative pathology (Carrano et al., 2014; Carrano et al., 2009; 
Heimbucher et al., 2015; Li et al., 2007; Liu et al., 2011; Vilchez et al., 2012; Gong et al., 2006; 
Harrison et al., 2009; Juhasz et al., 2007; Lee et al., 2010a; Matsumoto et al., 2011; Minnerly 
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et al., 2017; Mori et al., 1987; O'Rourke et al., 2013; Ryu et al., 2016; Soda et al., 2009). The 
lifespan and healthspan are increased by an improvement in DNA repair ability, an activation 
of histone methylation and a supplementation of NAD (Madabhushi et al., 2015; Suberbielle et 
al., 2013; Fang et al., 2016; Greer et al., 2010; Greer et al., 2011; Han et al., 2017; Li et al., 
2013; Merkwirth et al., 2016; Zhang et al., 2016). 
 
However, dozens of studies have demonstrated that some of the molecular mechanisms of the 
ageing process and neurodegeneration are opposite. For instance, it is well known that 
glutamate receptors are critical in memory formation and are reduced in AD brains. However, 
their silencing delays ageing of Drosophila (Verma et al., 2015). Another example to elucidate 
the odds between ageing and neurodegeneration is protection of mitochondrial function. A 
modest restriction of mitochondrial function improves the survival rate in C. elegans and 
Drosophila (Copeland et al., 2009; Ewbank et al., 1997; Felkai et al., 1999; Feng et al., 2001; 
Jonassen et al., 2001; Jonassen et al., 1998; Rea et al., 2007; Stenmark et al., 2001; Vajo et 
al., 1999; Wong et al., 1995), but mitochondrial function is impaired in AD or PD patients, so an 
improvement of mitochondrial dysfunction delays progression of AD and PD 
(Anandatheerthavarada et al., 2003; Caspersen et al., 2005; Devi et al., 2006; Hirai et al., 
2001; Wang et al., 2009a; Yao et al., 2009). 
 
The contributions of several age-related genes in neurodegenerative disease also appear 
contradictory. For example, an inhibition of IIS pathway is able to partially alleviate paralysis of 
Aβ42 worms, flies and APP/PS1 mice owing to an enhanced clearance of Aβ42 (Chiang et al., 
2010; Cohen et al., 2006; Cohen et al., 2009), while a restoration of IIS pathway is reported to 
protect against Aβ42 toxicity in mammalian models (Carro et al., 2006; Carro et al., 2002; Craft 
et al., 2012; Dudek et al., 1997). This alleviation is attributed to a promotion in memory 
formation. Also, suppression of mTOR by rapamycin has been proven to eliminate Aβ42 toxicity 
through an elevation of autophagy (Ravikumar et al., 2004; Spilman et al., 2010), whereas a 
block of mTOR gives rise to memory loss (Fortress et al., 2013; Jobim et al., 2012a; Jobim et 
al., 2012b; Mac Callum et al., 2014; Parsons et al., 2006; Schicknick et al., 2008). This 
opposite action resembles different roles of RAS and SIRT in ageing and neurodegeneration 
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as well. On one hand, activation of SIRT1 by resveratrol abolishes neurotoxicity in HD and AD 
(Parker et al., 2005); on the other hand, inhibition of SIRT1 is also indicated in neuroprotection 
(Li et al., 2008). Moreover, a reduction of SIRT2 expression by AKT1 facilitates neuronal 
survival in HD and PD (Luthi-Carter et al., 2010). This discrepancy is also seen in the role of 
the UPR in AD. Either a reduction of the UPR repressor Bip or elevation of UPR activator 
Xbp-1 is sufficient to increase longevity of Aβ42-expressing flies (Casas-Tinto et al., 2011; 
Niccoli et al., 2016), but suppression UPR through knockout of elF2α rescues memory deficits 
of AD mice models (Ma et al., 2013b) and upregulation of UPR
mt
 through overexpression of 
JNK3 aggravates amyloid-β toxicity (Yoon et al., 2012).  
 
This evidence suggests that although the cellular pathways involved in ageing and AD are 
overlapped, ageing might not to be the causative of AD. Ageing merely increases vulnerability 
to AD (Niccoli and Partridge, 2012; Rogers et al., 2012). Therefore, anti-ageing strategy might 
be an effective avenue to delay onset of age-related diseases, although it may not be a 
treatment for AD.  
1.3 Glutamategeric transmission with Alzheimer’s disease 
1.3.1 Glutamate release and uptake 
The main symptom experienced by AD patients is memory impairment. This is something 
essential for everyday life, allowing an individual to store and retrieve acquired knowledge and 
so beneficially affect subsequent behavior. During memory formation, glutamatergic 
transmission plays a crucial role. 
 
Glutamate is the principal excitatory transmitter that is pumped into vesicles through vesicular 
glutamate transporter (VGLUT) and then vesicles are released into the extracellular matrix 
(Daniels et al., 2004; Rossano et al., 2017). VGLUT can be divided into three subtypes 
(VGLUT1-3) and consists of 8-10 putative transmembrane domains (El Mestikawy et al., 2011; 
Schafer et al., 2002). It is mainly distributed in neurons and glial cells. VGLUT takes up 
cytoplasmic glutamate and transports glutamate inside vesicles. These then fuse with the 
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plasma membrane so that glutamate is exocytosed and released. This loading of glutamate 
into vesicles is driven by an electrochemical H
+
 gradient and mediated by Cl
-
. Low 
concentrations of Cl
-
 facilitate glutamate uptake by VGLUT while high concentrations inhibit it 
(Fremeau et al., 2001; Kaneko et al., 2002; Li et al., 2003). Once released into the extracellular 
space excess extracellular glutamate is taken up by excitatory amino acid transporters 
(EAATs), mostly located on glia. EAATs are composed of three homomeric subunits. This 
trimer forms a bowl-shaped structure and the glutamate-binding sites are located towards the 
bottom of the structure (Tzingounis and Wadiche, 2007). When extracellular Na
+
 or H
+
 bind to 
the gates of EAAT, the glutamate-binding site is exposed to the extracellular matrix and the 
glutamate is translocated inside (Barbour et al., 1988; Bouvier et al., 1992; Erecinska et al., 
1983; Kanai et al., 1995; Kanner and Bendahan, 1982; Kanner and Sharon, 1978; Klockner et 
al., 1993; Stallcup et al., 1979; Wadiche et al., 1995; Zerangue and Kavanaugh, 1996b). But 
when intracellular K
+
 binds to the gates, the glutamate-binding site faces the cytoplasm and 
glutamate uptake is blocked (Levy et al., 1998; Owe et al., 2006; Zerangue and Kavanaugh, 
1996a). Glutamate taken up by glia is converted into glutamine by glutamine synthetase in glia, 
which is exclusively expressed in astrocytes, and released into the extracellular space where it 
is taken up by neurons and used to generate glutamate. Therefore, glial cells are the source of 
glutamine for glutamate biosynthesis. Non-vesicular transporters such as xCT transporters are 
also located on glia cells. These transporters modulate glutamate release from glia (Augustin 
et al., 2007). Non-vesicular release of glutamate is regarded as a reversed glutamate uptake 
(Szatkowski et al., 1990). 
 
An increase in extracellular glutamate is found in both in vitro and in vivo model of AD. This is 
usually attributed to Aβ-induced impairment of glutamate uptake by glial cells (Cummings et al., 
2015; Hefendehl et al., 2016; Li et al., 2009; Talantova et al., 2013). However, one study 
suggests that neurons are directly involved in the elevated glutamate levels in the extracellular 
matrix (Cummings et al., 2015). Taken together, it is likely that glutamate excitotoxicity is linked 
to AD. 
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1.3.2 Glutamate excitotoxicity 
Glutamate activates glutamate receptors. In turn, glutamate receptor alters glutamate release 
by a retrograde messenger. Glutamate receptors fall into three groups: NMDAR, AMPAR and 
mGluR. All three types are involved in memory formation and decay. 
 
AMPARs are ionotropic GluRs (Benke et al., 1998; Derkach et al., 1999; Ehlers, 2000) and 
composed of four subunits (GluA1 – GluA4), formed by homomeric GluA1 subunits or 
heteromeric GluA1/GluA2 and GluA2/GluA3 subunits. GluA1 is a highly Ca
2+
-permeable 
AMPAR (CP-AMPAR) that is necessary for memory acquisition. During memory acquisition, 
GluA1 is trafficked to spines. However, GluA1 is not involved in memory retrieval because the 
selective blockade of GluA1-containing CP-AMPARs has no effect on memory after it has 
been established. After memory is established, synaptic GluA1-containing CP-AMPARs 
gradually switch back to GluA2-containing Ca
2+
-impermeable AMPARs (CI-AMPARs) by 
lateral diffusion. Memory loss is concomitant with GluA1 dephosphorylation and endocytosis. 
In addition to this, hippocalcin is transported to the plasma membrane and destabilizes GluA2 
(Palmer et al., 2005). This initiates the GluA2 recycling. Moreover, PICK1 is activated during 
memory loss and facilitates the internalization of GluA2. (Emond et al., 2010; Hanley and 
Henley, 2005; Lin and Huganir, 2007; Oliet et al., 1997; Peineau et al., 2009; Terashima et al., 
2008). Taken together, under basal conditions, the synapse is dominated by CI-AMPARs. 
During memory establishment, synaptic CI-AMPARs switch to CP-AMPARs. Next, synaptic 
CP-AMPARs gradually scale down synaptic strength via the replacement of synaptic 
CP-AMPARs with CI-AMPARs, while during memory decay, synaptic CP-AMPARs are 
internalized. After that, GluA2 is endocytosed and might scale up synaptic strength. 
 
The Drosophila nervous system also expresses different types of glutamate receptors (GluRs). 
Like mammalian glutamate receptors, Drosophila GluRs are composed of many subunits. Due 
to distinct properties of subunits, GluRs are further divided into: metabotropic glutamate 
receptors (mGluRs) and ionotropic glutamate receptors (iGluRs). mGluRs are 
glutamate-activated G-protein coupled receptors and formed by heteromeric GluRA/XR 
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subunits (Andlauer et al., 2014; Bogdanik et al., 2004; Mitri et al., 2004; Parmentier et al., 
1996). iGluRs are glutamate-gated ion channels and fall into four categories: NMDA, AMPA, 
kainate receptors and glutamate-gated chloride channels. NMDA receptors are formed by 
NR1/NR2 subunits (Ultsch et al., 1993; Xia et al., 2005). AMPA receptors are the main 
excitatory iGluRs and composed of two subtypes: A type and B type. Type A contains GluRIIA, 
C, D and E subunits (Schuster et al., 1991) while type B contains GluRIIB, C, D and E subunits 
(Petersen et al., 1997). Compared to AMPA receptors in mammalian neurons, Drosophila 
AMPA receptors require extremely high concentrations of glutamate for activation (Han et al., 
2015; Heckmann et al., 1996). However, like mammalian AMPA receptors, Drosophila AMPA 
receptors are permeable to calcium (Chang et al., 1994; Han et al., 2015). Another type of 
excitatory iGluRs are kainate receptors and these are composed of GluRIA or GluRIB subunits. 
Kainate receptors are activated by kainate rather than glutamate (Ultsch et al., 1992; Volkner 
et al., 2000). In addition to this, Drosophila has inhibitory iGluRs, glutamate-gated chloride 
channels, which are formed by GluCl subunits (Delgado et al., 1989; Liu and Wilson, 2013). 
The function of glutamate receptors is conserved in invertebrates. Drosophila’s glutamate 
receptors are involved in memory consolidation (Wu et al., 2007; Xia et al., 2005).  
 
In the past, glutamatergic transmission was found to be attenuated, concomitant with Aβ 
accumulation. For instance, either AMPARs or NMDARs is endocytosed upon Aβ exposure 
(500 nM) for 7 days (Hsieh et al., 2006; Shankar et al., 2007; Snyder et al., 2005; Zhao et al., 
2010). However, this idea has been disputed. Firstly, NR2B subunits of NMDARs are reported 
to be activated by Aβ oligomers and inhibition of NR2B prevents Aβ-mediated neurotoxicity 
(Hu et al., 2009a; Li et al., 2009; Li et al., 2011; Talantova et al., 2013). Secondly, the lines of 
evidence have shown that although GluA2 subunits of AMPAR are removed from cell surfaces, 
GluA1 subunits accumulate with low levels of Aβ (5 nM) for 2h. This suggests that low doses of 
Aβ leads to excitotoxicity as a primary response, while high doses of Aβ scales down synaptic 
strength and results in synaptic loss (Liu et al., 2010; Whitcomb et al., 2015).  
 
Recently the mechanism of how Aβ oligomers affect glutamate receptor has increasingly 
becoming clear. At least four interacting partners of Aβ oligomers have been identified. First, 
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Aβ oligomers physically interact with the α7 nicotinic acetylcholine receptor (α7 nAChR). The 
activation of α7 nAChR will induce CaMKII phosphorylation and therefore AMPAR activation, 
but this process is blocked by Aβ oligomer expression (Dineley et al., 2002a; Dineley et al., 
2002b; Wang et al., 2000; Wang et al., 2003). Aβ oligomers also bind to cellular prion protein 
(PrP
C
) and PrP
C
 interacts with NR2D or mGluR5. Either Aβ-PrP
C
-NR2D or Aβ-PrP
C
-mGluR5 
complex triggers Fyn activation and then synaptic loss (Lauren et al., 2009; Um et al., 2013; 
Um et al., 2012). Moreover, Aβ oligomers bind to EphB2 and lead to EphB2 degradation. 
EphB2 depletion dramatically reduces NR1 subunits on the cell surface and thus impairs 
memory acquisition (Cisse et al., 2011). Aβ oligomers have a high affinity for LilrB2. Aβ 
oligomers act on LilrB2 to activate PP2A and PP2B, which leads to internalization of AMPARs 
and impairment in memory (Kim et al., 2013a).  
1.4 Research progress in Alzheimer’s disease 
1.4.1 Mammalian models of AD 
Given the scarcity of postmortem brain tissues of AD patients and the fact that disease brain 
tissue of living patients is difficult to obtain, there is limited experimental access to human 
disease relevant samples. Therefore, various animal models have been developed to 
recapitulate AD phenotypes. The first human APP cell model is derived from SH-SY5Y cells. 
APP-expressing SH-SY5Y cells do not recapitulate severe AD phenotypes such as cell death, 
but they facilitate the understanding of the APP processing (Jamsa et al., 2011; Matsumoto et 
al., 2006). Recently, several human APP neuronal models have been established. These 
neurons differentiate from embryonic stem cells, human neural progenitor cells (hNPCs), 
induced pluripotent stem cells (iPSCs) or are directly converted from somatic cells (Choi et al., 
2014; Hu et al., 2015; Israel et al., 2012; Kondo et al., 2013). However, none of the APP 
mutations successfully recapitulated AD phenotypes except for increased Aβ42 levels. Only 
models with over-expression of APP develop detectable AD pathology including synaptic 
degeneration. However, this unphysiologically high level of APP caused by the overexpression 
induces a number of undesirable side effects. For example, over-expression of APP interferes 
with intracellular transport, synaptic adhesion, synaptogenesis and increases NMDAR 
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expression (Baumkotter et al., 2014; Choi et al., 2013; Cousins et al., 2009; Cousins et al., 
2013; Deyts et al., 2016; Deyts et al., 2012; Hoe et al., 2009; Koo, 2002; Osterhout et al., 2015; 
Wang et al., 2009b). In addition to APP over-expression, three-dimensional culture or 
extension of culture time might be an alternative way to promote toxicity (Choi et al., 2013; Shi 
et al., 2012). Primary neurons from APP fetal mice have also been used for AD studies for 
decades. These cells display cell death and decreased synaptic transmission (Baldassarro et 
al., 2017; Katsurabayashi et al., 2016). Administration of > 500 nM of Aβ42 to primary cultures 
also induces synaptic loss and cell death (Lauren et al., 2009; Um et al., 2013; Um et al., 2012). 
However, this model is considered very artefactual since it neglects the APP processing and 
uses extremely high, non-physiological concentrations of Aβ42.  
 
Mice models have also been instrumental for AD research, with numerous murine models 
having been developed. A typical example is APPSw transgenic mice that over-express the 
Swedish double mutant APP (e.g. APP23 and Tg2576) (Games et al., 1995; Hsiao et al., 1996; 
Saydoff et al., 2013). These mice are characterized by the increased Aβ42 production, amyloid 
plaques at 9 months, and synaptic and memory deficits at 6 months. However, they do not 
display neurofibrillary tangles (NFTs) and neuronal loss. APP/PS1 transgenic mice (e.g. 
PSAPP and 5XFAD) are the other commonly used mouse models that carry mutations in PS1. 
They display more severe AD phenotypes such as the enhanced Aβ42 production and Aβ42/ 
Aβ40 ratio at 2 month of age and amyloid plaques at 2-3 month of age (Girard et al., 2014; 
Holcomb et al., 1998; Oakley et al., 2006). These two models have been used to investigate 
FAD pathology. However, they suffer from over-expression artifacts derived from mutations of 
APP and PS1. In order to overcome this problem, several knock-in (KI) murine models have 
been recently generated. APP KI mice (APP
NL-F) lead to an increase in both β-cleavage and 
γ-cleavage of APP, which elevates the Aβ42 levels and Aβ42/Aβ40 ratio. These mice display 
accumulation of amyloid plaques and therefore impaired memory at 18 months, whereas the 
other APP KI mice with Arctic mutations (APP
NL-G-F) show Aβ pathology earlier from 2 months 
and memory problems at 6 months (Saito et al., 2014). BACE1 KI mice also display the 
elevated levels of Aβ42 and cognitive deficits (Plucinska et al., 2014). However, PSEN1 KI mice 
show a decrease in the Aβ42 levels but a significant increase in Aβ42/Aβ40 ratio. These mice 
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have Aβ deposition and memory impairment (Xia et al., 2015). 
 
Although numerous murine models have been established to study FAD pathology, no models 
successfully recapitulate SAD pathology. It is well established that overproduction of Aβ42 has 
failed to produce significant neurodegeneration in mice (Hsiao et al., 1996; Mucke et al., 2000). 
Therefore, the Aβ injected mouse model is developed. However, 100 uM of Aβ42 is 
unphysiologically high to induce Aβ toxicity. Therefore, this model is not widely used by 
researchers to study disease progression (Gotz et al., 2001; Roberson et al., 2007). With 
respect to the ApoE4 transgenic mice, the endogenous ApoE is replaced by human ApoE4. 
These mice have cognitive impairment without amyloid plaques deposits (Osorio et al., 2007). 
1.4.2 Drosophila model of AD 
A number of non-mammalian models have also been developed. Amongst these, Drosophila 
melanogaster serves as a model organism for genetic analysis mainly because it provides a 
compromise between experimental ease and evolutionary conservation. It has a hundred year 
history in genetic research and is still used as a favorite model organism for laboratory studies 
of embryonic development. It is a useful model in biological research due to its small size and 
low care requirements. It is cheap and easy to breed in big numbers. Its major advantage for 
the study of neurodegenerative diseases is its relatively short development time and lifespan, 
~10 days and ~3 months, respectively, and its relatively complex behaviors ranging from 
simple avoidance to learning and memory (Guo et al., 2000; Guo and Zhong, 2006; Shuai et 
al., 2010).  
 
Drosophila has complex and highly differentiated central (CNS) and peripheral nervous 
systems (PNS). For example, Drosophila has compound eyes, which give them sharp vision. 
Their eyes consist of 760 ommatidia and each ommatidium contains eight photoreceptor cells 
and pigment cells. Pigment cells are responsible for absorbing light and transducing light 
signals to photoreceptors. Subsequently, photoreceptors convert optical signals to chemical 
information and then send this information to optical lobes of brains. Under the normal 
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physiological condition, Drosophila compound eyes have highly organized arrangements of 
retinal neurons and a smooth surface. However, when neurons degenerate, their eyes 
gradually lose photoreceptors, which gives rise to a roughened surface. This phenotype is 
termed rough eye phenotype (REP). As REP is easily observed under light microscopy, it 
provides a convenient tool for genetic modifier screens (Armakola et al., 2012; Gitler et al., 
2009; Treusch et al., 2011; Chung et al., 2013; Kim et al., 2014; Tardiff et al., 2013). In addition 
to this, Drosophila motor systems are well developed. The most notable motor systems are the 
giant fiber (GF) system that controls locomotion, flight, and an escape response. The GF 
system comprises of a pair of interneurons whose cell bodies reside in the brains, with axons 
descending along the midline into the thoracic ganglion. The ventral ganglion in the thorax is 
connected to two muscle fibers: the dorsal longitudinal muscle (DLM) via chemical (cholinergic) 
synapses and tergotrochanteral muscle (TTM) via electric (glutamatergic) synapse (Allen and 
Godenschwege, 2010; Augustin et al., 2011). In Drosophila models of neurodegenerative 
diseases, the function of Drosophila nervous systems can be measured by locomotion and 
flight assays. Therefore, Drosophila behavioral deficiency is an important phenotype of 
neuronal dysfunction (Lasagna-Reeves et al., 2016; Park et al., 2013; Rousseaux et al., 2016). 
To coordinate sensory input and motor output, a delicate CNS, the mushroom body (MB), is 
developed in Drosophila. The mushroom body neurons (MBNs) are comprised of two classes: 
Kenyon cells (KCs) and output neurons (MBONs) (Aso et al., 2014; Campbell et al., 2013; Lin 
et al., 2014; Owald et al., 2015; Perisse et al., 2013; Turner et al., 2008). KCs receive 
information through their dendrites in the calyx, while MBONs convey information to 
downstream motor neurons (Pai et al., 2013; Placais et al., 2013). This learning process is 
also modulated by dopamine neurons (Boto et al., 2014; Claridge-Chang et al., 2009; Kim et 
al., 2007b; Mao and Davis, 2009; Qin et al., 2012; Riemensperger et al., 2005; Schroll et al., 
2006; Schwaerzel et al., 2003) The learned information is stored in the mushroom body that is 
also involved in memory acquisition, consolidation, forgetting and retrieval. Similar to 
mammalian memory, Drosophila memory is classified into: short-term memory (STM) (0–1 h), 
intermediate-term memory (ITM) (0.5-3 h), early-phase long-term memory (LTM) (9-24 h) and 
late-phase long-term memory (LP-LTM) (18-48 h). The formation of LTM and LP-LTM is 
dependent on protein synthesis (Akalal et al., 2010; Pascual and Preat, 2001; Tully et al., 1994; 
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Yu et al., 2006). In order to organize and store different forms of memory traces, the KCs 
differentiate into three highly organized subtypes: α/β, α’/β’ and γ MBNs. The γ MBNs are the 
primary site for STM formation (Akalal et al., 2006; Blum et al., 2009; Cervantes-Sandoval et 
al., 2013; Xie et al., 2013; Zars et al., 2000; Zhang and Roman, 2013). The γ MBNs then 
convey information to the α’/β’ MBNs for ITM formation (Cervantes-Sandoval et al., 2013; 
Davis, 2011; Krashes et al., 2007; Wang et al., 2008). The α/β MBNs are required for 
acquisition of all forms of memory, especially LTM (Akalal et al., 2010; Cervantes-Sandoval et 
al., 2013; Dubnau et al., 2001; Huang et al., 2013; Huang et al., 2012; McGuire et al., 2001; 
Perisse et al., 2013; Xie et al., 2013; Yu et al., 2006). In addition to this, a specific subtype of 
the γ MBNs plays an important role in LP-LTM acquisition (Akalal et al., 2010; Yu et al., 2004). 
The processes of STM, ITM and LTM are also modulated by the anterior paired lateral neuron 
(APLn) (Lin et al., 2014; Liu and Davis, 2009; Liu et al., 2007; Pitman et al., 2011), dorsal 
paired medial neurons (DPMn) (Keene et al., 2004; Krashes et al., 2007; Waddell et al., 2000; 
Yu et al., 2005) and dorsal anterior lateral DAL neurons (DALn) (Chen et al., 2012), 
respectively. In AD models, Drosophila memory is severely impaired, consistent with the fact 
that its mushroom body is degenerated (Chiang et al., 2010; Wang et al., 2012). 
 
Another advantage of the fly is the numerous well-established molecular tools and genetic 
database developed during its long history as an animal model in research. It was one of the 
first organisms with a fully sequenced genome. There are roughly 13600 genes, located on 
four chromosomes. Nearly 70% of human disease-causing genes have homologs in the fly. 
The fly also benefits from well-established binary expression systems such as the GAL4/UAS 
(upstream activation sequence) system. The GAL4/UAS system was first developed by Brand 
and Perrimon and is based on transcription factor (TF) enhancer sequences from yeast 
Saccharomyces cerevisiae (Brand and Perrimon, 1993). The relevant proteins are not present 
in Drosophila and their expression does not interfere with normal biological processes in the 
cell. GAL4 is cloned under the control of a tissue specific promoter, thus restricting its 
expression to a particular tissue of interest. The target gene is cloned under the control of the 
UAS promoter. GAL4 binds to the UAS enhancer sequence driving the expression of the gene 
of interest. Usually Gal4 lines and reporter lines expressing UAS-regulated transgenes are 
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separated. When required, two lines will be crossed with each other to drive the expression of 
the target gene in those tissues where GAL4 is expressed. 
 
However, the GAL4/UAS system is limited to spatial regulation because once the GAL4 and 
UAS-linked transgene coexist in the fly genome, this transgene will be immediately expressed. 
The development of the gene-switch (GS) system has extended the application of the 
GAL4/UAS system, allowing activation of genes only in the presence of steroid hormones or 
chemically related compounds, thus allowing temporal regulation (Ford et al., 2007; 
Osterwalder et al., 2001). In the GS system, GAL4 is fused with the regulatory domain of the 
human progesterone receptor, which is recognized and activated by the activator mifepristone 
(RU486) (Osterwalder et al., 2001; Poirier et al., 2008). In the absence of RU486, the GAL4 
loses its activity. Only when flies with the GS driver and the UAS component are fed a RU486 
dose, the GS system becomes transcriptionally active and induces gene expression.  
 
At least three Drosophila models have been widely used as Alzheimer’s disease models. 
Drosophila has the conserved γ-secretase (Takasugi et al., 2003) and APP-like protein (APPL), 
but not β-secretase. Therefore, Aβ42 is not detected in flies. Overexpression of human APP 
and BACE1 genes in fly brains recapitulates several AD phenotypes such as shortened 
lifespan, synaptic loss, locomotor and memory deficits (Chakraborty et al., 2011). Flies 
expressing Aβarc display similar neurodegenerative phenotypes (Crowther et al., 2005), while 
flies expressing single copy of Aβ42 merely exhibit the rough eye phenotype, synaptic 
degeneration and impairment in memory performance (Finelli et al., 2004). Like the murine 
model, the Drosophila model of Aβ42 displays amyloid deposits (Chiang et al., 2010; Iijima et 
al., 2004). 
 
Our Drosophila AD model is gifted from Dr. P. Fernandez-Funez that expresses two copies of 
Aβ42 (Casas-Tinto et al., 2011). UAS-Aβ42x2 is fused with an extracellular export signal that is 
driven by different Gal4 including elavGS, D42-Gal4 and Mef2-Gal2. ElavGS is a GS driver 
linked to the promoter of Elav. Elav encodes a neuronal specific protein, so this driver is only 
expressed in Drosophila neurons. Flies expressing two copies of Aβ42 in neurons recapitulate 
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some AD symptoms such as shortened lifespan, locomotor deficits and eye degenerative 
phenotypes (Figure 1.3). Moreover, this Aβ-expressing model develops amyloid plaques 
(Casas-Tinto et al., 2011). D42-Gal4 is restricted to expression in motor neurons and 
Mef2-Gal4 is limited to expression in muscles. Larvae expressing Aβ42 in either motor neurons 
or muscles display severe morphological defects in motor neurons (Mhatre et al., 2014). As 
single neurons are distinguishable in larvae muscles, Drosophila larvae are the alternative 
choice for unraveling neurodegeneration during AD progression. 
 
 
 
 
 
 
 
 
Figure 1.3 Schematic of the Gal4/UAS binary expression system. In the absence of the chemical RU486, the 
transcription factor, Gal4, is inactive. When the chemical RU486 is present in neurons, Gal4 binds to UAS and 
activates expression of Aβ42.  
 
Recently, a novel repressible binary system has been developed, which is utilized by the 
Neurospora crassa for the catabolism of quinic acid, and so named the Q system. It is 
constituted of two genes (QF and QS). QF is a transcriptional activator that binds to an 
enhancer termed QUAS. QF activity is repressed by a repressor, QS. This block is removed by 
quinic acid (Potter et al., 2010).  
 
The first Drosophila model of neurodegenerative diseases using the Q system is established 
by Pearce and colleagues (Pearce et al., 2015). In this model, the constitutive Q system is 
used to express the huntingtin protein. Subsequent work established the Drosophila model of 
AD using the inducible Q system. This model displays shortened lifespan (Niccoli et al., 2016). 
In my study, I used this inducible AD model. Briefly, QUAS was fused with Aβarc and expressed 
 Gal4 GS Elav 
UAS    Aβ 42 
UAS    Aβ42 
Neuron specific promoter 
RU486 
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in neurons under the control of syt-QF (Syt-QF is a pan-neuronal driver), while modifier genes 
are expressed in glia by a glial specific driver GSG3285-GS. The combination of the Q system 
and the Gal4/UAS system makes it possible to investigate the communication between 
neurons and glia. These two systems also allow for the restricting of Aβarc expression in 
neurons and the expression of modifiers in glial cells.  
 
Aside from these widely used models of AD, several novel AD models have emerged such as 
zebrafish, C. elegans and yeast (Boyd-Kimball et al., 2006; Treusch et al., 2011). Each model 
has significant strengths and weaknesses. For example, yeast is easy to perform genetic 
screens on. However, yeast does not have neurons and therefore lacks most AD phenotypes. 
Zebrafish is a vertebrate model which is easy to track protein localization in due to its 
transparency. However, the current zebrafish model does not recapitulate AD phenotypes. In 
summary, a combination of different animal models will be the best approach for AD research. 
1.4.3 Genetic screens in neurodegenerative diseases 
Due to the limited availability of human samples and the need for experimental analysis of 
mechanisms, animal models are indispensable for disease research. The success of model 
organisms such as Drosophila is in part linked to the power of its genetic screens. Genetic 
screens were first applied to identify dozens of molecular pathways during Drosophila 
development. This allows genetic screens to become a powerful tool to elucidate gene 
function and gene networks in various organisms, from human cells to mice. 
 
Forward genetic screens are used to determine the gene responsible for a phenotype. These 
screens are conducted using mutagens such as UV radiation to induce mutations. However, 
UV radiation has a disadvantage of deleting multiple loci, and it is hence difficult to map the 
resulting mutations. Many mutagenesis programmes have instead been conducted with 
chemicals such as EMS (Nusslein-Volhard and Wieschaus, 1980; Nusslein-Volhard et al., 
1984). EMS has many merits. First, this method is the most efficient. It induces mutations 
every 1 to 2 Mb. Second, it induces point mutations. Finally, EMS targets spermatogonial stem 
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cells, allowing mutations to be passed onto offspring. However, it is still very laborious to map 
and identify the mutations resulting from chemical mutagenesis (Berger et al., 2001; Martin et 
al., 2001). To overcome this problem, insertional mutagenesis has become a favored method. 
Insertional mutagenesis induces mutations by insertion of mobile genetic elements into the 
genome, and often is carried out using a P-element as the mutagen. The P-element inserts 
into its hotspots to disrupt gene function, and the mutated gene is rapidly and easily identified 
by inverse PCR methods. Although P-element insertion is much less efficient than 
EMS-induced mutagenesis, it is still widely used because it is economical and time-saving 
(Perrimon et al., 1996; Spradling et al., 1999). Unlike forward genetic screens, reverse genetic 
screens are the strategy to discover the phenotype caused by genetic manipulation. They are 
also categorized into gain-of-function and loss-of-function screens. In Drosophila, 
gain-of-function screens use P-element to insert a UAS element into the genome. When genes 
are in proximity of the UAS element, their expression will be affected by UAS activation (Rogge 
et al., 1991; Rorth et al., 1998). Loss-of-function screens begin with the knockout or 
knockdown of genes (Olivier et al., 1993; Duchek and Rorth, 2001; Duchek et al., 2001). 
Because the knockout of essential genes is lethal, the large-scale knockdown of genes by 
RNAi is the most frequently used type of reverse genetic screens (Fraser et al., 2000; Gonczy 
et al., 2000). 
 
RNA interference emerges as a potent, specific and ubiquitous means of gene silencing, which 
is characterized by base-pairing to target mRNA and thus post-transcriptionally regulating 
protein synthesis. In general, RNAi includes microRNAs (miRNAs), small interfering RNAs 
(siRNAs) and PIWI-interacting RNAs (piRNAs) pathways (Lee et al., 1993; Reinhart et al., 
2000). Among them, miRNA pathways rely on two principal regulations: miRNA-mediated 
repression of translation (Olsen and Ambros, 1999; Seggerson et al., 2002) and mRNA 
deadenylation that leads to mRNA decay (Behm-Ansmant et al., 2006; Eulalio et al., 2009; 
Eulalio et al., 2007; Giraldez et al., 2006; Piao et al., 2010; Rehwinkel et al., 2005; Wu et al., 
2006), while siRNA pathways cause transcript degradation (Fire et al., 1998).  
 
With respect to screen measurements, genetic screens can also be categorised into simple 
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screens, modifier screens, complementation screens and clonal screens (synthetic lethal 
screens). Simple screens aim to identify genes involved with a given phenotype, while in 
modifier screens, a phenotype is defined by genetic defects, and the modifier screen aims at 
finding second-site mutations that either enhance or suppress that phenotype (Olivier et al., 
1993; Rogge et al., 1991). Notably, Cao’s work is a typical modifier screen, which identifies 
enhancers and suppressors of Aβ42 toxicity (Cao et al., 2008). Similar to modifier screens, 
complementation screens are designed to reveal genes to restore phenotypical defects. In 
order to detect function of essential genes, clonal screens were developed by Tian and Rubin 
(1993). The principle of clonal screen is to use the Flp/FRT system to generate site-specific 
recombination in a given tissue. Flp is a recombinase from the yeast that targets the FRT sites. 
In the Flp/FRT screen, Flp and FRT are integrated into Drosophila genome. When Flp is 
placed under the control of a tissue-specific promoter, its mediated recombination is restricted 
to a specific tissue, thus potentially circumventing the lethality caused by constitutive 
knock-out in the whole body (Golic and Lindquist, 1989; Xu et al., 1995b). 
 
In neuroscience research, Drosophila genetic screens are commonly dependent on 
morphological screens and behavioral screens. As flies have small bodies, morphological 
changes are usually not visible to the naked eye. Therefore, a microscope is required to 
observe subtle phenotypes, such as the REP of Drosophila. In some cases, phenotypes like 
larval brain size are not clearly detectable under a dissecting microscope, but they are easily 
detected with the help of fluorescence reporters. Green fluorescence protein (GFP) is the most 
commonly used fluorescence reporter that is fused to a protein. Changes in GFP intensity or 
localization of a specific protein serve as readout (Brenman et al., 2001; Gao et al., 1999; Gao 
et al., 2000). This method is also useful in screens using transparent animal models like cells, 
worms and zebrafish. Behavioral analysis is the main method to dissect genetic pathways 
underlying animal behaviors. They are usually facilitated by video recording, like the 
sleep/wake activities of zebrafish, the locomotion and flight of flies and the resistant 
movements of worms (Burchell et al., 2013; Denzel et al., 2014; Rihel et al., 2010; Tufi et al., 
2014). In summary, genetic screens are an efficient method to discover unknown genes and 
their functions.  
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In terms of research on neurodegenerative diseases, Drosophila is a powerful model for 
high-throughput screening for an abundance of causative or therapeutic targets. Both forward 
and reverse methods are easily applied to Drosophila screens. The rough eye phenotype 
(REP) of Drosophila is a detectable phenotype during neurodegeneration, which is widely 
used to identify unappreciated modifiers of neurodegenerative diseases such as Huntington’s 
disease (HD), AD, Amyotrophic lateral sclerosis (ALS) and Spinocerrebellar ataxia (SCA) (Kim 
et al., 2014; Lasagna-Reeves et al., 2016; Lu et al., 2013; Park et al., 2013). However, the 
novel identified genetic targets for disease intervention in Drosophila are required to be 
confirmed by subsequent mammalian studies (Yamamoto et al., 2014). Drosophila eye 
screening was first applied to seek modifiers of Aβ42 toxicity in 2008 (Cao et al., 2008). 
However, in this study, firstly, the authors used constitutive knockout flies, which cannot limit 
gene silencing in eyes and led to numerous lethality. Secondly, they only screened about 2000 
mutants, which covered a small amount of the Drosophila genome. Thirdly, they did not use 
other measurements to confirm the reliability of their screens. Therefore, my collaborators and 
I intended to screen 7593 strains corresponding to 7025 genes using a RNAi library of flies and 
validated the efficiency of Drosophila eye screening in identification of modifiers of Aβ42 toxicity. 
1.4.3 Aims of work 
The aim of this work is to investigate candidate modifiers of Aβ toxicity from GWAS and from a 
Drosophila screen. 
 
In terms of chapter 3 and 4, although GWAS studies have implicated PICALM and BIN1 in AD 
pathology, little is known about their contributions to Aβ pathology in vivo. My work aimed to 
uncover the roles of the Drosophila homologues of PICALM and BIN1, lap and Amph 
respectively, in Aβ pathology. Furthermore, my work explored the molecular mechanisms 
underlying the contributions of lap and Amph to Aβ pathogenesis. 
 
With regard to chapter 5, Drosophila is a powerful model system for rapidly screening 
therapeutic targets in neurodegenerative diseases. However, only one prior study applied this 
to AD research. As this study has several disadvantages, my collaborators and I performed a 
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genome-wide screen using a Drosophila model of AD and aimed to identify novel genetic 
targets for AD treatment. 
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2. Methods 
2.1 Fly strains 
The following fly strains were obtained from the Bloomington Drosophila Stock Center: w
1118
, 
w
Dah
, all UAS-Rab stocks, all UAS lines, unless otherwise stated, UAS-Amph, lap RNAi line 
(TRiP.HMS01939), nSyb-QF2, tubulin-QS (tub-QS), D42-Gal4, Mef2-Gal4 and GSG3285-GS. 
Other stains: Elav-GS was derived from the original elavGS 301.2 line (Osterwalder et al., 
2001) that was kindly given by Dr. H. Tricoire (CNRS); the UAS-Aβ42 stock was gifted from Dr. 
P. Fernandez-Funez (University of Minnesota, Twin Cities, USA); the UAS-cindr line was gifted 
from Dr. H. Stenmark (University of Oslo, Oslo, Norway). The UAS-lap line was generated by 
me. The QUAS-Aβarc line was generated by Dr. T. Niccoli. The UAS-Rab8-HA and 
UAS-Rab11-HA were obtained from the FlyORF. The Amph RNAi (v9264) line and all RNAi 
lines in chapter 5 were obtained from the Vienna Drosophila RNAi Center. 
 
As flies with different genetic backgrounds exhibit nonspecific mutations, all transgenic flies 
are required to backcross with the w
Dah
 stock to guarantee that all transgenic lines have 
uniform genetic backgrounds unless stated. The wild-type white Dahomey (w
Dah
) has been 
captured and maintained in the laboratory since 1970 in population cages with overlapping 
generations. This method of culture keeps the flies outbred and avoids the large reductions in 
lifespan that happens with the methods of fly culture generally used in laboratories. 
Backcrossing ensures that any difference between the mutant and control flies are only 
attributable to the expression of the transgene alone rather than any mutation present in the 
genetic background (Partridge and Gems, 2007). In order to attain this goal, all stocks are 
necessarily backcrossed at least six generations. 
2.2 Fly husbandry and culture 
All stocks were maintained at 18˚C while experimental flies were grown at 25˚C and 65% 
humidity. They were all raised on a 12:12 light: dark cycle and on a standard sugar/yeast (SY) 
medium. The standard SY medium was made by dissolving 15 g agar in 700 ml distilled water 
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and heating the medium until boiling. Then 100 g of autolysed yeast powder and 50 g of sugar 
were added and the medium was boiled again. After this additional 170 ml of distilled water 
were added into the medium that was left to cool down. When temperature of the medium 
reached under 60 ˚C, 30 ml of nipagin (100 g/L) and 3 ml propionic acid (both were anti-fungal 
preservatives) were added. Finally, the medium was dispensed (4 ml per vial) into plastic vials 
and allowed to be left at room temperature overnight before storing at 4 ˚C (Bass et al., 2007; 
Burnett et al., 2011). 
For induction with mifepristone (RU486), 24–48 hr after eclosion, female flies carrying a 
heterozygous copy of elavGS and at least one UAS construct were fed SYA medium 
supplemented with 200 mM mifepristone (RU486) to induce transgene expression. For 
induction with quinic acid (QA), flies were put on food containing 7.5 g of QA per liter. This 
allows for Aβarc expression.  
2.3 Lifespan analysis 
It is necessary for a lifespan analysis to ensure that all flies are born at the same time. For this 
reason, a prevalent lifespan analysis was to allow parental flies to lay eggs less than 24 hours 
on grape juice plates with yeast paste. The grape juice plates are made as follows: 25 g agar 
was dissolved in 500 ml distilled water and boiled. Next 300 ml of red grape juice were added 
and the mixture was heated again. After adding additional 50 ml of distilled water, the medium 
was cooled to below 60 ˚C. To avoid bacterial infection, 21 ml of nipagin (100g/L) were added. 
Eventually, the medium was dispensed into plastic petri dishes and allowed to set at room 
temperature before storing at 4 ˚C. 
 
The eggs collected from the plates were washed with phosphate buffered saline (PBS) 
solution and transferred into falcon tubes. The eggs were washed for several times and then 
20 µl of egg suspension was dispensed into 200 ml glass bottles containing 70 ml SY food 
(~300 eggs per bottle). After eclosion, adults were allowed to mate for 24–48 h. Finally, these 
flies were separated into 10 vials (15 flies per vial). For each genotype and/or experimental 
condition, 10 vials were set up, equaling to 150 flies per genotype/condition. Importantly, flies 
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were tipped to fresh vials of SY food three times a week throughout life. The number of dead 
flies found during each tipping was recorded and accidental escapees were censored from the 
experiment. Data were presented as cumulative survival curves using the Kaplan-Meier 
method, and survival rates were compared between different genotypes or experimental 
conditions using log-rank tests.  
2.4 Negative geotaxis assay 
The locomotor age-related decline is a hallmark of the dysfunctional capacity of flies (Gargano 
et al., 2005; Jones et al., 2009). It was assessed with a negative geotaxis assay. As described 
in a previous article (Niccoli et al., 2016), 45 flies were placed in a glass walled chamber 25 cm 
tall (at least 3 replicates per genotype and/or experimental condition). The chamber was 
divided into the top 5 cm, center 15 cm, and bottom 5 cm. After a recovery of flies for 20 min, 
the chamber was disposed vertically and flies were gently tapped down to the bottom. Then 
flies were free to climb up and their numbers at the top, middle or bottom were scored after 20 
sec. Data were presented as a cumulative graph and a performance index (PI) was calculated 
for each time point and plotted using a formula below. Statistical analysis was evaluated by 
two-ways ANOVA followed by Tukey post-hoc test. 
 
PI =
0.5 ∗ [Number(top) + Number(middle) + Number(bottom) + Number(top) − Number(bottom)]
Number(top) + Number(middle) + Number(bottom)
 
2.5 Generation of transgenic line 
To generate a UAS-lap transgenic line, a 1.4 kb DNA fragment containing the lap A isoform 
was amplified by PCR using primers CACCATGACCATGGCAGGG and 
TTACTGTGCGGCGCCG, gateway cloned into an entry vector and transferred into a pUAST 
vector that was achieved. The UAS-lap construct was transformed into the w
1118
 background. 
This transgene was inserted on chromosome 2 in the attP40 site. The expression of lap was 
confirmed by qPCR and western blotting. To ensure a homogeneous genetic background 
between transgenic lines, UAS-lap was backcrossed to the W
Dah
 stock for six generations. All 
experiments were carried out on mated females, unless otherwise stated. 
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2.6 Quantitative PCR 
Total RNA was extracted from 20-25 fly heads per sample using TRIzol (GIBCO) according to 
the manufacturer’s instructions. The concentration of total RNA purified for each sample was 
measured using an Eppendorf biophotometer. One microgram of total RNA was then 
subjected to DNA digestion using DNase I (Ambion), immediately followed by reverse 
transcription using the SuperScript II system (Invitrogen) with oligo(dT) primers. Quantitative 
PCR was performed using the PRISM 7000 sequence-detection system (Applied Biosystems) 
and SYBR Green (Molecular Probes) by following the manufacturer’s instructions. Each 
sample was analyzed in duplicate and values were presented as the mean of three-four 
independent biological repeats ± SEM. Primers used were: 
lap   GCACTTGGACTATTTGGTGCAC + GCATAAATCGCTCTTGCCATATG 
eIF1A ATCAGCTCCGAGGATGACGC + GCCGAGACAGACGTTCCAGA 
2.7 Co-immunoprecipitation 
Adult fly heads were isolated from W
Dah
 flies. 40 fly heads were cut off with scissors. The 
heads were transferred to a 1.5-mL Eppendorf tube and homogenized in 600 μL of lysis buffer 
[50 mM Tris (pH 7.5), 150 mM NaCl, 0.5% NP-40 (v/v), 0.1 mM MgCl2, 0.1 mM Na3VO4, 5 mM 
NEM, 1:10 dilution of protease inhibitor cocktail (Roche, P8340), 1:100 dilution of phosphatase 
inhibitor cocktail 2 (Sigma) and 1 mM phenylmethylsulfonyl fluoride (PMSF)] and spun at 
13000 rpm (17,949 × g) for 15 min at 4°C. 50 μL of the supernatant was taken for input, while 
200 uL of the remaining supernatant was subjected to IP. The lysates were precleared with 10 
uL of protein G dynabeads (Life Technologies, 10004D) for 10 min at 4°C. 50 uL of the same 
beads were crosslinked with anti-PICALM antibody by 20 mM DMP (dissolved in 0.2 M 
triethanolamine) followed by incubation with the precleared lysates for 1h at 4°C. Anti-PICALM 
beads were collected by a magnetic stand and 200 μL of supernatant was removed with a 
narrow-end pipette. The beads were washed for five times with 1 mL PBS with 0.5% BSA 
(PBSB). Elution of the immuneprecipitated proteins were performed by heating beads at 70°C 
for 5 min with 20 uL 2x SDS sample buffer and 200 mM DTT. The immunoprecipitated proteins 
and beads were magnetically separated and the IP fraction was saved. Input and supernatant 
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were diluted in 2x SDS sample buffer to a 1× final concentration with 200 mM DTT.  
2.8 Western blotting 
15 fly heads were flash frozen in liquid nitrogen, vortexed and separated through a small sieve 
(no. 25, 710 µm, Precision Eforming, LLC). Protein samples were prepared by homogenizing 
in 2x SDS Laemmli sample buffer [4% SDS, 20% glycerol, 120 mM Tris-HCl (pH 6.8), 200 mM 
DTT with bromophenol blue] and boiled at 95°C for 10 min. Samples were separated on 
pre-cast 4%–12% Invitrogen Bis-Tris gels (NP0322) or customized 10% Bis-Tris gels. Then 
samples were blotted onto PVDF (for Atg8 and Grp78) or nitrocellulose membrane (for 
PICALM and VGlut) in Tris-glycine buffer supplemented with 20% methanol. Membranes were 
blocked in 5% milk in TBST (Tris-buffered saline with 0.1% Tween-20) for 1 hr at room 
temperature (RT) and then incubated with primary antibodies overnight at 4°C or 1 hr at RT 
(for Grp78). Primary antibody dilutions used were as follows: anti-PICALM, 1:3,000 (Abcam, 
ab127551); anti-Actin, 1:10,000 (Abcam, ab1801); anti-Atg8, 1:1,000 and anti-VGlut, 1:10,000 
(a gift from Dr A. DiAntonio, Washington University, St. Louis). Secondary antibodies used 
were anti-rabbit and anti-mouse HRP (Abcam, ab6789 and ab6721) at 1:10,000 dilutions for 1 
hr at RT. Bands were visualized with Luminata Forte (Millipore) and imaged with ImageQuant 
LAS4000 (GE Healthcare Life Sciences). Quantification was carried out with ImageQuant 
software. 
2.9 Aβ42 ELISA 
Five fly heads were homogenized in 50 ml GnHCl extraction buffer [5 M guanidinium HCl, 50 
mM HEPES (pH 7.3), 1:10 dilution of protease inhibitor cocktail (Roche, P8340), and 5 mM 
EDTA) and centrifuged at 21,000 x g for 5 min at 4 °C. The cleared supernatant was retained 
as the total fly Aβ42 sample. Aβ42 levels were measured with an ELISA kit (Thermal Fisher, 
KHB3441), according to the manufacturer’s instructions, and total protein levels were 
measured with a Bradford assay (Bio-Rad protein assay reagent). The amount of Aβ42 in each 
sample was expressed as a ratio of the total protein content (pictograms per microgram of total 
protein). Data are expressed as the mean ± SEM obtained from three biological repeats for 
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each genotype. 
2.10 Immunohistochemistry 
Wandering third-instar larvae were dissected in HL3 solution and fixed in Bouin’s fixative (for 
VGlut and GluRII) or 4% PFA (for Amph) for 20 min. Larvae were then rinsed in PBS with 0.2% 
Triton-100 (PBST) and blocked in 5% BSA in PBST for 1 hr at RT. Larvae were then incubated 
with primary antibodies overnight at 4°C and washed in PBST three times. Primary antibody 
dilutions used were as follows: anti-GluRIIA, 1:100 (8B4D2 obtained from the Developmental 
Studies Hybridoma Bank, University of Lowa, Lowa City, IA); anti-VGlut, 1:10,000; 
anti-GluRIIB, 1:2500; anti-GluRIIC, 1: 1000 (a gift from Dr A. DiAntonio, Washington University, 
St. Louis) and anti-Amph, 1: 2500 (a gift from Dr A. Zelhof, Indiana University, Bloomington). 
Secondary antibodies were anti-HRP, 1:200 (Jackson ImmunoResearch, West Grove, PA); 
anti-rabbit Alexa Fluor 568, 1:1000 (Thermal Fisher, A11036) and anti-mouse Alexa Fluor 568, 
1:1000 (Thermal Fisher, A11019), which were incubated for 1 hr at RT. After washing, larvae 
were mounted in Vectashield (Vector Laboratories, Burlingame, CA). 
 
All images were acquired using a Zeiss LSM700 inverted confocal microscope, with the 63x 
objective. The images were shown as maximum intensity projections of the complete Z-stack. 
The 10 µm of stacks were taken from muscles 7 and 6 of segments A2-A4. All images for one 
experiment were taken at the same microscopy settings. The mean fluorescence intensity of 
each slice of the NMJ was measured with ImageJ. Values shown were the averages for 5–10 
NMJ ± SEM. Samples were compared by one-way ANOVA followed by Tukey’s post hoc test. 
2.11 Live imaging 
Heterozygous D42-Gal4 > UAS-iGluSnFR L2 larvae were prepared for live imaging essentially 
as described and imaged on a Zeiss LSM880 airyscan confocal microscope, with the 40x 
objective. We immobilized larvae by gently squeezing them under a cover glass in halocarbon 
oil. Images were collected at a rate of 1 frame/s. A single plane was taken from the ventral 
nerve cord (VNC). All images for one experiment were taken at the same microscopy settings.  
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Imaged iGluSnFR fluorescence intensity was used to calculate spontaneous activity as the 
fractional change in fluorescence intensity and reported as % ΔF/F0. F0 is the minimum 
fluorescence intensity. For each animal only one trial was collected. We imaged one plane of 
focus per animal and drew one ROI to quantify the magnitude of signal fluctuation at each pixel 
over time. Each ROI displayed a local and transient increase in the fluorescence intensity. The 
same size of ROI was analyzed in each field of view. We set the baseline of measurements to 
0. All images for one experiment were taken at the same microscopy settings. Values shown 
were the averages for 5 VNC ± SEM. Samples were compared by one-way ANOVA followed 
by Tukey’s post hoc test. 
2.12 Statistical analysis 
Data were presented as means +SEM. Comparisons were performed using Student’s t-test 
(for two groups), one-way ANOVA followed by Turkey post-hoc test (for more than two groups), 
or two-way ANOVA followed by Turkey post-hoc test (for groups across two variables, with 
multiple comparisons between individual groups). All comparison tests were two-tailed. 
Results with p < 0.05 were considered significant.  
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3. PICALM reduces Aβ42 toxicity by modulating 
glutamate transmission 
3.1 Background  
Genome-wide association studies (GWAS) are a powerful tool to identify numerous unknown 
genetic variants to AD. One of these mutations has been linked to PICALM 
(phosphatidylinositol-binding clathrin assembly protein), which is involved in 
clathrin-dependent endocytosis (Harold et al., 2009; Lambert et al., 2013). PICALM is a 
brain-specific adaptor in humans, and is involved in cargo selection (Tian et al., 2013). It 
physically binds to soluble NSF (N-ethylmaleimide-sensitive factor) attachment protein 
receptors (SNAREs) like VAMP2, VAMP8, RAB5, RAB11 to guide synaptic vesicles (SV) from 
the plasma membrane into endosomes (Koo et al., 2015; Koo et al., 2011; Moreau et al., 2014; 
Zhao et al., 2015b). PICALM expression is decreased in brain samples of AD patients (Ando et 
al., 2013; Parikh et al., 2014). However, the role of PICALM in Alzheimer’s disease remains 
controversial. On one hand, PICALM knockdown reduces Aβ42 generation by limiting APP or 
γ-secretase internalization and promotes tau degradation by triggering autophagy (Kanatsu et 
al., 2014; Moreau et al., 2014; Xiao et al., 2012; Yu et al., 2010). On the other hand, PICALM 
over-expression modulates APP degradation via elevated autophagy and Aβ42 clearance 
through transcytosis (Tian et al., 2013b; Zhao et al., 2015b). Although several studies have 
implicated PICALM in Aβ42 production and turn-over (Xiao et al., 2012), little is known about its 
contribution to the development of AD pathology downstream of Aβ production.  
 
PICALM-mediated endocytosis regulates the cell surface expression of proteins and controls 
protein internalization. Its cargos include the vesicular glutamate transporters (VGlut). 
Glutamate excitotoxicity has long been speculated to play an important role in AD 
development (Abramov et al., 2009; Hynd et al., 2004). Glutamate uptake and release are 
changed in Alzheimer’s disease, giving rise to excess extracellular glutamate (Cummings et al., 
2015; Hefendehl et al., 2016; Li et al., 2009; Talantova et al., 2013).  
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Here I demonstrated that overexpression of the Drosophila PICALM orthologue, lap, alleviated 
Aβ42-induced shortened lifespan and locomotor defects in a Drosophila AD model without 
affecting Aβ42 levels. I then demonstrated that Aβ expression led to the accumulation of 
vesicular glutamate transporters (VGlut) near the presynaptic active zone. Lap directly 
interacted with VGlut and reduced its accumulation back to control levels. Aβ expression also 
elevated glutamate release, while lap expression reduced this excessive glutamate release. 
Therefore, I identified a novel mechanism by which lap could modulate aberrant glutamatergic 
transmission in Alzheimer’s disease, and possibly affect disease development. 
3.2 Results 
3.2.1 Lap reduces Aβ42 toxicity 
To explore the role of PICALM in vivo, I looked at the role that the Drosophila homologue, lap, 
played in the development of Aβ pathology in Drosophila. I used an adult onset model of Aβ 
toxicity expressing two copies of wild type Aβ42 (Casas-Tinto et al., 2011) under the control of 
an inducible pan-neuronal driver (elav-GS). Elav-GS is only induced in the presence of the 
drug RU486 (Osterwalder et al., 2001), which I fed to the flies only after eclosion. This 
restricted expression of Aβ to adult, post-mitotic neurons (Figure 1.2). In all cases these 
Aβ42-expressing flies have a shortened lifespan (compared to the Aβ RU0 condition, the Aβ 
RU200 condition had 42% mean lifespan) and display locomotor deficits from day 14 onwards 
(Figure 3.1), suggesting that wild type Aβ42 is toxic to adult neurons. Moreover, I generated the 
UAS-lap line and this line showed a marked increase in lap expression (Figure 3.1A, relative to 
elF1A; elavGS > lap RU0: 100 + 13.59 %, n = 3; elavGS > lap RU200: 256.8 + 7.14 %, n = 3. p 
< 0.01, Student’s t-test). eIF1A is used as a reference gene for our experiments since it 
showed the least fluctuation in our Aβ expressing flies when tested together with a panel of 
reference genes (Ling and Salvaterra, 2011; Niccoli et al., 2016). I found that 
co-overexpression of lap attenuated Aβ42 toxicity. Comparing to Aβ42 expression, 
co-expression of Aβ42 and lap led to lifespan extension of 12% (Figure 3.1B, mean lifespan, Aβ 
RU0: 100 %; Aβ RU200: 42 %; Aβ lap RU0: 100 %; Aβ lap RU200: 47 %, n > 120 per condition. 
p was shown in Figure 3.1B, log-rank test) and a small but significant improvement in 
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locomotor performance (Figure 3.1C and Table 3.1, PI, day 7, Aβ RU0: 89.67 + 0.36 %; Aβ 
RU200: 94.13 + 1.26 %; Aβ lap RU0: 93.8 + 0.56 %; Aβ lap RU200: 89.01 + 0.77 %; day 10, 
Aβ RU0: 84.27 + 0.47 %; Aβ RU200: 87.05 + 0.95 %; Aβ lap RU0: 89.31 + 2.12 %; Aβ lap 
RU200: 82.71 + 0.89 %; day 14, Aβ RU0: 90.77 + 1.96 %; Aβ RU200: 72.71 + 0.69 %; Aβ lap 
RU0: 85.38 + 3.26 %; Aβ lap RU200: 83.56 + 2.60 %; day 18, Aβ RU0: 91.07 + 1.13 %; Aβ 
RU200: 54.40 + 2.20 %; Aβ lap RU0: 83.21 + 0.98 %; Aβ lap RU200: 70.79 + 3.23 %; day 21, 
Aβ RU0: 82.20 + 1.78 %; Aβ RU200: 35.29 + 4.49 %; Aβ lap RU0: 78.09 + 4.58 %; Aβ lap 
RU200: 52.54 + 2.90 %; day 25, Aβ RU0: 84.80 + 1.77 %; Aβ RU200: 18.92 + 0.71 %; Aβ lap 
RU0: 80.92 + 1.76 %; Aβ lap RU200: 30.56 + 1.43 %, n = 3 per condition. Interaction of time 
and genotype, p < 0.0001; time, p < 0.0001, genotype, p < 0.0001, two-ways ANOVA), without 
affecting Aβ42 levels (Figure 3.1F, Aβ RU0: 4.02 + 0.01 pg/ug protein; Aβ RU200: 58.54 + 8.14 
pg/ug protein; Aβ lap RU0: 3.01 + 0.66 pg/ug protein; Aβ lap RU200: 59.57 + 7.25 pg/ug 
protein, n = 3 per condition. p < 0.0001; one-way ANOVA). In contrast, inhibition of lap, using 
lap RNAi, enhanced Aβ42 toxicity leading to worsening of the mean lifespan from 43% to 38% 
(Figure 3.1D, mean lifespan, Aβ RU0: 100 %; Aβ RU200: 42 %; Aβ lap RNAi RU0: 100 %; Aβ 
lap RNAi RU200: 47 %, n > 120 per condition. p was shown in Figure 3.1D, log-rank test). In 
this case, I backcrossed the lap RNAi line with the w
+
v
-
 W
Dah
 stock for six generations and then 
crossed it with the w
-
v
+
 W
Dah
 stock to remove different genetic backgrounds. However, I still 
see a difference in lifespan between the uninduced control of Aβ and that of Aβ and lap RNAi. 
As the attP insertion site of Trip lines has no effect on the expression of endogenous genes, I 
supposed the most likely explanation for the difference between the Aβ RU0 and Aβ lap RU0 
condition is therefore RNAi leakage. The RNAi leakage is often observed in the Trip lines and 
this leakage might lead to that Aβ lap RNAi RU0 group had longer lifespan. Additionally, the 
effect of RNAi leakage was seen in locomotion because the Aβ RU0 group had better 
locomotor performance than the Aβ lap RNAi RU0 group. Therefore, although the 
co-expression of Aβ and lap RNAi worsened climbing defects, it is unclear whether inhibition of 
lap affected climbing defects of Aβ-expressing flies (Figure 3.1E and Table 3.2, PI, day 7, Aβ 
RU0: 89.67 + 0.36 %; Aβ RU200: 94.13 + 1.26 %; Aβ lap RNAi RU0: 63.88 + 4.3 %; Aβ lap 
RNAi RU200: 44.17 + 9.1 %; day 10, Aβ RU0: 84.27 + 0.47 %; Aβ RU200: 87.05 + 0.95 %; Aβ 
lap RNAi RU0: 50.56 + 0.74 %; Aβ lap RNAi RU200: 41.67 + 0.48 %; day 14, Aβ RU0: 90.77 + 
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1.96 %; Aβ RU200: 72.71 + 0.69 %; Aβ lap RNAi RU0: 50.29 + 0.74 %; Aβ lap RNAi RU200: 
21.94 + 2 %; day 18, Aβ RU0: 91.07 + 1.13 %; Aβ RU200: 54.40 + 2.20 %; Aβ lap RNAi RU0: 
43.78 + 2.79 %; Aβ lap RNAi RU200: 0 + 0 %; day 21, Aβ RU0: 82.20 + 1.78 %; Aβ RU200: 
35.29 + 4.49 %; Aβ lap RNAi RU0: 43.72 + 1.51 %; Aβ lap RNAi RU200: 0 + 0 %; day 25, Aβ 
RU0: 84.80 + 1.77 %; Aβ RU200: 18.92 + 0.71 %; Aβ lap RNAi RU0: 37.29 + 3.39 %; Aβ lap 
RNAi RU200: 0 + 0 %, n = 3 per condition. interaction of time and genotype, p < 0.0001; time, 
p < 0.0001, genotype, p < 0.0001, two-ways ANOVA). 
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                           (F) 
Figure 3.1 Lap alleviates Aβ42 toxicity. 
(A) Lap mRNA levels in heads of 7-day-old flies expressing lap (RU200) or not in neurons (RU0), measured by qPCR 
(relative to eIF1A), plotted as means ± SEM. Genotypes: UAS-lap; elavGS. Statistical significance was determined by 
Student’s t-test, **p < 0.01. 
(B) Survival curves of flies expressing Aβ with lap or not in adult neurons (RU200) and uninduced controls (RU0). 
Expression of Aβ in the neurons shortened lifespan, but lap expression extended lifespan, n > 120. Aβ RU0 vs Aβ 
RU200, p < 0.0001; Aβ RU0 vs Aβ lap RU0, n.s., not significant; Aβ lap RU0 vs Aβ lap RU200, p < 0.0001; Aβ RU200 
vs Aβ lap RU200, p < 0.0001, determined by log-rank test. 
(C) Locomotor performance index of flies of the same genotypes. Aβ caused climbing defects from day 14 onwards, 
but expression of lap resulted in a small but significant improvement in locomotor performance compared to Aβ alone 
(Aβ RU200 vs Aβ lap RU200), n = 3 (50 animals per condition). Interaction of time and genotype, p < 0.0001; time, p < 
0.0001, genotype, p < 0.0001, determined by two-ways ANOVA followed by Tukey’s post-hoc test. Statistical analyses 
were shown in Table 3.1 
(D) Adult survival of flies harboring Aβ with or without lap RNAi in adult neurons (RU200) and uninduced controls 
(RU0). Inhibition of lap reduced longevity of Aβ-expressing flies, n > 120. Aβ RU0 vs Aβ RU200, p < 0.0001; Aβ RU0 
vs Aβ lap RU0, p < 0.0001; Aβ lap RU0 vs Aβ lap RU200, p < 0.0001; Aβ RU200 vs Aβ lap RU200, p < 0.0001, 
determined by log-rank test. 
(E) Climbing index of flies of the same genotypes, n = 3 (50 animals per condition). Interaction of time and genotype, p 
< 0.0001; time, p < 0.0001, genotype, p < 0.0001, determined by two-ways ANOVA followed by Tukey’s post-hoc test. 
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Statistical analyses were shown in Table 3.2 
(F) Aβ42 protein levels, measured by ELISA, in the heads of 21-day-old flies expressing Aβ or Aβ and lap in neurons 
(RU200) and uninduced controls (RU0). Means ± SEM, n = 3. ****p < 0.0001, determined by one way ANOVA; Aβ RU0 
vs Aβ RU200, ***p < 0.001; Aβ RU0 vs Aβ lap RU0, n.s., not significant; Aβ lap RU0 vs Aβ lap RU200, ***p < 0.001; Aβ 
RU200 vs Aβ lap RU200, n.s., not significant, comparison by Tukey’s post-hoc test. 
 
Table 3.1 Statistical summary of locomotor performance index of flies expressing Aβ with or without lap 
Day 7 Aβ RU0 Aβ RU200 Aβ lap RU0 Aβ lap RU200 
Aβ RU0  n.s. n.s. n.s. 
Aβ RU200  n.s. n.s. 
Aβ lap RU0  n.s. 
Aβ lap RU200  
Day 10 Aβ RU0 Aβ RU200 Aβ lap RU0 Aβ lap RU200 
Aβ RU0  n.s. n.s. n.s. 
Aβ RU200  n.s. n.s. 
Aβ lap RU0  n.s. 
Aβ lap RU200  
Day 14 Aβ RU0 Aβ RU200 Aβ lap RU0 Aβ lap RU200 
Aβ RU0  < 0.0001 n.s. n.s. 
Aβ RU200  < 0.001 n.s. 
Aβ lap RU0  < 0.01 
Aβ lap RU200  
Day 18 Aβ RU0 Aβ RU200 Aβ lap RU0 Aβ lap RU200 
Aβ RU0  < 0.0001 n.s. < 0.0001 
Aβ RU200  < 0.0001 < 0.0001 
Aβ lap RU0  < 0.001 
Aβ lap RU200  
Day 21 Aβ RU0 Aβ RU200 Aβ lap RU0 Aβ lap RU200 
Aβ RU0  < 0.0001 n.s. < 0.0001 
 
 
 
 
 
 
 
 
 
 
 
 
 59 
 
Aβ RU200  < 0.0001 < 0.0001 
Aβ lap RU0  < 0.0001 
Aβ lap RU200  
Day 25 Aβ RU0 Aβ RU200 Aβ lap RU0 Aβ lap RU200 
Aβ RU0  < 0.0001 n.s. < 0.0001 
Aβ RU200  < 0.0001 < 0.01 
Aβ lap RU0  < 0.0001 
Aβ lap RU200  
 
Table 3.2 Statistical summary of locomotor performance index of flies expressing Aβ with or without lap RNAi 
Day 7 Aβ RU0 Aβ RU200 Aβ lap RNAi RU0 Aβ lap RNAi RU200 
Aβ RU0  n.s. < 0.0001 < 0.0001 
Aβ RU200  < 0.0001 < 0.0001 
Aβ lap RNAi RU0  < 0.0001 
Aβ lap RNAi RU200  
Day 10 Aβ RU0 Aβ RU200 Aβ lap RNAi RU0 Aβ lap RNAi RU200 
Aβ RU0  n.s. < 0.0001 < 0.0001 
Aβ RU200  < 0.0001 < 0.0001 
Aβ lap RNAi RU0  n.s. 
Aβ lap RNAi RU200  
Day 14 Aβ RU0 Aβ RU200 Aβ lap RNAi RU0 Aβ lap RNAi RU200 
Aβ RU0  < 0.0001 < 0.0001 < 0.0001 
Aβ RU200  < 0.0001 < 0.0001 
Aβ lap RNAi RU0  < 0.0001 
Aβ lap RNAi RU200  
Day 18 Aβ RU0 Aβ RU200 Aβ lap RNAi RU0 Aβ lap RNAi RU200 
Aβ RU0  < 0.0001 < 0.0001 < 0.0001 
Aβ RU200  < 0.0001 < 0.0001 
Aβ lap RNAi RU0  < 0.0001 
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Aβ lap RNAi RU200  
Day 21 Aβ RU0 Aβ RU200 Aβ lap RNAi RU0 Aβ lap RNAi RU200 
Aβ RU0  < 0.0001 < 0.0001 < 0.0001 
Aβ RU200  < 0.0001 < 0.0001 
Aβ lap RNAi RU0  < 0.0001 
Aβ lap RNAi RU200  
Day 25 Aβ RU0 Aβ RU200 Aβ lap RNAi RU0 Aβ lap RNAi RU200 
Aβ RU0  < 0.0001 < 0.0001 < 0.0001 
Aβ RU200  < 0.0001 < 0.0001 
Aβ lap RNAi RU0  < 0.0001 
Aβ lap RNAi RU200  
3.2.2 Lap regulates longevity 
As PICALM has been suggested to influence ageing (Piaceri et al., 2011; Ponomareva et al., 
2017), I analyzed the effect of lap on ageing, I over-expressed and down-regulated lap in 
Drosophila neurons through feeding RU486. Until now, addition of RU486 has not been found 
to affect lifespan in previous studies, but there is a possible concern. Here I found that lap 
over-expression shortened lifespan of 9% (Figure 3.2A, elavGS > lap RU0: 100 %; elavGS > 
lap RU200: 90 %, n > 120 per condition. p < 0.0001, log-rank test), while lap RNAi extended 
lifespan of 9%. This indicated that the inhibition of lap expression was neuroprotective in 
ageing (Figure 3.2B, elavGS > lap RNAi RU0: 100 %; elavGS > lap RNAi RU200: 110 %, n > 
120 per condition. p < 0.0001, log-rank test). So the neuroprotective effect of lap 
over-expression was specific to Aβ toxicity and not due to a broader effect on ageing. As 
glutamate neurotransmission declines with age (Segovia et al., 2001), it is possible that 
increased glutamate transmission, probably associated with downregulation of lap, might be 
crucial in delaying ageing. I did not investigate the effect of lap alone on locomotor 
performance, so I merely concluded that, from lifespan analysis, the benefit of lap is 
dependent on modulating Aβ toxicity. Collectively, my data is in supports that lap 
over-expression attenuates Aβ-induced phenotypes observed. 
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(A) 
 
(B) 
Figure 3.2 Inhibition of lap in neurons increases longevity. (A-B) Adult survival curves of lap over-expressing or lap 
RNAi flies in adult neurons (+RU) and uninduced controls (-RU), n > 120. p < 0.0001, by log-rank test.  
3.2.3 Lap does not alter UPR and autophagy 
I sought to uncover the molecular mechanism by which lap reduced Aβ42 toxicity. Aβ has been 
reported to impair autophagy, UPR and proteostasis (Niccoli et al., 2016). I first investigated 
whether Aβ affected autophagy, as assayed by Atg8. Atg8 is the Drosophila homologue of LC3. 
There are two forms of Atg8: Atg8-I is a 13.6 kD protein and Atg8-II is a ~12 kD protein. During 
autophagosome formation, cytosolic Atg8-I is converted to membrane-bound Atg8-II. As 
Atg8-II is an active form of autophagy, an increase in the ratio of Atg8-II/Atg8-I is an indicator of 
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autophagic induction (Kabeya et al., 2000; Mizushima et al., 1998). The ratio of Atg8-II/Atg8-I 
was not altered upon Aβ expression, indicating that autophagy activity was not impaired in the 
Aβ42-expressing flies (Figure 3.3A). In a previous study (Moreau et al., 2014), lap was shown 
to be a negative regulator of Atg8-II expression. However, I did not find that lap expression 
altered Atg8-II levels (Figure 3.3A, Aβ RU0: 100 + 20.63 %; Aβ RU200: 83.58 + 11.54 %; Aβ 
lap RU0: 98.11 + 8.07 %; Aβ lap RU200: 101.5 + 1.11 %, n = 3 per condition. p > 0.05, 
one-way ANOVA). 
  
Next, I analyzed the influence of Aβ expression on the UPR. BiP (Grp78) is a negative 
regulator of the UPR. Its expression has been found to elevate upon Aβ expression, indicating 
UPR activity is increased upon Aβ expression (Ma et al., 2013b; (Niccoli et al., 2016). 
Unexpectedly, BiP levels were down-regulated in my Aβ42-expressing flies and this was not 
reversed back upon lap expression (Figure 3.3B, Aβ RU0: 100 + 13.93 %; Aβ RU200: 45.62 + 
5.74 %; Aβ lap RU0: 102.4 + 23.74 %; Aβ lap RU200: 46.10 + 6.13 %, n = 3 per condition. p < 
0.001, one-way ANOVA). Therefore, my results found that Aβ expression inhibited BiP 
expression. However, a reduction in BiP protein could lift the block of UPR inhibition and 
therefore induce UPR activation through a negative feedback. So it is not a good marker of 
UPR activity. It is still unknown that UPR is activated or inhibited upon Aβ expression. My 
results merely showed that the neuroprotective effect of lap was independent of UPR activity.  
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(B) 
Figure 3.3 Lap’s neuroprotective effect is independent of autophagy and UPR. 
(A) Western blot of Atg8 in 21-day-old flies of the same genotypes, plotted below as means ± SEM (n = 3). Aβ does not 
affect Atg8 levels. Genotypes: UAS-Aβ; elavGS, UAS-Aβ/UAS-lap; elavGS. n.s., not significant, determined by one- 
way ANOVA.  
(B) Western blot of Grp78 in 21-day-old flies of the same genotypes, plotted below as means ± SEM (n = 3). The 
image is a representative gel of the same samples. Genotypes are above. ***p < 0.001, determined by one-way 
ANOVA; Aβ RU0 vs Aβ RU200, *p < 0.01; Aβ RU0 vs Aβ lap RU0, n.s., not significant; Aβ lap RU0 vs Aβ lap RU200, 
*p < 0.01; Aβ RU200 vs Aβ lap RU200, n.s., not significant, comparison by Tukey’s post-hoc test. 
3.2.4 Lap mediates VGlut localization 
As noted above, PICALM is involved in clathrin-mediated endocytosis (Bao et al., 2005), which 
is disrupted by Aβ oligomers (Treusch et al., 2011). Clathrin-mediated endocytosis is crucial for 
either sending misfolded or toxic proteins for degradation or regulating the cell surface 
expression of proteins. Given that lap has been shown to bind to vesicular glutamate 
transporters (VGlut) (Vanlandingham et al., 2014), I next investigated whether lap affected the 
internalization of VGlut. I confirmed that lap directly interacted with VGlut by 
co-immunoprecipitation (Figure 3.4A). Then I measured the total expression of VGlut in 
Drosophila’s brains and its expression did not change. Given that the total expression of VGlut 
in brains might not reflect the expression of VGlut in neurons, it was difficult to conclude that 
lap did not regulate VGlut expression in neurons (Figure 3.4B, Aβ RU0: 100 + 12.85 %; Aβ 
RU200: 98.44 + 18.78 %; Aβ lap RU0: 96.88 + 11.47 %; Aβ lap RU200: 111.16 + 18.94 %, n = 
3 per condition. p > 0.05, one-way ANOVA). I then examined whether this interaction mediated 
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VGlut distribution, because defects in endocytic trafficking have been shown to maintain 
receptors on the plasma membrane (Treusch et al., 2011). As Drosophila fly brains have a high 
density of neurons, it is difficult to monitor individual synapses. I therefore turned to larval 
neuromuscular junctions (NMJ), which provide an excellent model system for monitoring 
individual synapses, and are extensively used to analyze cellular and molecular mechanisms 
of protein localization and synaptic neurotransmission (Keshishian et al., 1996). Total number 
of synaptic boutons is markedly reduced at motor neurons upon expression of Aβ42, indicating 
that expression of Aβ42 leads to changes of the morphology of NMJ (Mhatre et al., 2014). I 
expressed Aβ42 and lap in motor neurons using D42-Gal4, and found that VGlut was 
abnormally accumulated near the presynaptic active zone upon Aβ42 expression and this 
accumulation was abrogated by lap over-expression (Figure 3.4C, D42: 100 + 20.10 %, n = 10; 
D42 > Aβ: 181 + 21.73 %, n = 10; D42 > lap: 113.2 + 18.26 %, n = 10; D42 > Aβ lap: 93.36 + 
26.67, n = 8. p < 0.05; one-way ANOVA), suggesting that Aβ42 expression affects 
glutamatergic synaptic transmission and this is modulated by lap over-expression. 
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(C) 
Figure 3.4 Lap reduces Aβ-induced accumulation of VGlut at the NMJ. 
(A) Western blot of lap and VGlut on a PICALM pull-down showing co-IP of VGlut both in induced (RU200) and 
un-induced (RU0) flies. Inputs were samples before the IP and IgG control was a beads-only pull-down. 
(B) Western blot of VGlut levels in heads of 21-day-old flies, plotted below as means ± SEM, n = 3. The image was a 
representative gel of the same samples. Genotypes: UAS-Aβ; elavGS, UAS-Aβ/UAS-lap; elavGS. n.s., not significant, 
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determined by one-way ANOVA.   
(C) Confocal images of the NMJ of wandering third-instar larvae expressing Aβ, lap or Aβ and lap, driven by D42-Gal4. 
Fluorescence intensity scores were plotted as means ± SEM, n > 8. Genotypes: D42-Gal4, UAS-Aβ; D42-Gal4, 
UAS-lap; D42-Gal4, UAS-Aβ/UAS-lap; D42-Gal4. *p < 0.05, determined by one-way ANOVA; control (D42-Gal4) vs 
Aβ, *p < 0.05; control vs lap, n.s., not significant; lap vs Aβ lap, n.s., not significant; Aβ vs Aβ lap, *p < 0.05, 
comparison by Tukey’s post-hoc test. Scale bar, 10 μm. 
3.2.5 Lap regulates glutamate release 
Alzheimer’s disease has been found to be associated with glutamate excitotoxicity (Abramov 
et al., 2009; Hynd et al., 2004; Ping et al., 2015). This was attributed to Aβ-induced impairment 
of glutamate uptake, giving rise to excess extracellular glutamate (Li et al., 2009; Talantova et 
al., 2013). Here I used the fluorescent extracellular glutamate reporter iGluSnFR to detect 
extracellular glutamate levels (Marvin et al., 2013; Stork et al., 2014). iGluSnFR is a genetically 
encoded glutamate indicator which composed of a Escherichia coli GltI protein and a circularly 
permutated (cp) GFP. When glutamate binds to the Gltl protein, the Gltl protein changes its 
conformation and therefore the coupled cpGFP produces a fluorescence increase. iGluSnFR 
can detect 4 uM of glutamate. I expressed UAS-iGluSnFR in motor neurons of intact L2 larvae 
using D42-Gal4 and observed spontaneous, local bursts of fluorescence in the neuropil, and 
coordinated waves of activity running along the anterior-posterior axis associated with larval 
crawling (Movie 1, Figure 3.5A, B, F, G, H and I). Co-expression of iGluSnFR and Aβ revealed 
an increase in glutamate responsive fluorescence and number of glutamate response in the 
neuropil, but not the duration of each glutamate response (Movie 2, Figure 3.5A, C, F, G, H 
and I, average response time, D42: 15.41 + 1.22 s; D42 > Aβ: 12.97 + 1.04 s; D42 > lap: 14.5 
+ 0.89 s; D42 > Aβ lap: 11.92 + 1.17 s, n = 5 per condition. p < 0.0001; one-way ANOVA), 
which was consistent with a murine study (Hefendehl et al., 2016). Lap expression reduced the 
increase in glutamate responsive fluorescence (Movie 3 and 4, Figure 3.5A, E and F, average 
response, D42: 12.34 + 1.26 %; D42 > Aβ: 47.52 + 3.23 %; D42 > lap: 19.82 + 1.25 %; D42 > 
Aβ lap: 13.93 + 1.81 %, n = 5 per condition. p < 0.0001; one-way ANOVA) and total area under 
the curve describing the glutamate response back to control levels (Figure 3.5A, E and G, total 
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areal under response, D42: 39.56 + 4.23; D42 > Aβ: 172 + 17.66; D42 > lap: 75.34 + 6.01; 
D42 > Aβ lap: 76.66 + 8.51, n = 5 per condition. p < 0.0001; one-way ANOVA). However, lap 
expression did not affect the increased number of glutamate release events upon Aβ 
expression (Movie 3 and 4, Figure 3.5A, E and H, average number of response, D42: 4.2 + 
0.58; D42 > Aβ: 30 + 2.3; D42 > lap: 31.8 + 1.86; D42 > Aβ lap: 26.6 + 2.16, n = 5 per condition. 
p < 0.0001; one-way ANOVA). Collectively, my work suggested that Aβ might enhance 
glutamate release due to the increased accumulation of VGlut. Lap reduced glutamate release 
due to the decreased accumulation of VGlut. 
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                  (F)                                      (G) 
 
(H)                                      (I) 
Figure 3.5 Lap decreases excess glutamate release upon Aβ expression. 
(A) Confocal time-lapse analysis of intact L2 larvae. Neuronally expressed iGluSnFR shows local and transient 
increases in fluorescence reflecting the release of the neurotransmitter glutamate. The image is a representative burst 
of the movie. Genotypes: D42-Gal4/UAS-iGluSnFR, UAS-Aβ; D42-Gal4/UAS-iGluSnFR, UAS-lap; 
D42-Gal4/UAS-iGluSnFR, UAS-Aβ/UAS-lap; D42-Gal4/UAS-iGluSnFR. Scale bar, 20 μm. 
(B-E) The respective trace of iGluSnFR fluorescence changes displays the spontaneous activity in the neuropil. 
Fluorescence signals are normalized to minimum fluorescence in each trace. Genotypes are as above. 
(F) Quantification of the percent change of fluorescence in the neuropil of L2 larvae expressing Aβ, lap or Aβ and lap, 
driven by D42-Gal4, plotted as means ± SEM, n = 5. Genotypes are as above. ****p < 0.0001, determined by one-way 
ANOVA; control (D42-Gal4) vs Aβ, ****p < 0.0001; control vs lap, n.s., not significant; lap vs Aβ lap, n.s., not significant; 
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Aβ vs Aβ lap, ****p < 0.0001, comparison by Tukey’s post-hoc test.  
(G) Quantification of the area under the response in the neuropil of L2 larvae expressing Aβ, lap or Aβ and lap, driven 
by D42-Gal4, plotted as means ± SEM, n = 5. Genotypes are as above. ****p < 0.0001, determined by one-way 
ANOVA; control (D42-Gal4) vs Aβ, ****p < 0.0001; control vs lap, n.s., not significant; lap vs Aβ lap, n.s., not significant; 
Aβ vs Aβ lap, ****p < 0.0001, comparison by Tukey’s post-hoc test. 
(H) Quantification of the number of the response in the neuropil of L2 larvae expressing Aβ, lap or Aβ and lap, driven 
by D42-Gal4, plotted as means ± SEM, n = 5. Genotypes are as above. ****p < 0.0001, determined by one-way 
ANOVA; control (D42-Gal4) vs Aβ, ****p < 0.0001; control vs lap, ****p < 0.0001; lap vs Aβ lap, n.s., not significant; Aβ 
vs Aβ lap, n.s., not significant, comparison by Tukey’s post-hoc test.  
(I) Quantification of the duration of the glutamate response in the neuropil of L2 larvae expressing Aβ, lap or Aβ and 
lap, driven by D42-Gal4, plotted as means ± SEM, n = 5. Genotypes are as above. n.s., not significant, determined by 
one-way ANOVA. 
3.2.6 Lap in glia is possibly involved in Aβ42 pathology 
Glial cells were previously reported to be abnormally activated in AD (Ando et al., 2013; Parikh 
et al., 2014). Moreover, PICALM is abundant in glial and endothelial cells (Baig et al., 2010). 
However, the role of lap in glial cells remains elusive. To this end, I used a model developed in 
the lab where Aβarc was under the control of Q expression system. The Q expression system 
consists of two qa genes (QF and QS). QF is a transcriptional activator that binds to the 
promoter QUAS. QS is a repressor to QF. The repression of QF by QS is liberated by quinic 
acid (Potter et al., 2010). In our QUAS-Aβarc line, QUAS is fused with Aβarc and driven by a 
neuronal driver (Syn-QF2). Syn-QF2 is inhibited by QS expressed from a ubiquitous promoter 
(Tub-QS). QS is blocked by the chemical quinic acid thus relieving its inhibition and allowing 
activation of the QF2 driver. Lap expression, on the other hand, was regulated by a 
glial-specific geneswitch driver (GSG3285-GS) and activated by RU486. Therefore, this novel 
AD model allows Aβarc expression in neurons and concomitant lap expression in glial cells 
(Figure 3.6A). Aβarc carries a mutation associated with familial AD. This mutation is thought to 
enhance Aβ42 fibrillation and toxicity. Therefore, although the Q system failed to induce a 
robust expression of Aβarc (Figure 3.6D, Aβ -QA -RU: 11.64 + 0.77 pg/ug protein; Aβ -QA +RU: 
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9.96 + 0.24 pg/ug protein; Aβ lap -QA -RU: 10.6 + 0.6 pg/ug protein; Aβ lap -QA +RU: 12.33 + 
0.61 pg/ug protein; Aβ +QA -RU: 13.37 + 0.81 pg/ug protein; Aβ +QA +RU: 15.96 + 0.22 pg/ug 
protein; Aβ lap +QA -RU: 15.19 + 2.47 pg/ug protein; Aβ lap +QA +RU: 16.3 + 1.06 pg/ug 
protein, n = 3 per condition; p < 0. 01; one-way ANOVA), the QUAS-Aβarc flies still displayed 
reduced lifespan and progressive impairment in climbing performance (Aβ -QA -RU vs Aβ +QA 
-RU and Aβ -QA +RU vs Aβ +QA +RU) (Figure 3.6B and C). This confirmed that this model is 
useful to investigate the role of glial cells in AD pathogenesis. Notably, lap over-expression 
significantly increased longevity of Aβarc-expressing flies. However, the presence of the lap 
construct (Aβ lap +QA -RU) also increased longevity compared to expression of the 
glial-specific drive alone (Aβ +QA –RU and Aβ +QA +RU) (Figure 3.6B, mean lifespan, Aβ -QA 
-RU: 100 %; Aβ -QA +RU: 100 %; Aβ lap -QA -RU: 100 %; Aβ lap -QA +RU: 100 %; Aβ +QA 
-RU: 60 %; Aβ +QA +RU: 53 %; Aβ lap +QA -RU: 68 %; Aβ lap +QA +RU: 69 %, n > 120 per 
condition; p was shown in Figure 3.6B, log-rank test). Moreover, although lap over-expression 
attenuated locomotor defects of Aβarc-expressing flies, its corresponding uninduced control 
(Aβ lap -QA +RU) also improved age-related locomotor defects compared to other uninduced 
controls (Aβ-QA –RU; Aβ -QA +RU and Aβ lap -QA -RU) (Figure 3.6C, PI, day 7, Aβ -QA -RU: 
93.46 + 1.59 %; Aβ -QA +RU: 96.03 + 0.73 %; Aβ lap -QA -RU: 92.16 + 3.54 %; Aβ lap -QA 
+RU: 94.04 + 1.99 %; Aβ +QA -RU: 96.81 + 1.16 %; Aβ +QA +RU: 93.5 + 0.52 %; Aβ lap +QA 
-RU: 93.49 + 1.71 %; Aβ lap +QA +RU: 94.95 + 1.43 %; day 10, Aβ -QA -RU: 91.52 + 1.6 %; 
Aβ -QA +RU: 90.52 + 0.5 %; Aβ lap -QA -RU: 96.08 + 0.98 %; Aβ lap -QA +RU: 96.38 + 1.92 %; 
Aβ +QA -RU: 78.22 + 2.12 %; Aβ +QA +RU: 88.24 + 1.14 %; Aβ lap +QA -RU: 88.87 + 2.06 %; 
Aβ lap +QA +RU: 86.19 + 2.26 %; day 14, Aβ -QA -RU: 87.04 + 2.33 %; Aβ -QA +RU: 87.8 + 
1.66 %; Aβ lap -QA -RU: 97.06 + 0 %; Aβ lap -QA +RU: 92.42 + 0.76 %; Aβ +QA -RU: 79.21 + 
2.34 %; Aβ +QA +RU: 84.96 + 1.5 %; Aβ lap +QA -RU: 85.42 + 2.73 %; Aβ lap +QA +RU: 
93.43 + 0.51 %; day 18, Aβ -QA -RU: 80.86 + 7.12 %; Aβ -QA +RU: 81.79 + 4.29 %; Aβ lap 
-QA -RU: 82.35 + 3.4 %; Aβ lap -QA +RU: 91.67 + 3.33 %; Aβ +QA -RU: 71.54 + 1.97 %; Aβ 
+QA +RU: 74.54 + 1.04 %; Aβ lap +QA -RU: 84.06 + 1.71 %; Aβ lap +QA +RU: 90.86 + 2.85 %; 
day 21, Aβ -QA -RU: 70.99 + 1.24 %; Aβ -QA +RU: 73.4 + 1.6 %; Aβ lap -QA -RU: 71.88 + 
3.13 %; Aβ lap -QA +RU: 89.17 + 2.21 %; Aβ +QA -RU: 53.78 + 2.92 %; Aβ +QA +RU: 55.86 + 
2.27 %; Aβ lap +QA -RU: 55.09 + 2.02 %; Aβ lap +QA +RU: 73.89 + 1.86 %; day 25, Aβ -QA 
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-RU: 67.31 + 5.88 %; Aβ -QA +RU: 66.67 + 3.7 %; Aβ lap -QA -RU: 66.67 + 2.08 %; Aβ lap -QA 
+RU: 78.33 + 1.67 %; Aβ +QA -RU: 30.21 + 2.13 %; Aβ +QA +RU: 46 + 4.32 %; Aβ lap +QA 
-RU: 50.98 + 5.12 %; Aβ lap +QA +RU: 68.18 + 1.31 %; day 28, Aβ -QA -RU: 62.83 + 0.59 %; 
Aβ -QA +RU: 60.21 + 1.44 %; Aβ lap -QA -RU: 59.38 + 5.41 %; Aβ lap -QA +RU: 65.83 + 
5.47 %; Aβ +QA -RU: 19.17 + 2.73 %; Aβ +QA +RU: 28.97 + 4.68 %; Aβ lap +QA -RU: 29.17 + 
3.65 %; Aβ lap +QA +RU: 43.33 + 3.63 %; day 31, Aβ -QA -RU: 60.33 + 2.85 %; Aβ -QA +RU: 
55.69 + 0.86 %; Aβ lap -QA -RU: 64.58 + 2.76 %; Aβ lap -QA +RU: 65 + 2.89 %; Aβ +QA -RU: 
22.99 + 3.04 %; Aβ +QA +RU: 31.07 + 2.33 %; Aβ lap +QA -RU: 26.67 + 2.55 %; Aβ lap +QA 
+RU: 40.15 + 4.61 %; day 36, Aβ -QA -RU: 41.28 + 1.48 %; Aβ -QA +RU: 36.32 + 1.34 %; Aβ 
lap -QA -RU: 27.78 + 5.56 %; Aβ lap -QA +RU: 47.5 + 2.89 %; Aβ +QA -RU: 8.33 + 2.73 %; Aβ 
+QA +RU: 15.15 + 2 %; Aβ lap +QA -RU: 11.54 + 5.09 %; Aβ lap +QA +RU: 12.5 + 6.37 %, n = 
3 per condition. Interaction of time and genotype, p < 0.0001; time, p < 0.0001, genotype, p < 
0.0001, two-ways ANOVA). Therefore, I cannot conclude that lap in glial cells diminished Aβ42 
toxicity. It is still unclear the contribution of glial lap to AD progression.  
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                           (D) 
Figure 3.6 Lap in glia possibly suppresses Aβarc toxicity. 
(A) Schematic of the Q repressible binary expression system. In the absence of the transcription factor, Syn-QF, the 
QUAS-Aβarc does not express. When Syn-QF and QUAS-Aβarc transgenes are present in neurons where QF is 
expressed, QF binds to QUAS and activates expression of Aβarc. When Tub-QS, Syn-QF, and QUAS-Aβarc transgenes 
are present in neurons and both QF and QS are active, QS represses QF and Aβarc is not expressed. When flies are 
fed quinic acid, QS is repressed and QF is activated. Again, Aβarc is expressed.  
(B) Survival curves of flies expressing lap in glia under the control of the GSG3285 promoter, while Aβarc was induced 
by feeding flies QA, n > 120. Genotypes: QUAS-Aβ; GSG3285/nSybQF2 tubQS, QUAS-Aβ/UAS-lap; 
GSG3285/nSybQF2 tubQS. Statistical analyses were determined by log-rank test and shown in Table 3.3. 
(C) Climbing performance index of flies of the same genotypes. The climbing performance of Aβ lap (+RU) was 
significantly better than those of other groups, n = 3 (50 animals per condition). Interaction of time and genotype, p < 
0.0001; time, p < 0.0001, genotype, p < 0.0001, determined by two ways ANOVA followed by Tukey’s post-hoc test. 
Statistical analyses were shown in Table 3.4. 
(D) Aβ42 protein levels, measured by ELISA, in the heads of 28-day-old flies expressing Aβ (+QA), Aβ and lap (+QA) 
and uninduced controls (-QA). Means ± SEM, n = 3. **p < 0.01, determined by one way ANOVA; Aβ -QA -RU vs Aβ 
+QA -RU, n.s., not significant; Aβ -QA +RU vs Aβ +QA +RU, *p < 0.05; Aβ lap -QA -RU vs Aβ lap +QA -RU, ****p < 
0.0001; Aβ lap -QA +RU vs Aβ lap +QA +RU, ****p < 0.0001; Aβ +QA -RU vs Aβ lap +QA +RU, n.s., not significant; Aβ 
+QA +RU vs Aβ lap +QA +RU, n.s., not significant; Aβ lap +QA -RU vs Aβ lap +QA +RU, n.s., not significant, 
comparison by Tukey’s post-hoc test. 
A
β
4
2
 (
p
g
/μ
g
 p
r
o
te
in
)
A
β
 G
S
G
3
2
8
5
 -
Q
A
 -
R
U
A
β
 G
S
G
3
2
8
5
 +
Q
A
 -
R
U
A
β
 G
S
G
3
2
8
5
 -
Q
A
 +
R
U
A
β
 G
S
G
3
2
8
5
 +
Q
A
 +
R
U
A
β
 G
S
G
3
2
8
5
>
L
a
p
 -
Q
A
 -
R
U
A
β
 G
S
G
3
2
8
5
>
L
a
p
 +
Q
A
 -
R
U
A
β
 G
S
G
3
2
8
5
>
L
a
p
 -
Q
A
 +
R
U
A
β
 G
S
G
3
2
8
5
>
L
a
p
 +
Q
A
 +
R
U
0
5
1 0
1 5
2 0 * * *
ns
ns
ns
ns
 75 
 
Table 3.3 Statistical summary of survival curves of flies expressing Aβ with or without lap in glia 
 Aβ +QA 
-RU 
Aβ +QA 
+RU 
Aβ lap 
+QA -RU 
Aβ lap 
+QA +RU 
Aβ -QA 
-RU 
Aβ -QA 
+RU 
Aβ lap 
-QA -RU 
Aβ lap 
-QA +RU 
Aβ +QA 
-RU 
 < 0.0001 < 0.0001 < 0.0001 < 0.0001 < 0.0001 < 0.0001 < 0.0001 
Aβ +QA 
+RU 
 < 0.0001 < 0.0001 < 0.0001 < 0.0001 < 0.0001 < 0.0001 
Aβ lap 
+QA -RU 
 < 0.0001 < 0.0001 < 0.0001 < 0.0001 < 0.0001 
Aβ lap 
+QA +RU 
 < 0.0001 < 0.0001 < 0.0001 < 0.0001 
Aβ -QA 
-RU 
 n.s. n.s. n.s. 
Aβ -QA 
+RU 
 n.s. n.s. 
Aβ lap 
-QA -RU 
 n.s. 
Aβ lap 
-QA +RU 
 
 
Table 3.4 Statistical summary of locomotor performance index of flies expressing Aβ with or without lap in glia 
Day 7 Aβ +QA 
-RU 
Aβ +QA 
+RU 
Aβ lap 
+QA -RU 
Aβ lap 
+QA +RU 
Aβ -QA 
-RU 
Aβ -QA 
+RU 
Aβ lap 
-QA -RU 
Aβ lap 
-QA +RU 
Aβ +QA 
-RU 
 n.s. n.s. n.s. n.s. n.s. n.s. n.s. 
Aβ +QA 
+RU 
 n.s. n.s. n.s. n.s. n.s. n.s. 
Aβ lap 
+QA -RU 
 n.s. n.s. n.s. n.s. n.s. 
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Aβ lap 
+QA +RU 
 n.s. n.s. n.s. n.s. 
Aβ -QA 
-RU 
 n.s. n.s. n.s. 
Aβ -QA 
+RU 
 n.s. n.s. 
Aβ lap 
-QA -RU 
 n.s. 
Aβ lap 
-QA +RU 
 
Day 10 Aβ +QA 
-RU 
Aβ +QA 
+RU 
Aβ lap 
+QA -RU 
Aβ lap 
+QA +RU 
Aβ -QA 
-RU 
Aβ -QA 
+RU 
Aβ lap 
-QA -RU 
Aβ lap 
-QA +RU 
Aβ +QA 
-RU 
 n.s. n.s. n.s. < 0.05 n.s. < 0.001 < 0.001 
Aβ +QA 
+RU 
 n.s. n.s. n.s. n.s. n.s. n.s. 
Aβ lap 
+QA -RU 
 n.s. n.s. n.s. n.s. n.s. 
Aβ lap 
+QA +RU 
 n.s. n.s. n.s. n.s. 
Aβ -QA 
-RU 
 n.s. n.s. n.s. 
Aβ -QA 
+RU 
 n.s. n.s. 
Aβ lap 
-QA -RU 
 n.s. 
Aβ lap 
-QA +RU 
 
Day 14 Aβ +QA Aβ +QA Aβ lap Aβ lap Aβ -QA Aβ -QA Aβ lap Aβ lap 
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-RU +RU +QA -RU +QA +RU -RU +RU -QA -RU -QA +RU 
Aβ +QA 
-RU 
 n.s. n.s. n.s. <0.05 n.s. <0.001 <0.5 
Aβ +QA 
+RU 
 n.s. n.s. n.s. n.s. n.s. n.s. 
Aβ lap 
+QA -RU 
 n.s. n.s. n.s. n.s. n.s. 
Aβ lap 
+QA +RU 
 n.s. n.s. n.s. n.s. 
Aβ -QA 
-RU 
 n.s. n.s. n.s. 
Aβ -QA 
+RU 
 n.s. n.s. 
Aβ lap 
-QA -RU 
 n.s. 
Aβ lap 
-QA +RU 
 
Day 18 Aβ +QA 
-RU 
Aβ +QA 
+RU 
Aβ lap 
+QA -RU 
Aβ lap 
+QA +RU 
Aβ -QA 
-RU 
Aβ -QA 
+RU 
Aβ lap 
-QA -RU 
Aβ lap 
-QA +RU 
Aβ +QA 
-RU 
 n.s. n.s. < 0.001 n.s. n.s. n.s. < 0.001 
Aβ +QA 
+RU 
 n.s. < 0.01 n.s. n.s. n.s. < 0.01 
Aβ lap 
+QA -RU 
 n.s. n.s. n.s. n.s. n.s. 
Aβ lap 
+QA +RU 
 n.s. n.s. n.s. n.s. 
Aβ -QA 
-RU 
 n.s. n.s. n.s. 
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Aβ -QA 
+RU 
 n.s. n.s. 
Aβ lap 
-QA -RU 
 n.s. 
Aβ lap 
-QA +RU 
 
Day 21 Aβ +QA 
-RU 
Aβ +QA 
+RU 
Aβ lap 
+QA -RU 
Aβ lap 
+QA +RU 
Aβ -QA 
-RU 
Aβ -QA 
+RU 
Aβ lap 
-QA -RU 
Aβ lap 
-QA +RU 
Aβ +QA 
-RU 
 n.s. n.s. < 0.001 < 0.01 < 0.001 < 0.001 < 0.0001 
Aβ +QA 
+RU 
 n.s. < 0.001 < 0.01 < 0.01 < 0.01 < 0.0001 
Aβ lap 
+QA -RU 
 < 0.001 < 0.01 < 0.001 < 0.01 < 0.0001 
Aβ lap 
+QA +RU 
 n.s. n.s. n.s. < 0.01 
Aβ -QA 
-RU 
 n.s. n.s. < 0.001 
Aβ -QA 
+RU 
 n.s. < 0.01 
Aβ lap 
-QA -RU 
 < 0.01 
Aβ lap 
-QA +RU 
 
Day 25 Aβ +QA 
-RU 
Aβ +QA 
+RU 
Aβ lap 
+QA -RU 
Aβ lap 
+QA +RU 
Aβ -QA 
-RU 
Aβ -QA 
+RU 
Aβ lap 
-QA -RU 
Aβ lap 
-QA +RU 
Aβ +QA 
-RU 
 < 0.01 < 0.0001 < 0.0001 < 0.0001 < 0.0001 < 0.0001 < 0.0001 
Aβ +QA  n.s. < 0.0001 < 0.0001 < 0.0001 < 0.0001 < 0.001 
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+RU 
Aβ lap 
+QA -RU 
 < 0.01 < 0.01 < 0.01 < 0.01 < 0.001 
Aβ lap 
+QA +RU 
 n.s. n.s. n.s. n.s. 
Aβ -QA 
-RU 
 n.s. n.s. n.s. 
Aβ -QA 
+RU 
 n.s. n.s. 
Aβ lap 
-QA -RU 
 n.s. 
Aβ lap 
-QA +RU 
 
Day 28 Aβ +QA 
-RU 
Aβ +QA 
+RU 
Aβ lap 
+QA -RU 
Aβ lap 
+QA +RU 
Aβ -QA 
-RU 
Aβ -QA 
+RU 
Aβ lap 
-QA -RU 
Aβ lap 
-QA +RU 
Aβ +QA 
-RU 
 n.s. n.s. < 0.0001 < 0.0001 < 0.0001 < 0.0001 < 0.0001 
Aβ +QA 
+RU 
 n.s. < 0.05 < 0.0001 < 0.0001 < 0.0001 < 0.0001 
Aβ lap 
+QA -RU 
 < 0.05 < 0.0001 < 0.0001 < 0.0001 < 0.0001 
Aβ lap 
+QA +RU 
 < 0.001 < 0.01 < 0.01 < 0.0001 
Aβ -QA 
-RU 
 n.s. n.s. n.s. 
Aβ -QA 
+RU 
 n.s. n.s. 
Aβ lap 
-QA -RU 
 n.s. 
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Aβ lap 
-QA +RU 
 
Day 31 Aβ +QA 
-RU 
Aβ +QA 
+RU 
Aβ lap 
+QA -RU 
Aβ lap 
+QA +RU 
Aβ -QA 
-RU 
Aβ -QA 
+RU 
Aβ lap 
-QA -RU 
Aβ lap 
-QA +RU 
Aβ +QA 
-RU 
 n.s. n.s. < 0.01 < 0.0001 < 0.0001 < 0.0001 < 0.0001 
Aβ +QA 
+RU 
 n.s. n.s. < 0.0001 < 0.0001 < 0.0001 < 0.0001 
Aβ lap 
+QA -RU 
 < 0.05 < 0.0001 < 0.0001 < 0.0001 < 0.0001 
Aβ lap 
+QA +RU 
 < 0.0001 < 0.01 < 0.0001 < 0.0001 
Aβ -QA 
-RU 
 n.s. n.s. n.s. 
Aβ -QA 
+RU 
 n.s. n.s. 
Aβ lap 
-QA -RU 
 n.s. 
Aβ lap 
-QA +RU 
 
Day 36 Aβ +QA 
-RU 
Aβ +QA 
+RU 
Aβ lap 
+QA -RU 
Aβ lap 
+QA +RU 
Aβ -QA 
-RU 
Aβ -QA 
+RU 
Aβ lap 
-QA -RU 
Aβ lap 
-QA +RU 
Aβ +QA 
-RU 
 n.s. n.s. n.s. < 0.0001 < 0.0001 < 0.001 < 0.0001 
Aβ +QA 
+RU 
 n.s. n.s.  < 0.0001 < 0.0001 n.s. < 0.0001 
Aβ lap 
+QA -RU 
 n.s. < 0.0001 < 0.0001 < 0.01 < 0.0001 
Aβ lap  < 0.0001 < 0.0001 < 0.01 < 0.0001 
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+QA +RU 
Aβ -QA 
-RU 
 n.s. < 0.05 n.s. 
Aβ -QA 
+RU 
 n.s. n.s. 
Aβ lap 
-QA -RU 
 < 0.001 
Aβ lap 
-QA +RU 
 
3.3 Discussion 
PICALM is linked to sporadic AD. A number of publications have described the role of PICALM 
in Aβ42 production. However, the contribution of PICALM to modulating the downstream effect 
of Aβ42 toxicity is unknown. My work provides a new link between the Drosophila homologue of 
PICALM, lap and glutamatergic transmission in Alzheimer’s disease.  
3.3.1 Autophagy and UPR in AD 
Autophagy and UPR have been reported to be impaired in AD. My results have found that Atg8 
expression was not altered upon Aβ expression. However, I cannot exclude the possibility that 
autophagy is changed in our model because autophagy is a multi-step process. In the future, it 
would be good to investigate the expression of more autophagy markers, such as p62. 
 
My data have another limitation that it is still not understood whether UPR activity is activated 
or inhibited in AD. This limitation is caused by the fact that Grp78 is not a good marker of UPR 
induction. The future work needs to examine the expression of other UPR markers like Xbp1 
mRNA and Grp78 mRNA levels.  
3.3.2 Imbalance in glutamatergic transmission in AD  
My work has shown that Aβ42 expression leads to VGlut accumulation, which could increase 
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glutamate release. Elevated extracellular glutamate concentrations can give rise to glutamate 
excitotoxicity (Abramov et al., 2009; Ping et al., 2015). Alterations in expression of glutamate 
transporters have been observed in sporadic AD patients, mouse AD models and excess 
glutamate release is found in an in vitro model of AD (Cummings et al., 2015; Hefendehl et al., 
2016; Li et al., 2009; Talantova et al., 2013). Presynaptic glutamate has been reported to 
negatively modulate the number of GluRII receptors (Featherstone et al., 2002). Therefore, 
Aβ42 could possibly affect GluRII localization as well, again leading to an imbalance in 
glutamatergic transmission. 
3.3.3 Contributions of glia in AD progression 
Astrocyte and microglia are over-activated in AD. They take up Aβ42 peptides and promote 
their clearance. Here, I show that lap over-expression in glial cells might protect neurons from 
Aβ42 toxicity without affecting Aβ42 levels. However, as QF2 and quinic acid are toxic (Riabinina 
et al., 2015), I cannot exclude the possibility that lap expression only reduces QF2 or quinic 
acid induced toxicity. Moreover, the feeding quinic acid and RU486 exacerbates toxicity 
compared to feeding quinic acid alone. Finally, the presence of the lap construct gives rise to 
lifespan extension. It is unknown whether the neuroprotection of glial lap is specific to Aβ42 
toxicity. Taken together, I do not think that the Q system is a good binary expression system to 
investigate gene function because it might confer exogenous toxicity. 
3.3.4 Role of lap in longevity 
A GWAS study has linked PICALM to longevity. However, the role of lap in the ageing process 
is still unclear. I show that inhibition of lap promotes longevity. Given that glutamatergic 
neurotransmission declines with age (Segovia et al., 2001), this lifespan extension could 
possibly result from an increase in VGlut localization and glutamatergic transmission by the 
downregulation of lap. My work has used a genetically encoded transmitter indicator (GETI) to 
visualize glutamate dynamics in larval VNC. It will be interesting to test whether this method 
allows for detecting extracellular glutamate in adults’ brains and therefore revealing changes of 
glutamatergic transmission with age. 
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My work has showed that lap ameliorates Aβ toxicity. Lap reduces the accumulation of 
vesicular glutamate transporters (VGlut) near the pre-synaptic active zone and therefore 
reduces glutamatergic transmission. 
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4. Roles of BIN1 and RAB5 in Alzheimer’s 
disease 
4.1 Background 
I showed in Chapter 3 that lap slightly diminishes Aβ toxicity, but its downstream effector is 
unknown. Although the expression of other clathrin-mediated endocytic proteins is altered in 
AD, the link between these proteins and disease progression is not firmly established.  
 
Clathrin-dependent endocytosis starts with nucleation. This nucleation localizes at the sites 
where clathrin will be recruited. At the same time, receptors on the plasma membrane are 
recruited to the clathrin-coated pits by the adaptor protein AP2 (Blondeau et al., 2004; Honing 
et al., 2005; Ohno et al., 1995). AP2 interacts with different accessory adaptor proteins to 
select different cargos (Collins et al., 2002; Kelly et al., 2008). These accessory proteins are 
divided into two main groups: AP180 (also known as PICALM) and epsin (Chidambaram et al., 
2008; Dittman and Kaplan, 2006; Ford et al., 2002; Ford et al., 2001; Reider et al., 2009; 
Stimpson et al., 2009). After the cargo selection, the clathrin cage is polymerized and 
assembled into vesicles (Boucrot et al., 2010; Motley et al., 2003; Saffarian et al., 2009; Tebar 
et al., 1996). Then vesicles are cliped by dynamin (Ferguson et al., 2009; Kosaka and Ikeda, 
1983; Sundborger et al., 2011; Wigge et al., 1997), which curves the vesicle neck along with 
amphiphysin and endophilin, allowing the vesicle to detach from the plasma membrane 
(Bashkirov et al., 2008; Hinshaw and Schmid, 1995; Macia et al., 2006; Roux et al., 2006; 
Stowell et al., 1999; Sweitzer and Hinshaw, 1998; van der Bliek et al., 1993). The clathrin coat 
is then disassembled by HSC70 and auxilin (also known as GAK) (Fotin et al., 2004; Massol et 
al., 2006; Rapoport et al., 2008; Scheele et al., 2001; Schlossman et al., 1984; Taylor et al., 
2011; Xing et al., 2010). Once the vesicle is eased, the subsequent cascade is vesicle 
trafficking, docking and fusion. Vesicle trafficking is mediated by two families of GTPases: Rab 
and Arf. They serve as a switch to regulate activities of their effectors (Pryor et al., 2008). Rab 
and Arf are activated by conversion from a GDP-bound to a GTP-bound form, catalyzed by 
guanidine exchange factors (GEFs) (Delprato et al., 2004). Then the GTP-bound form can be 
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switched back to the GDP-bound form by GTPase-activating proteins (GAPs) (Eathiraj et al., 
2005). Inactive Rabs are further stabilized by GDP dissociation inhibitor (GDIs) while they are 
recycled back to the cytosol (Matsui et al., 1990). The Rab family is composed of at least 38 
proteins (Haas et al., 2007) and the Arf family comprises of 6 proteins and several relatives 
(Kahn et al., 2006; Pasqualato et al., 2002). Different proteins are localized at distinct 
membrane microdomains, so they are specific to particular intracellular trafficking pathways. 
For example, Rab4 and Rab5 are mainly located at early endosome (Gorvel et al., 1991; 
Rubino et al., 2000). Rab4 is also found in recycling endosome as well as Rab11 (Sonnichsen 
et al., 2000). Rab7 and Rab9 are existed in late endosome (Barbero et al., 2002). RAB5 
regulates the transport of cargos to early endosomes, whereas its effector, VPS39, activates 
Rab7 through RAB7 GEF activity (Rink et al., 2005). This allows for cargos to be transported to 
late endosomes. Rab proteins also contribute to vesicle tethering and fusion through the 
recruitment of membrane-tethering factors and t-SNARE respectively. Vesicle docking is 
required for the closing of the vesicle membrane and the target membrane. This process is 
mediated by membrane-tethering factors and Sec1-Munc18 protein (SM proteins). 
Membrane-tethering factors consist in two classes: the coiled-coil (e.g. golgins) and the 
multisubunit tethering complexes (e.g. Exocyst). Membrane-tethering factors work together 
with SM proteins (e.g. vps) to promote SNARE assembly (Archbold et al., 2014; Block et al., 
1988; Clary et al., 1990; Ma et al., 2013a; McNew et al., 2000; Miller et al., 2011; Zick and 
Wickner, 2014). SNAREs are more crucial to membrane fusion, rather than vesicle tethering. 
They are categorized into v-SNAREs such as synaptobrevin and t-SNAREs like syntaxin and 
SNAP25. The association of synaptobrevin, syntaxin and SNAP25 between the two 
membranes forms a trans-SNARE complex that drives membrane fusion. During membrane 
fusion, this trans-SNARE complex converts to a cis-SNARE complex that is subsequently 
disassembled by NSF and SNAP. There are 20 or more SNAREs that also specify different 
intracellular trafficking pathways (Hanson et al., 1997). In the process of exocytosis, vesicle 
fusion is triggered by Ca
2+
 via its sensor synaptotagmin (Fernandez-Chacon et al., 2001; 
Geppert et al., 1994). When cargos enter early endosomes, they are delivered to lysosomes 
for degradation or to recycling endosomes for secretion. This event is regulated by the ESCRT 
(endosomal sorting complex required for transport). These pathways are a downstream 
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cascade of the clathrin-mediated endocytosis (Henne et al., 2011; Williams and Urbe, 2007). 
However, whether they are involved in AD pathogenesis is rarely studied. 
 
BIN1 plays a crucial role in intracellular endosome trafficking through interaction with the 
GTPase dynamin (Takei et al., 1999). BIN1 mice knockouts present learning deficits (Di Paolo 
et al., 2002). It is not clear whether BIN1 is increased or decreased in AD (Chapuis et al., 2013; 
Glennon et al., 2013) and so BIN1’s role in AD pathology is still unclear. BIN1 has mostly been 
implicated in tau pathology, however its role is unclear, with some studies suggesting that 
upregulation blocks the spread of tau (Calafate et al., 2016) while others suggesting that 
downregulation ameliorates tau toxicity (Chapuis et al., 2013). BIN1 also plays a role in Aβ 
production, with reduction of BIN1 linked to increased BACE1 and Aβ production (Miyagawa et 
al., 2016; Ubelmann et al., 2017), however, whether it plays a role in downstream Aβ toxicity 
remains unknown.  
 
Glutamate release is abnormal with Aβ expression (Cummings et al., 2015; Hefendehl et al., 
2016; Li et al., 2009; Talantova et al., 2013), while glutamate excitotoxicity is also attributed to 
the altered localization of glutamate receptors. Aβ affects the localization of glutamate 
receptors. For instance, Aβ expression leads to a reduction in AMPAR and NMDAR from the 
cell surface (Hsieh et al., 2006; Shankar et al., 2007; Snyder et al., 2005; Zhao et al., 2010). 
However, more recently, this idea has been challenged. Firstly, NR2B subunits of NMDARs are 
found to be activated by Aβ oligomers. NR2B antagonist ameliorates Aβ-mediated 
neurotoxicity (Hu et al., 2009a; Li et al., 2009; Li et al., 2011; Talantova et al., 2013). Therefore, 
NR2B activation could be responsible for Aβ-mediated excitotoxicity. Secondly, a large body of 
evidence shows that high doses of Aβ give rise to the internalization of GluA1 subunits of 
AMPAR from the cell surface, while low doses leads to the accumulate GluA1 subunits on the 
plasma membrane. Also this might explain why Aβ leads to glutamate excitotoxicity and 
synaptic loss (Liu et al., 2010; Whitcomb et al., 2015). 
 
I performed a small-scale targeted genetic screen of endocytic-exocytic genes and identified 
Rab5, EndoA, Bin1 and Snap25 as suppressors of Aβ42-induced degeneration. I showed that 
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Amph, the BIN1 orthologue, localization was disrupted upon Aβ expression and restored by 
lap. I also showed that Amph modulated the localization of glutamate receptors (GluRII) which 
was also altered by Aβ expression. Therefore, these results suggest that Amph might be 
downstream effectors of lap, and contribute to the amelioration in Aβ pathology. 
4.2 Results 
4.2.1 Endocytic and exocytic regulators modify Aβ42 toxicity 
I have shown that lap modestly attenuated Aβ toxicity. I next investigated whether other 
endocytic-exocytic proteins were involved with Aβ42 toxicity. As PICALM physically interacted 
with endocytic genes like VAMP2 (nSyb), Rab5 and Rab11 (Zhao et al., 2015b), I performed a 
genetic screen of all accessible lines over-expressing genes regulating endocytosis or 
endocytic recycling. Among them, Rab4, Rab8, Rab10 and Rab11 mediate endocytic recycling, 
whereas Rab5 and Rab7 regulate endocytosis. In particular, Rab5 contributes to trafficking 
from the plasma membrane to early endosomes and Rab7 controls transporting from early 
endosomes to late endosomes. In addition to this, I screened genes engaged in vesicle 
formation. For example, clathrin helps to form coated vesicles. Epsin (Lqf) and Eps15 (other 
types of adaptors) recruit cargos to the plasma membrane. Bin1 (Amph), Dynamin (Shi) and 
EndoA are involved with vesicle scission and release. Aux is involved in the disassembly of 
coated vesicles. Snap25 is widely located in the plasma membrane and in multi-vesicular 
bodies (MVBs) that drives vesicle fusion.  
 
I crossed the lines over-expressing these genes to Aβ42-expressing flies under the control of 
the neuronal elav promoter and induced gene expression in adult flies by feeding RU once the 
flies has eclosed. I then monitored their lifespan relative to flies over-expressing Aβ42 alone. 
This screen showed that apart from the overexpression of wild type Rab5, overexpression of 
Rab4, Rab7, Rab8, Rab10 and Rab11 (Rab11-GFP) dramatically exacerbated Aβ42 toxicity 
(Rab11-HA did not decrease lifespan of Aβ42-expressing flies) (Figure 4.1, Figure 4.2 and 
Table 4.1, mean lifespan, Aβ RU200: 100 %; Aβ Snap25 RU200: 108 %; Aβ Syt RU200: 103 %; 
Aβ nSyb RU200: 100 %; Aβ Eps15 RU200: 100 %; Aβ Shi RU200: 100 %; Aβ Rab5[CA] 
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RU200: 100 %; Aβ Rab11-HA RU200: 100 %; Aβ Rab14 RU200: 97 %; Aβ Aux RU200: 92 %; 
Aβ Rab7 RU200: 92 %; Aβ Clc RU200: 89 %; Aβ Rab11-GFP RU200: 89 %; Aβ Rab30 RU200: 
89 %; Aβ Rab4 RU200: 87 %; Aβ Rab8 RU200: 87 %; Aβ Lqf RU200: 84 %, n > 100 per 
condition. p was shown in Figure 4.1, log-rank test). 
 
Consistent with a study on mammalian neurons, these results support the idea that active 
endocytosis, but not membrane recycling, can reverse Aβ42–induced neurodegenerative 
defects (Treusch et al., 2011). However, my work further suggested that not all endocytic 
factors were beneficial in AD amelioration and some actually accelerated AD progression.  
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Figure 4.1 A genetic screen identifies regulators of Aβ42 toxicity. Survival curves of flies expressing Aβ with 
endocytic-exocytic gene (red) or not (black) in adult neurons (+RU), n > 100. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 
0.0001, n.s., not significant, comparison by log-rank test. 
 
Table 4.1 Endocytic-exocytic genes in the Drosophila screen 
Human gene Drosophila homolog Function 
Effect on lifespan 
BIN1 Amph Vesicular scission  
Increased  
CD2AP Cindr Vesicular formation 
Decreased 
CLC Clc Vesicular formation 
Decreased 
DYNAMIN Shi Vesicular scission 
NA 
ENDOA EndoA Vesicular scission 
Increased 
EPS15 Eps15 Cargo selection 
Decreased 
EPSIN Iqf Cargo selection 
Decreased 
GAK Aux Vesicular disassembly 
Decreased 
RAB4 Rab4 Early endosome 
Decreased 
RAB5 Rab5 Early endosome 
Increased 
RAB7 Rab7 Late endosome 
Decreased 
RAB8 Rab8 Recycling endosome 
Decreased 
RAB10 Rab10 Recycling endosome 
Decreased 
RAB11 Rab11 Recycling endosome 
Decreased 
RAB14 Rab14 Recycling endosome 
NA 
SNAP25 Snap25 Exocytosis 
Increased 
SYT1 Syt Exocytosis 
Increased 
VAMP2 nSyb Endocytosis 
NA 
4.2.2 Rab5, EndoA and Snap25 ameliorates Aβ42 vulnerability  
Although I found that a number of components did not improve Aβ42 toxicity, I found that Rab5, 
EndoA and Snap5 could alleviate Aβ42 toxicity. In particular, I found that over-expression of 
wild type Rab5 alleviated Aβ42 toxicity, while active Rab5 elevated Aβ42 toxicity. Wild type Rab5 
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overexpression extended lifespan (Figure 4.2A, mean lifespan, Aβ RU0: 100 %; Aβ RU200: 
49 %; Aβ Rab5 RU0: 106 %; Aβ Rab5 RU200: 58 %, n > 120 per condition. p was shown in 
Figure 4.2B, log-rank test) and also delayed the onset of climbing defects of Aβ42-expressing 
flies (Figure 4.2B, PI, day 6, Aβ RU0: 89.67 + 0.36 %; Aβ RU200: 91.36 + 1.55 %; Aβ Rab5 
RU0: 93.8 + 0.56 %; Aβ Rab5 RU200: 93.84 + 1.41 %; day 11, Aβ RU0: 90.42 + 1.67 %; Aβ 
RU200: 94.96 + 1.98 %; Aβ Rab5 RU0: 93.59 + 0.74 %; Aβ Rab5 RU200: 89.49 + 0.36 %; day 
14, Aβ RU0: 90.77 + 1.96 %; Aβ RU200: 79.74 + 0.74 %; Aβ Rab5 RU0: 85.38 + 3.26 %; Aβ 
Rab5 RU200: 91.67 + 1.04 %; day 18, Aβ RU0: 88.16 + 0.76 %; Aβ RU200: 71.16 + 1.16 %; 
Aβ Rab5 RU0: 83.21 + 1.51 %; Aβ Rab5 RU200: 77.48 + 3.41 %; day 21, Aβ RU0: 84.8 + 
1.77 %; Aβ RU200: 50.67 + 2.45 %; Aβ Rab5 RU0: 80.92 + 1.76 %; Aβ Rab5 RU200: 58.7 + 
3.38 %; day 25, Aβ RU0: 82.2 + 1.78 %; Aβ RU200: 36.34 + 3.2 %; Aβ Rab5 RU0: 78.09 + 
4.58 %; Aβ Rab5 RU200: 44.84 + 1.05 %, n = 3 per condition. Interaction of time and genotype, 
p < 0.0001; time, p < 0.0001, genotype, p < 0.0001, two-ways ANOVA). Although the Aβ Rab5 
RU0 condition showed a lifespan increase when comparing to the Aβ RU0 condition, the Aβ 
Rab5 RU200 condition had relative longer lifespan compared to the Aβ RU200 condition 
(Mean lifespan of Aβ RU200 vs Aβ RU0 is 49%; mean lifespan of Aβ Rab5 RU200 vs Aβ Rab5 
RU0 is 55%). Moreover, EndoA over-expression exclusively restored the lifespan of 
Aβ42-expressing flies from 50% to 62% (Figure 4.2D, mean lifespan, Aβ RU0: 100 %; Aβ 
RU200: 50 %; Aβ EndoA RU0: 95 %; Aβ EndoA RU200: 59 %, n > 120 per condition. p was 
shown in Figure 4.2D, log-rank test) and Snap25 over-expression attenuated their locomotor 
defects (Figure 4.2E, PI, day 7, Aβ RU0: 91.33 + 1.45 %; Aβ RU200: 88.19 + 1.84 %; Aβ 
Snap25 RU0: 69.33 + 2.37 %; Aβ Snap25 RU200: 89.7 + 3.07 %; day 14, Aβ RU0: 95.33 + 
1.33 %; Aβ RU200: 82.23 + 1.05 %; Aβ Snap25 RU0: 66.77 + 1.83 %; Aβ Snap25 RU200: 
72.67 + 1.27 %; day 24, Aβ RU0: 90.57 + 2.5 %; Aβ RU200: 51.9 + 1.66 %; Aβ Snap25 RU0: 
64.93 + 3.42 %; Aβ Snap25 RU200: 63.21 + 2.09 %; day 28, Aβ RU0: 79.25 + 2.78 %; Aβ 
RU200: 24.06 + 1.2 %; Aβ Snap25 RU0: 46.12 + 8.01 %; Aβ Snap25 RU200: 32.36 + 3.68 %; 
day 31, Aβ RU0: 70.75 + 2.78 %; Aβ RU200: 16.18 + 1.47 %; Aβ Snap25 RU0: 41.32 + 2.5 %; 
Aβ Snap25 RU200: 24.36 + 0.03 %, n = 3 per condition. Interaction of time and genotype, p < 
0.0001; time, p < 0.0001, genotype, p < 0.0001, two-ways ANOVA). As mean lifespan of the 
Aβ EndoA RU0 condition was shorter than that of the Aβ RU0 condition and locomotor 
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performance of the Aβ Snap25 RU0 condition was worse than that of the Aβ RU0 condition, if 
all uninduced conditions have the same lifespan and locomotor performance, co-expression of 
Aβ and EndoA might show a bigger lifespan increase and co-expression of Aβ and Snap25 
might have a better alleviation of locomotor defects. Similar to lap, neuroprotection of these 
genes was independent of Aβ42 clearance (Figure 4.2C and F). Collectively, my work 
suggested a lap-EndoA-Rab5-Snap25 pathway that protected neurons from Aβ42 toxicity. 
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(F) 
Figure 4.2 Rab5 delays onset of Aβ-induced neurodegeneration. 
(A) Lifespan curves of flies expressing Aβ with or without Rab5 wild type version in neurons (+RU) and uninduced 
controls (-RU). Genotypes: UAS-Aβ; elavGS, UAS-Aβ/UAS-rab5; elavGS. n > 120. Aβ RU0 vs Aβ RU200, p < 0.0001; 
Aβ RU0 vs Aβ Rab5 RU0, p < 0.0001; Aβ Rab5 RU0 vs Aβ Rab5 RU200, p < 0.0001; Aβ RU200 vs Aβ Rab5 RU200, p 
< 0.0001, comparison by log-rank test. 
(B) Locomotor performance index for the same flies plotted over time. n = 3. Genotypes are as above. Interaction of 
time and genotype, p < 0.0001; time, p < 0.0001, genotype, p < 0.0001, determined by two-ways ANOVA followed by 
Tukey’s post-hoc test. Statistical analyses were shown in Table 4.2. 
(C) Aβ42 protein levels, measured by ELISA, in the heads of 24-day-old flies. Co-expression of Aβ and Rab5 did not 
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change Aβ42 levels when comparing Aβ-expressing flies. Means ± SEM, n = 3. ***p < 0.001, determined by one-way 
ANOVA; Aβ RU0 vs Aβ RU200, **p < 0.01; Aβ RU0 vs Aβ Rab5 RU0, n.s., not significant; Aβ Rab5 RU0 vs Aβ Rab5 
RU200, **p < 0.01; Aβ RU200 vs Aβ Rab5 RU200, n.s., not significant, comparison by Tukey’s post-hoc test. 
(D) Adult survival of flies harboring Aβ with or without EndoA in adult neurons (+RU) and uninduced controls (-RU). 
Over-expression of EndoA modestly suppressed shortened lifespan induced by Aβ, n > 120. Aβ RU0 vs Aβ RU200, p 
< 0.0001; Aβ RU0 vs Aβ EndoA RU0, n.s., not significant; Aβ EndoA RU0 vs Aβ EndoA RU200, p < 0.0001; Aβ RU200 
vs Aβ EndoA RU200, p < 0.0001, by log-rank test. 
(E) Climbing index of flies expressing Aβ with or without Snap25 in adult neurons (+RU) and uninduced controls (-RU). 
Overexpression of Snap25 attenuated climbing defects induced by Aβ, n = 3. Interaction of time and genotype, p < 
0.0001; time, p < 0.0001, genotype, p < 0.0001, determined by two-ways ANOVA followed by Tukey’s post-hoc test. 
Statistical analyses were shown in Table 4.3. 
(F) Flies expressing Aβ had similar levels of Aβ42 when comparing flies expressing either Aβ EnodA or Aβ Snap25, 
indicating that EnodA and Snap25 do not alter Aβ clearance. Means ± SEM, n = 3. **p < 0.01, determined by one-way 
ANOVA; *p < 0.05, **p < 0.01, ns, not significant, by Tukey’s post-hoc test. 
 
Table 4.2 Statistical summary of locomotor performance index of flies expressing Aβ with or without Rab5 
Day 6 Aβ RU0 Aβ RU200 Aβ Rab5 RU0 Aβ Rab5 RU200 
Aβ RU0  n.s. n.s. n.s. 
Aβ RU200  n.s. n.s. 
Aβ Rab5 RU0  n.s. 
Aβ Rab5 RU200  
Day 11 Aβ RU0 Aβ RU200 Aβ Rab5 RU0 Aβ Rab5 RU200 
Aβ RU0  n.s. n.s. n.s. 
Aβ RU200  n.s. n.s. 
Aβ Rab5 RU0  n.s. 
Aβ Rab5 RU200  
Day 14 Aβ RU0 Aβ RU200 Aβ Rab5 RU0 Aβ Rab5 RU200 
Aβ RU0  < 0.01 n.s. n.s. 
Aβ RU200  n.s. < 0.001  
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Aβ Rab5 RU0  < 0.001 
Aβ Rab5 RU200  
Day 18 Aβ RU0 Aβ RU200 Aβ Rab5 RU0 Aβ Rab5 RU200 
Aβ RU0  < 0.0001 n.s. < 0.01 
Aβ RU200  < 0.001 n.s. 
Aβ Rab5 RU0  n.s. 
Aβ Rab5 RU200  
Day 21 Aβ RU0 Aβ RU200 Aβ Rab5 RU0 Aβ Rab5 RU200 
Aβ RU0  < 0.0001 n.s. < 0.0001 
Aβ RU200  < 0.0001 < 0.05 
Aβ Rab5 RU0  < 0.0001 
Aβ Rab5 RU200  
Day 25 Aβ RU0 Aβ RU200 Aβ Rab5 RU0 Aβ Rab5 RU200 
Aβ RU0  < 0.0001 n.s. < 0.0001 
Aβ RU200  < 0.0001 < 0.05 
Aβ Rab5 RU0  < 0.0001 
Aβ Rab5 RU200  
 
Table 4.3 Statistical summary of locomotor performance index of flies expressing Aβ with or without Snap25 
Day 7 Aβ RU0 Aβ RU200 Aβ Snap25 RU0 Aβ Snap25 RU200 
Aβ RU0  n.s. < 0.0001 n.s. 
Aβ RU200  < 0.001 n.s. 
Aβ Snap25 RU0  < 0.0001 
Aβ Snap25 RU200  
Day 14 Aβ RU0 Aβ RU200 Aβ Snap25 RU0 Aβ Snap25 RU200 
Aβ RU0  < 0.05 < 0.0001 < 0.0001 
Aβ RU200  < 0.01 n.s. 
Aβ Snap25 RU200  n.s. 
Aβ Snap25 RU200  
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Day 24 Aβ RU0 Aβ RU200 Aβ Snap25 RU0 Aβ Snap25 RU200 
Aβ RU0  < 0.0001 < 0.0001 < 0.0001 
Aβ RU200  < 0.05 < 0.05 
Aβ Snap25 RU0  n.s. 
Aβ Snap25 RU200  
Day 28 Aβ RU0 Aβ RU200 Aβ Snap25 RU0 Aβ Snap25 RU200 
Aβ RU0  < 0.0001 < 0.0001 < 0.0001 
Aβ RU200  < 0.0001 < 0.05 
Aβ Snap25 RU0  < 0.01 
Aβ Snap25 RU200  
Day 31 Aβ RU0 Aβ RU200 Aβ Snap25 RU0 Aβ Snap25 RU200 
Aβ RU0  < 0.0001 < 0.0001 < 0.0001 
Aβ RU200  < 0.0001 < 0.05 
Aβ Snap25 RU0  < 0.001 
Aβ Snap25 RU200  
4.2.3 Amph alleviates Aβ42 toxicity 
Together with Rab5, EndoA and Snap25, Amph was another hit to ameliorate Aβ toxicity. 
Amph is the Drosophila homologue of BIN1 that is linked to AD. Like EndoA, Amph is involved 
in vesicle scission. Amph slightly prolonged the lifespan of Aβ42-expressing flies (Fig 4.3A, Aβ 
RU0: 100 %; Aβ RU200: 47 %; Aβ Amph RU0: 100 %; Aβ Amph RU200: 51 %, n > 120 per 
condition. p was shown in Figure 4.3A, log-rank test; Figure 4.3B, day 5, Aβ RU0: 87.64 + 
9.4 %; Aβ RU200: 81.41 + 4.6 %; Aβ Amph RU0: 91.48 + 0.74 %; Aβ Amph RU200: 90.94 + 
2.02 %; day 8, Aβ RU0: 92.84 + 2.64 %; Aβ RU200: 67.26 + 1.49 %; Aβ Amph RU0: 83.22 + 
1 %; Aβ Amph RU200: 86.27 + 0.42 %; day 11, Aβ RU0: 86.61 + 1.72 %; Aβ RU200: 59.57 + 
2.46 %; Aβ Amph RU0: 79.37 + 2.78 %; Aβ Amph RU200: 83.97 + 1.4 %; day 14, Aβ RU0: 87 
+ 2.65 %; Aβ RU200: 54.71 + 3.22 %; Aβ Amph RU0: 74.52 + 5.67 %; Aβ Amph RU200: 67.35 
+ 0 %; day 18, Aβ RU0: 87.58 + 1.63 %; Aβ RU200: 32.52 + 2.93 %; Aβ Amph RU0: 72.36 + 
2.85 %; Aβ Amph RU200: 36.47 + 2.98 %; day 23, Aβ RU0: 82.49 + 2.39 %; Aβ RU200: 8.33 + 
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2.79 %; Aβ Amph RU0: 62.77 + 2.18 %; Aβ Amph RU200: 19.58 + 1.82 %; day 26, Aβ RU0: 
70.19 + 1.11 %; Aβ RU200: 2.56 + 1.28 %; Aβ Amph RU0: 57.08 + 1.5 %; Aβ Amph RU200: 
5.83 + 0.42 %, n = 3 per condition. Interaction of time and genotype, p < 0.0001; time, p < 
0.0001, genotype, p < 0.0001, two-ways ANOVA) without affecting Aβ levels (Fig 4.3D, Aβ 
RU0: 4.02 + 0.01 pg/ug protein; Aβ RU200: 58.54 + 8.14 pg/ug protein; Aβ Amph RU0: 3.50 + 
0.73 pg/ug protein; Aβ lap RU200: 73.28 + 1.89 pg/ug protein, n = 3 per condition; p < 0.0001; 
one-way ANOVA). This suggested that Amph plays a role in downstream Aβ toxicity. RNAi of 
Amph, on the other hand, worsened the phenotype of Aβ expressing flies (Figure 4.3C, Aβ 
RU0: 100 %; Aβ RU200: 59 %; Aβ Amph RNAi RU0: 100 %; Aβ Amph RNAi RU200: 56 %, n > 
120 per condition. p was shown in Figure 4.3C, log-rank test). These findings are in line with 
the fact that the Amph mutant was reported to display a flightless phenotype and climbing 
defects (Leventis et al., 2001; Razzaq et al., 2001). However, Amph is expressed 
post-synaptically (Razzaq et al., 2001; Zelhof et al., 2001) and participates in protein 
localization.  
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Figure 4.3 Amph reduces Aβ42 toxicity. 
(A) Survival curves of flies expressing Aβ with Amph or not in adult neurons (+RU) and uninduced controls (-RU). 
Over-expression of Amph in neurons restored lifespan, n > 120. Aβ RU0 vs Aβ RU200, p < 0.0001; Aβ RU0 vs Aβ 
Amph RU0, n.s., not significant; Aβ Amph RU0 vs Aβ Amph RU200, p < 0.0001; Aβ RU200 vs Aβ Amph RU200, p < 
0.01, by log-rank test.  
(B) Locomotor performance index of flies of the same genotypes. Aβ caused climbing defects, which was diminished 
by expression of Amph, n = 3. Interaction of time and genotype, p < 0.0001; time, p < 0.0001, genotype, p < 0.0001, 
comparison by two-ways ANOVA followed by Tukey’s post-hoc test. Statistical analyses were shown in Table 4.4. 
(C) Survival curves of flies expressing Aβ with Amph RNAi or not in adult neurons (+RU) and uninduced controls (-RU). 
Downregulation of Amph suppressed lifespan, n > 120. Aβ RU0 vs Aβ RU200, p < 0.0001; Aβ RU0 vs Aβ Amph RNAi 
RU0, n.s., not significant; Aβ Amph RNAi RU0 vs Aβ Amph RNAi RU200, p < 0.0001; Aβ RU200 vs Aβ Amph RNAi 
RU200, p < 0.01, by log-rank test.  
(D) Aβ42 protein levels, measured by ELISA, in the heads of 21-day-old flies expressing Aβ with Amph or not in 
neurons (+RU) and uninduced controls (-RU). Means ± SEM, n = 3. ****p < 0.0001, by one-way ANOVA; Aβ RU0 vs 
Aβ RU200, ****p < 0.0001; Aβ RU0 vs Aβ Amph RU0, n.s., not significant; Aβ Amph RU0 vs Aβ Amph RU200, ****p < 
0.0001; Aβ RU200 vs Aβ Amph RU200, n.s., not significant, by Tukey’s post-hoc test. 
 
Table 4.4 Statistical summary of locomotor performance index of flies expressing Aβ with or without Amph 
Day 5 Aβ RU0 Aβ RU200 Aβ Amph RU0 Aβ Amph RU200 
Aβ RU0  n.s. 
n.s. n.s. 
Aβ RU200  
n.s. n.s. 
Aβ Amph RU0  n.s. 
Aβ lap RNAi RU200  
Day 8 Aβ RU0 Aβ RU200 Aβ Amph RU0 Aβ Amph RU200 
Aβ RU0  < 0.0001 n.s. n.s. 
Aβ RU200  < 0.01 < 0.001 
Aβ Amph RU0  n.s. 
Aβ Amph RU200  
Day 11 Aβ RU0 Aβ RU200 Aβ Amph RU0 Aβ Amph RU200 
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Aβ RU0  < 0.0001 n.s. n.s. 
Aβ RU200  < 0.0001 < 0.0001 
Aβ Amph RU0  
n.s. 
Aβ Amph RU200  
Day 14 Aβ RU0 Aβ RU200 Aβ Amph RU0 Aβ Amph RU200 
Aβ RU0  < 0.0001 < 0.05 < 0.001 
Aβ RU200  < 0.0001 < 0.05 
Aβ Amph RU0  n.s. 
Aβ Amph RU200  
Day 18 Aβ RU0 Aβ RU200 Aβ Amph RU0 Aβ Amph RU200 
Aβ RU0  < 0.0001 < 0.01 < 0.0001 
Aβ RU200  < 0.0001 n.s. 
Aβ Amph RU0  < 0.0001 
Aβ Amph RU200  
Day 23 Aβ RU0 Aβ RU200 Aβ Amph RU0 Aβ Amph RU200 
Aβ RU0  < 0.0001 < 0.001 < 0.0001 
Aβ RU200  < 0.0001 < 0.05 
Aβ Amph RU0  < 0.0001 
Aβ Amph RU200  
Day 26 Aβ RU0 Aβ RU200 Aβ Amph RU0 Aβ Amph RU200 
Aβ RU0  < 0.0001 < 0.05 < 0.0001 
Aβ RU200  < 0.0001 n.s. 
Aβ Amph RU0  < 0.0001 
Aβ Amph RU200  
4.2.4 Amph modulates GluRII accumulation 
Amph has been shown to modulate the localization of Dlg. Dlg is the Drosophila homolog of 
the PSD-95 protein that stabilizes glutamate receptors (GluRII) (Razzaq et al., 2001; Zelhof et 
al., 2001). GluRII is composed of regulatory GluRIIA, GluRIIB and constitutive GluRIIC, 
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GluRIIA was found to increase postsynaptic sensitivity, while GluRIIB decreased it (Davis et al., 
1998; DiAntonio et al., 1999; Petersen et al., 1997; Schuster et al., 1991). I checked whether 
Amph regulated GluRII localization. I used Mef2-Gal4 to express Aβ42 post-synaptically and 
imaged GluRII localization in larval NMJ. I found that GluRIIA substantially accumulated on the 
plasma membrane (Figure 4.4A, Mef2: 100 + 6.46 %, n = 7; Mef2 > Aβ: 164 + 23.01 %, n = 8; 
Mef2 > Amph: 44.52 + 4.16 %, n = 10; Mef2 > Aβ Amph: 47 + 3.31, n = 10. p < 0.0001; 
one-way ANOVA), while GluRIIB decreased upon Aβ42 exposure (Figure 4.4B, Mef2: 100 + 
19.62 %, n = 10; Mef2 > Aβ: 23.11 + 7.64 %, n = 10; Mef2 > Amph: 14.77 + 4.13 %, n = 8; 
Mef2 > Aβ Amph: 23.83 + 9.39, n = 8. p < 0.001; one-way ANOVA). GluRIIC localization was 
not changed (Figure 4.4C, Mef2: 100 + 19.07 %, n = 8; Mef2 > Aβ: 102.4 + 15.21 %, n = 10; 
Mef2 > Amph: 41.46 + 17.95 %, n = 7; Mef2 > Aβ Amph: 26.11 + 9.72, n = 7. p < 0.01; one-way 
ANOVA), suggesting that Aβ expression can alter the composition of GluRII receptors 
post-synaptically. In fact, the elevated Aβ levels lead to hyperexcitability (Ping et al., 2015). 
Next we over-expressed Amph post-synaptically leading to a dramatic decrease in the 
localization of all the GluRII subunits at the NMJ (Fig 4.4A, B and C), indicating that Amph 
modulates glutamate receptor localization. Given that Amph also reduced the accumulation of 
GluRII without Aβ expression, this suggested that Amph modulates the localization of GluRII 
independent of Aβ induction, namely, Amph is a modulator of Aβ toxicity. In conclusion, Aβ 
expression leads to an increase in GluRIIA accumulation at the synapse with glutamate 
excitotoxicity, whereas Amph decreases GluRIIA levels back down and therefore reduces 
glutamate excitotoxicity. 
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Figure 4.4 Amph modulates GluRIIA, GluRIIB and GluRIIC localization. 
(A) Confocal images of the NMJ of wandering third-instar larvae expressing Aβ, Amph or both driven by Mef2-Gal4. 
Fluorescence intensity scores are plotted as means ± SEM, n > 7. Genotypes: Mef2-Gal4, UAS-Aβ; Mef2-Gal4, 
UAS-amph; Mef2-Gal4, UAS-Aβ; UAS-amph/Mef2-Gal4. ****p < 0.0001, determined by one-way ANOVA; control 
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(Mef2-Gal4) vs Aβ, **p < 0.01; control vs Amph, **p < 0.01; Amph vs Aβ Amph, n.s., not significant; Aβ vs Aβ Amph, 
****p < 0.0001, comparison by Tukey’s post-hoc test. Scale bar, 10 μm. 
(B) Quantification of GluRIIB fluorescence at the NMJ of wandering third-instar larvae expressing Aβ, Amph or both 
driven by Mef2-Gal4, plotted as means ± SEM, n > 8. Genotypes: Mef2-Gal4, UAS-Aβ; Mef2-Gal4, UAS-amph; 
Mef2-Gal4, UAS-Aβ; UAS-amph/Mef2-Gal4. ***p < 0.001, by one-way ANOVA; control (Mef2-Gal4) vs Aβ, ***p < 
0.001; control vs Amph, ***p < 0.001; Amph vs Aβ Amph, n.s., not significant; Aβ vs Aβ Amph, n.s., not significant, by 
Tukey’s post-hoc test. Scale bar, 10 μm. 
(C) Quantification of GluRIIC fluorescence at the NMJ of wandering third-instar larvae expressing Aβ, Amph or both 
driven by Mef2-Gal4, plotted as means ± SEM, n > 7. Genotypes are as above. **p < 0.01, by one-way ANOVA; 
control (Mef2-Gal4) vs Aβ, n.s., not significant; control vs Amph, *p < 0.05; Amph vs Aβ Amph, n.s., not significant; Aβ 
vs Aβ Amph, *p < 0.05, by Tukey’s post-hoc test. Scale bar, 10 μm. 
4.2.5 Loss of Amph is rescued by lap  
Next I further examined the effect of Aβ on Amph expression and localization. Amph is 
post-synaptic whereas our previous data suggest Aβ and lap act pre-synaptically. I therefore 
assessed Amph localization at the NMJ while expressed Aβ both pre-synaptically with 
D42-Gal4 or post-sypaptically with Mef2-Gal4. Interestingly I saw that, in both cases, Amph 
abundance was significantly decreased upon Aβ42 expression (Figure 4.5A and B, Mef2: 100 + 
9.49 %, n = 5; Mef2 > Aβ: 30.76 + 5.7 %, n = 7. p < 0.001; Student’s t-test). Over-expression of 
lap pre-synaptically together with Aβ42 rescued Amph localization at the NMJ (Fig 4.5A, D42: 
100 + 9.3 %, n = 7; D42 > Aβ: 37.38 + 6.81 %, n = 7; D42 > lap: 116.6 + 15.36 %, n = 9; D42 > 
Aβ lap: 108.6 + 10.1, n = 10. p < 0.001; one-way ANOVA). Amph localization has been shown 
previously to be post-synaptic, so it is really intriguing that pre-synaptic proteins can effect 
localization of Amph post-synaptically. 
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(B) 
Figure 4.5 Lap restores Amph intensity in Aβ-expressing flies. 
(A) Quantification of Amph fluorescence at the NMJ of wandering third-instar larvae expressing Aβ, lap or both driven 
by D42-Gal4, plotted as means ± SEM, n > 7. Genotypes are as above. ***p < 0.001, determined by one-way ANOVA; 
control (D42-Gal4) vs Aβ, **p < 0.01; control vs Amph, n.s., not significant; Amph vs Aβ Amph, n.s., not significant; Aβ 
vs Aβ Amph, ***p < 0.001, comparison by Tukey’s post-hoc test. Scale bar, 20 μm. 
(B) Quantification of Amph fluorescence at the NMJ of wandering third-instar larvae expressing Aβ or not driven by 
Mef2-Gal4, plotted as means ± SEM, n > 5. Genotypes: Mef2-Gal4, UAS-Aβ; Mef2-Gal4. ***p < 0.001, comparison by 
Student’s t-test. Scale bar, 20 μm. 
4.2.6 Lap and Amph modulate glutamatergic transmission 
I proposed a model where lap and Amph collaborated to modulate glutamatergic transmission 
and so affected disease progression. First, lap participated in vesicle formation and cargo 
selection. The cargo included VGlut. Second, lap rescued Amph accumulation at the NMJ 
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which decreased upon Aβ expression. Amph modulated the localization of glutamate 
receptors (GluRII) and so affected disease development (Figure 4.6). 
 
Figure 4.6 A model depicting the possible signalling pathways linking Aβ42 to glutamatergic transmission seen in AD. 
Aβ causes the accumulation of VGlut and loss of Amph. Lap promotes the endocytosis of VGlut and therefore reduces 
glutamate release. Lap also rescues the loss of Amph, which leads to retrival of GluRIIA.  
4.3 Discussion 
4.3.1 Endocytosis is important for Aβ pathology 
Endocytosis is severely impaired in AD, but secretion remains intact. An in vitro study has 
indicated that PICALM can ameliorate AD toxicity through eliminating endocytic defects 
(Treusch et al., 2011). My study has supported this in vivo. Furthermore, other endocytic genes 
also attenuate AD vulnerability including Rab5, EndoA and Snap25. Rab5 is localized at the 
plasma membrane, clathrin-coated pits, and recycling endosomes, which plays a role in 
mediating the formation of clathrin coated pits at the plasma membrane (McLauchlan et al., 
1998), as well as a primary role in the fusion of endocytic vesicles with early endosomes. In 
previous studies, Rab5 was reported to be involved with Aβ42 production (Grbovic et al., 2003; 
Kim et al., 2016). EndoA also plays an important role in clathrin-mediated endocytosis through 
controlling membrane tubulation and membrane association (Matta et al., 2012). A prior report 
has revealed that EndoA directly interacts with VGlut (Vinatier et al., 2006). It remains to be 
seen elusive whether EndoA’s neuroprotection is dependent on removing excess VGlut from 
the synaptic terminal. Snap25 regulates both endocytosis and exocytosis via membrane fusion 
(Zhang et al., 2013). Gain of Snap25 compromises the Ca
2+
 responsiveness in glutamatergic 
synapses, while its absence gives rise to the ADHD phenotype (Feng et al., 2005).  
 
 110 
 
I also showed that not all endocytic genes were able to suppress Aβ toxicity. For example, 
epsin and dynamin-mediated endocytosis exacerbated Aβ toxicity. CD2AP is linked to AD by 
GWAS (Naj et al., 2011) and is involved in the regulation of receptor endocytosis (Cormont et 
al., 2003). The Drosophila homolog of CD2AP, Cindr, also increased Aβ toxicity. Moreover, 
almost all exocytic genes I screened accelerated AD progression, so it would be interesting to 
investigate whether the slowdown of membrane recycling can diminish Aβ toxicity.  
4.3.2 Alterations in the ratio of GluRIIA/GluRIIB in AD 
I showed that Aβ expression led to an increase in GluRIIA, concomitant with a decrease in 
GluRIIB. Aβ has been reported to up-regulate calcium permeable (CP) GluA1-containing 
AMPARs, while down-regulating calcium impermeable (CI) GluA2-containing AMPARs in 
mammalian neurons. This alteration is attributed to the fact that expression of GluRIIA reduces 
GluRIIB expression (Sigrist et al., 2002). The switch from CI-AMPARs to CP-AMPARs induces 
a Ca
2+
 influx and elevates intracellular Ca
2+
 loads that results in ER stress and neuronal 
toxicity (Liu et al., 2010; Whitcomb et al., 2015).  
4.3.3 Amph is a modulator of GluRII localization 
Amph also plays an important role in endocytosis, and again its role in Aβ toxicity remains 
unexplored. Amph localization is disrupted upon Aβ expression. Moreover, this defect is 
rescued by lap expression. This study highlights a role for Amph in regulating the localization 
of the glutamate receptor GluRII at the synapse since my data also show that Amph decreases 
GluRIIA levels postsynaptically. Taken together, since this counteracts Aβ’s effect on GluRIIA 
localization, this could contribute to its suppression of Aβ toxicity. 
4.3.4 Feedback control of glutamatergic transmission 
As discussed in chapter 3, presynaptic glutamate has been reported to negatively modulate 
the number of GluRII receptors (Featherstone et al., 2002). In turn, GluRII also mediates 
presynaptic glutamate release via retrograde signals. An upregulation of GluRIIA and a 
downregulation of GluRIIB increase postsynaptic sensitivity and elicit a compensation to 
 111 
 
decrease presynaptic glutamate release (DiAntonio et al., 1999). However, it will be interesting 
to know whether lap, via Amph, could possibly modulate GluRII localization and Amph, via 
retrograde signals, could modulate VGlut localization. 
 
My work has demonstrated that Rab5, EndoA, Snap25 and Amph suppress Aβ toxicity. Among 
them, Amph accumulation at the NMJ is rescued by lap. Amph reduces the accumulation of 
glutamate receptors (GluRIIA) at the NMJ and therefore could account for its suppression of 
Aβ toxicity. 
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5. Genome-wide screen for suppressors of 
Aβ42 toxicity 
5.1 Background 
Most AD cases are sporadic AD (SAD), but 1% is familial AD (FAD). Both types of cases are 
thought to be caused by amyloid-β peptide (Aβ) accumulation and tau hyperphosphorylation, 
resulting in amyloid plaques and neurofibrillary tangles. A century of research on AD has 
revealed several molecular mechanisms underlying Aβ toxicity. For example, Aβ oligomers 
disrupt processes such as cell signaling, epigenetic, endocytosis and ER stress (Gjoneska et 
al., 2015; Minami et al., 2014; Seo et al., 2014; Suberbielle et al., 2015). However, there is still 
no effective treatment for AD. Therefore, novel therapies are desperately needed to delay the 
onset of symptoms, slow disease progression or reverse the course of this disease.  
 
Drosophila has proven to be a powerful model system for rapidly screening therapeutic targets 
in neurodegenerative diseases such as Huntington’s disease (HD), AD, Amyotrophic lateral 
sclerosis (ALS) and Spinocerebellar ataxia (SCA) disease models (Kim et al., 2014; 
Lasagna-Reeves et al., 2016; Lu et al., 2013; Park et al., 2013). An example of this is its rough 
eye phenotype (REP), which allows for high-throughput screening. Using a REP screen, my 
collaborators performed a genome-wide genetic screen to identify modifiers of Aβ toxicity. I 
took their primary hits, validated them and checked for rescue of adult phenotypes such as 
negative geotaxis and lifespan analysis. 
 
This unbiased screen identified 4 of gene-knockdown suppressors of Aβ42 toxicity. They were 
CG15011, Larp, Pxn, and Sodh2. 
5.2 Materials and Methods 
5.2.1 Drosophila screening in the eye 
UAS-Aβ; GMR-GAL4 flies were crossed to RNAi flies at 29°C on SYA food. We stuck fly heads 
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on a 45°-angled piece of wood, such that the left eye pointed to the top. Eye phenotypes of 
anesthetized female flies were evaluated with a Leica MZ 75 stereomicroscope and 
photographed with a Leica M 165C. Scoring of the REP was performed. Comparison of scores 
was performed by a Student’s t-test of the conditions of interest using the Prism software. 
 
In detail, we first analyzed the effect of the construct independent of Aβ42 toxicity in the 
progeny of crosses of GMR-Gal4 stock with each RNAi line. We assessed eye morphology 
while sorting the progeny of the crosses and excluded RNAi strains that modulated eye 
appearance. We further crossed the GMR-Gal4 > UAS-Aβ42/Cyo stock with each RNAi/UAS 
line. We also crossed the GMR-Gal4 > UAS-Aβ42 line with w
-
 w
1118
 lines as a control line. We 
assessed the effect of the construct on Aβ42 toxicity in the non Cyo progeny. We chose the 
GMR-Gal4 > UAS-Aβ42 line in the first generation as the control to cover the different numbers 
of UAS and different doses of the w
+
 gene expressed in the screened lines as these may 
modulate Aβ42 toxicity. The screened lines were crossed over several times and each time the 
two controls were crossed in parallel. We always compared the screened lines with controls of 
the same day. The progeny was anesthetized until the REP measurement. We photographed 
and quantified only female flies, which are bigger. We analyzed 10 flies per screened line and 
per control, with exceptions for lethality. We compared the changes of the REP between the 
screened line and the controls (10 values for the screened line versus 10 values for the control) 
by scoring. We calculated the scores of the REP and determined significant modifiers based 
on the scores (45 RNAi lines + 4 overexpression lines = 49 lines in total).  
 
For significant modifiers, they were re-tested in an independent lab (by me). For the graphs 
and table, we calculated the mean of the median of each experiment. We also tested 
overexpression lines when available. To avoid any false positive results, we performed an 
independent screen using a different GMR-Gal4 > UAS-Aβ42/Cyo stock. This way, several 
primary hits in the first screen went in the opposite direction in the second screen (Figure 5.1D). 
To be robust, RNAi lines were considered positive only if they suppressed the REP either in 
the screen done by my collaborators or my screen. For these reasons, the 30 primary hits 
were considered as positive hits as RNAi lines of these genes suppressed Aβ42 toxicity. 
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5.3 Results 
5.3.1 Genome-wide screen for modifiers of Aβ42 toxicity 
My collaborators used the well characterized Drosophila model expressing human Aβ42 under 
the control of the GMR-Gal4 driver for the primary screen (Crowther et al., 2005). This model 
recapitulated key features of AD like rough eye phenotype (REP), shortened lifespan and 
locomotor deficits. REP has proven to be successful in screening modifiers in other 
neurodegenerative diseases. Using the REP (Figure 5.1B), my collaborators screened 7593 
strains corresponded to 7025 genes and covered 88% of the Drosophila genome. Firstly, they 
excluded 866 RNAi strains that modulated eye appearance under the control of GMR-Gal4 
alone. Secondly, they screened 6727 RNAi strains from Vienna Drosophila RNAi Center 
(VDRC). This primary screen identified 938 primary hits including 625 subtle enhancers and 
313 subtle suppressors. Among these hits, 45 showed strong modification (24 suppressors, 15 
enhancers and 6 lethality) (Figure 5.1A). To validate the roles of these preliminary hits in Aβ42 
toxicity, I conducted the subsequent screen with a different Aβ42-expressing strain that 
expressed two copies of Aβ42 and displayed more severe neuronal dysfunction (Casas-Tinto et 
al., 2011). I found that 27 hits exhibited reproducible and consistent results in two independent 
screens (16 suppressors and 11 enhancers) (Figure 5.1C and D). Gene ontology (GO) term 
analysis of the entire set of hits from the screen grouped them into five groups including 
endocytic trafficking, mitochondrial biogenesis, metabolic process, signaling transduction and 
transcription (Table 5.1). Notably, there was no overlap between the hits found in this 
genome-wide screen and those in a previous mini screen (Cao et al., 2008).  
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(D) 
Figure 5.1 Primary genome-wide screens for the REP modifiers in Drosophila.  
(A) Flow chart for the unbiased screen in Drosophila. REP is used to assess the Aβ42 toxicity in the primary genetic 
screen that is followed by lifespan and locomotor assay to monitor the Aβ42–induced defects. siRNA lines that reduce 
Aβ42 toxicity in all assessments are regarded as potential suppressors.  
(B) Schematic of the REP for modifiers of Aβ toxicity.  
(C) Pie chart of RNAi strains scored in the screen.  
(D) Venn diagram of the identified suppressor candidates. 
 
Table 5.1 Drosophila RNAi genes that enhance or suppress Aβ toxicity using two independent Aβ42-expressing lines. 
Drosophila gene Human homolog Function Type 
CG1965 GCFC1  DNA binding protein 
Increased 
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CG6972  Protein of unknown function 
Increased 
CG8086 ODF3  Protein required for sperm movement 
Increased 
CAH2 CA2  Carbonic anhydrase 
Increased 
DHC64C DYNC1H1  Dynein heavy chain  
Increased 
ETS97D GABPA  DNA-binding protein 
Increased 
NUB POU2F1  Transcription factor of the POU family 
Increased 
R RAP1A Ras-related protein 
Increased 
RAB30 RAB30 Intra-Golgi traffic 
Increased 
SMOX SMAD3 Transcription factor of the TGFβ family 
Increased 
SPX SF3B4 Nuclear mRNA splicing protein 
Increased 
CG7757 PRPF3 Protein of the U4 and U6 snRNPs Decreased 
CG7849 TRUB2 Pseudouridine synthesis  Decreased 
CG15011 NFXL1  Nuclear transcription factor Decreased 
CG16886  Protein of unknown function Decreased 
ARFGAP3 ARFGAP3 GTPase-activating proteins for ARF Decreased 
BAP60 SMARCD3  Part of the SWI/SNF complex Decreased 
MED15 MED15 Transcription factor of the Gal4 family Decreased 
MRPL15 MRPL15 Mitochondrial mRNA translation protein Decreased 
LILII AFF4  Transcription factor of the AF4 family Decreased 
PXN PXDN Enzyme in extracellular matrix Decreased 
RNO PHF16  Histone H4-specific acetyltransferase Decreased 
RTF1 RTF1 RNA polymerase-associated protein Decreased 
SF2 SRSF1 Nuclear mRNA splicing protein Decreased 
SODH2 SORD Sorbitol pathway Decreased 
SU(TPL) ELL2  RNA polymerase II elongation factor Decreased 
5.3.2 Secondary validation in Drosophila adulthood 
To evaluate the contributions of preliminary hits on AD in adulthood, I used the 
Aβ42-expressing fly described in chapter 3 and 4. Elav-GS is induced in the nervous system 
 118 
 
upon eclosion. These Aβ42-expressing flies displayed locomotor performance impairment and 
reduced lifespan. I crossed all the suppressor RNAi lines identified above and scored their 
lifespan. I also obtained all available Drosophila over-expression strains that corresponded to 
gene-knockdown enhancers in the first screen and crossed them to Aβ42-expressing flies. The 
lifespan analysis yielded 17 of the 30 hits that increased the shortened lifespan of 
Aβ42-expressing flies and no overexpression lines that extended the lifespan of 
Aβ42-expressing flies (Figure 5.2, mean lifespan, Aβ RU200: 100 %; Aβ Btl RNAi RU200: 
103 %; Aβ Cdk5α RNAi RU200: 103 %; Aβ Pxn RNAi RU200: 103 %; Aβ Rtf1 RNAi RU200: 
103 %; Aβ Sodh2 RNAi RU200: 106 %; Aβ mRpL15 RNAi RU200: 106 %; Aβ Nat1 RNAi 
RU200: 106 %; Aβ Gβ13F RNAi RU200: 106 %; Aβ CG16886 RNAi RU200: 109 %; Aβ Med15 
RNAi RU200: 112 %; Aβ Kermit RNAi RU200: 112 %; Aβ CG13889 RNAi RU200: 115 %; Aβ 
CG15011 RNAi RU200: 115 %; Aβ Lilli RNAi RU200: 115 %; Aβ CG7849 RNAi RU200: 118 %; 
Aβ Larp RNAi RU200: 118 %; Aβ CG7757 RNAi RU200: 129 %, n > 100 per condition. p was 
shown in Figure 5.2, log-rank test).  
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Figure 5.2 Secondary validation screens in Drosophila adults for genetic modifiers of Aβ42 toxicity. Survival curves of 
flies expressing Aβ with shRNA hits (red) or not (black) in adult neurons (+RU), n > 100. *p < 0.05, **p < 0.01,***p < 
0.001, ****p < 0.0001, comparison by log-rank test.  
5.3.3 Counter validation in Drosophila adulthood  
Based on 17 potential hits from lifespan analysis, I assessed effects of these hits on the 
locomotor performance of Aβ42-expressing flies. The first behavioral analysis examined all 
RNAi lines without backcrossing and found that 3 candidate genes improved climbing 
performance of Aβ42-expressing flies. They were Pxn, Sodh2 and Rtf1 (Figure 5.3A). As my 
previous data showed that the Aβ42-expressing flies displayed locomotor deficits from day 14 
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onwards, I measured the climbing performance on day 7 and day 15 in the second behavioral 
analysis. The second behavioral analysis assessed all RNAi lines with backcrossing and 
revealed 4 hits were able to attenuate climbing deficits of Aβ42-expressing flies. They were 
CG15011, Larp, Pxn, and Sodh2 (Figure 5.3B, PI, day 7, Aβ RU200: 92.84 + 2.64 %; Aβ 
CG15011 RNAi RU200: 90.94 + 2.61 %; Aβ Larp RNAi RU200: 93 + 2.65 %; Aβ Pxn RNAi 
RU200: 90.63 + 1.04 %; Aβ Sodh2 RNAi RU200: 90.19 + 0.64 %; day 15, Aβ RU200: 68.57 + 
1.64 %; Aβ CG15011 RNAi RU200: 81.11 + 2.57 %; Aβ Larp RNAi RU200: 85.37 + 2.38 %; Aβ 
Pxn RNAi RU200: 81.06 + 2.85 %; Aβ Sodh2 RNAi RU200: 78.23 + 1.23 %, n = 3 per 
condition. p was shown in Figure 5.3B, two-ways ANOVA). These 4 modifiers acted as 
significant knockdown suppressors to modify Aβ42 toxicity, which were reproducible and 
consistent in all assessments. It was important to note that 4 genes showed potential 
improvements of climbing performance. They were cep290 (CG13889), Gβ13F, Lilli and Prp3 
(CG7757) (Figure 5.3B, PI, day 7, Aβ RU200: 92.84 + 2.64 %; Aβ cep290 RNAi RU200: 98.26 
+ 0.92 %; Aβ Gβ13F RNAi RU200: 96.18 + 0.92 %; Aβ Lilli RNAi RU200: 96.18 + 0.69 %; Aβ 
Prp3 RNAi RU200: 92.6 + 1.34 %; day 15, Aβ RU200: 68.57 + 1.64 %; Aβ cep290 RNAi 
RU200: 80.65 + 4.09 %; Aβ Gβ13F RNAi RU200: 76.84 + 0.5 %; Aβ Lilli RNAi RU200: 76.69 + 
1.4 %; Aβ Prp3 RNAi RU200: 78.88 + 1.68 %, n = 3 per condition. p was shown in Figure 5.3B, 
two-ways ANOVA). It remains to investigate whether these 4 candidates will show significant 
improvements of climbing performance after 15 days. Given that Rtf1 was excluded in the 
second screen after backcrossing and CG15011 and Larp did not appear in the first screen, 
my work also emphasized the importance of backcrossing. 
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(B) 
Figure 5.3 In vivo validation of the hits from the secondary screen. Climbing performance index of flies of the potential 
knockdown suppressors, n = 3 (50 animals per condition). *p < 0.05; **p < 0.01; ***p < 0.001; n.s., not significant, 
determined by two-ways ANOVA followed by Tukey’s post-hoc test. Statistical analyses were shown in Table 5.2. 
 
Table 5.2 Statistical summary of locomotor performance index of flies expressing Aβ with or without Sodh2 RNAi 
Day 5 Aβ RU0 Aβ RU200 Aβ Sodh2 RNAi RU0 Aβ Sodh2 RNAi RU200 
Aβ RU0  < 0.001 n.s. n.s. 
Aβ RU200  < 0.05 < 0.0001 
Aβ Sodh2 RNAi RU0  n.s. 
Aβ Sodh2 RNAi RU200  
Day 8 Aβ RU0 Aβ RU200 Aβ Sodh2 RNAi RU0 Aβ Sodh2 RNAi RU200 
Aβ RU0  < 0.0001 n.s. n.s. 
Aβ RU200  < 0.0001 < 0.0001 
Aβ Sodh2 RNAi RU0  n.s. 
Aβ Sodh2 RNAi RU200  
Day 11 Aβ RU0 Aβ RU200 Aβ Sodh2 RNAi RU0 Aβ Sodh2 RNAi RU200 
Aβ RU0  < 0.0001 n.s. n.s. 
Aβ RU200  < 0.0001 < 0.0001 
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Aβ Sodh2 RNAi RU0  n.s. 
Aβ Sodh2 RNAi RU200  
Day 14 Aβ RU0 Aβ RU200 Aβ Sodh2 RNAi RU0 Aβ Sodh2 RNAi RU200 
Aβ RU0  < 0.0001 n.s. n.s. 
Aβ RU200  < 0.0001 < 0.0001 
Aβ Sodh2 RNAi RU0  n.s. 
Aβ Sodh2 RNAi RU200  
Day 18 Aβ RU0 Aβ RU200 Aβ Sodh2 RNAi RU0 Aβ Sodh2 RNAi RU200 
Aβ RU0  < 0.0001 n.s. < 0.0001 
Aβ RU200  < 0.0001 < 0.0001 
Aβ Sodh2 RNAi RU0  < 0.0001 
Aβ Sodh2 RNAi RU200  
Day 23 Aβ RU0 Aβ RU200 Aβ Sodh2 RNAi RU0 Aβ Sodh2 RNAi RU200 
Aβ RU0  < 0.0001 n.s. < 0.0001 
Aβ RU200  < 0.0001 < 0.0001 
Aβ Sodh2 RNAi RU0  < 0.0001 
Aβ Sodh2 RNAi RU200  
Day 26 Aβ RU0 Aβ RU200 Aβ Sodh2 RNAi RU0 Aβ Sodh2 RNAi RU200 
Aβ RU0  < 0.0001 < 0.01 < 0.0001 
Aβ RU200  < 0.0001 < 0.001 
Aβ Sodh2 RNAi RU0  < 0.0001 
Aβ Sodh2 RNAi RU200  
 
Statistical summary of locomotor performance index of flies expressing Aβ with or without shRNA 
First locomotor assay Interaction of time and genotype time genotype 
Sodh2 p < 0.0001 p < 0.0001 p < 0.0001 
Pxn p < 0.01 p < 0.0001 p < 0.05 
Rtf1 p < 0.001 p < 0.0001 p < 0.01 
Second locomotor assay Interaction of time and genotype time genotype 
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CG15011 p < 0.05 p < 0.0001 p < 0.05 
cep290 ns p < 0.0001 p < 0.05 
Gβ13F ns p < 0.0001 p < 0.01 
Larp p < 0.01 p < 0.001 p < 0.01 
Lilli ns p < 0.001 p < 0.05 
Prp3 ns p < 0.001 p < 0.05 
Pxn p < 0.01 p < 0.0001 p < 0.05 
Sodh2 p < 0.01 p < 0.0001 p < 0.05 
5.3.4 Aβ42 measurement 
I next measured total Aβ42 levels in flies described above using Aβ ELISA. I found that 
downregulation of Prp3 (CG7757) and CG15011 reduced Aβ42 levels, while other genes did 
not change (Figure 5.4, Aβ RU0: 4.02 + 0.01 pg/ug protein; Aβ RU200: 48.63 + 4.71 pg/ug 
protein; Aβ CG15011 RNAi RU200: 24.8 + 4.87 pg/ug protein; Aβ Prp3 RNAi RU200: 34.97 + 
10.74 pg/ug protein, Aβ Btl RNAi RU200: 59.84 + 14.31 pg/ug protein; Aβ Cdk5α RNAi RU200: 
69.83 + 12.76 pg/ug protein; Aβ Gβ13F RNAi RU200: 45.13 + 8.41 pg/ug protein; Aβ Larp 
RNAi RU200: 39.1 + 17.21 pg/ug protein; Aβ mRpL15 RNAi RU200: 44.92 + 2.5 pg/ug protein; 
Aβ Nat1 RNAi RU200: 45.54 + 11.08 pg/ug protein; Aβ Pxn RNAi RU200: 65.26 + 23.41 pg/ug 
protein; Aβ Sodh2 RNAi RU200: 64.82 + 10.21 pg/ug protein, n = 3 per condition. p < 0.05, 
one-way ANOVA). To eliminate the possibility that these genes alter Aβ42 transcription, in the 
future I intend to monitor Aβ42 transcription by RT-qPCR. 
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Figure 5.4 Aβ42 protein levels, measured by ELISA, in the heads of 21-day-old flies expressing Aβ or Aβ shRNA hits in 
neurons (+RU) and uninduced controls (-RU). Means ± SEM, n = 3. *p < 0.05, determined by one-way ANOVA, *p < 
0.05, comparison by Tukey’s post-hoc test. 
5.4 Discussion 
5.4.1 Potential pathways underpinning novel modifiers of Aβ42 toxicity 
Reducing Aβ42 levels was believed to be an effective strategy in AD treatment. However, drugs 
that promoted Aβ42 clearance failed to ameliorate symptoms in patients with mild dementia 
(Abbott and Dolgin, 2016), indicating that decreasing Aβ42 levels may not be sufficient to 
attenuated AD symptoms once the disease is established. Here I present a genome-wide 
screen to identify modifiers of Aβ toxicity and Aβ levels. Together with my collaborators, we 
identified 3 suppressors of Aβ toxicity and 1 suppressors of Aβ abundance in Drosophila. 
Inhibition of Prp3 and CG15011 reduced Aβ levels. However, only knockdown of CG15011 
attenuated all Aβ-induced phenotype. Reduction in Larp, Pxn and Sodh2 suppressed the toxic 
effects of Aβ and ameliorated Aβ-induced neurodegeneration without influencing Aβ levels. 
However, Larp RNAi showed a decreasing tendency in Aβ levels, though not at a statistically 
significant level. I have not measured the impact of Lilli and cep290 on Aβ levels. 
 
Sodh-2 is a Drosophila orthologue of sorbitol dehydrogenase (SDH) and appears as an 
enzyme that converts sorbitol into fructose. Inhibition of SDH was reported to suppress 
neurodysfunction in diabetes (Cameron et al., 1997; Ng et al., 1998; Obrosova et al., 1999; 
Tilton et al., 1995). As previously shown, AD gave rise to progressive impairment of metabolic 
processes, indicating that metabolic interventions might ameliorate the AD phenotype (Niccoli 
et al., 2016; Tien et al., 2016; Winkler et al., 2015; Yoon et al., 2012). Peroxiredoxin (Pxn) is a 
secreted peroxidase and has never linked to AD (Colon and Bhave, 2016; Nelson et al., 1994). 
Peroxiredoxin, a related peroxidase, has been shown to be upregulated in APP mice and AD 
patient brains (Schonberger et al., 2001; Sizova et al., 2007). Peroxidasin (Pxn) is the other 
peroxidase that secrets into the ECM. It remains unclear why a reduction in an antioxidant 
protein is neuroprotective. Gβ13F is a subunit of G protein. Its mutation is linked to 
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neurodevelopmental disorder (Petrovski et al., 2016; Ramaker et al., 2013). Larp regulates 
translation of specific classes of mRNAs, which is downstream of the mTORC (Fonseca et al., 
2015; Hong et al., 2017; Lahr et al., 2017; Tcherkezian et al., 2014). Lilli is required for mRNA 
transcription (Lin et al., 2010). However, gain of function mutations in its homologue AFF4 
causes a developmental syndrome (Izumi et al., 2015). Cep290 encodes a centrosomal 
protein (Sayer et al., 2006; Valente et al., 2006). The link between these hits and AD 
progression has not been firmly established. 
5.4.2 Inhibition of exocytic genes does not attenuate Aβ42 toxicity 
As discussed in chapter 4, it is unclear whether the block of endocytic recycling can suppress 
Aβ toxicity. Here a genome-wide screen included genes that are involved in endocytic 
recycling. However, RNAi of these genes did not show a reduction in Aβ toxicity. The function 
of endocytic recycling in AD is under debate. On one hand, limitation of endocytic recycling 
could enhance Aβ elimination through lysosomal degradation (Li et al., 2012); on the other 
hand, abundant Aβ accumulation gives rise to enlarged endosomes, abnormal multivesicular 
bodies (MVBs) and lysosomal accumulation (Edgar et al., 2015; Gowrishankar et al., 2015; 
Sollvander et al., 2016). Therefore, this controversy might explain why any manipulation of 
endocytic recycling is detrimental to AD progression. 
 
In summary, my study combined different screening strategies to identify at least 4 modifiers of 
Aβ toxicity. The identified hits are novel modulators, and so could provide novel avenues for 
modulation of downstream Aβ toxicity. 
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6. Perspectives 
6.1 Lap and Amph suppress Aβ42 toxicity 
My work demonstrated that lap is an interacting partner of glutamate transporters and Amph is 
a novel modulator of glutamate receptors. Based on the work in chapters 3 and 4, I proposed a 
model where lap and Amph collaborated to modulate glutamatergic transmission and so 
affected disease progression (Figure 6.1). Firstly, lap participated in vesicle formation and 
cargo selection. The cargo included VGlut. Secondly, EndoA engaged in membrane tubulation 
and membrane association. Thirdly, Rab5 was involved in translocation from the plasma 
membrane to early endosomes. Finally, Snap25 played an important role in membrane fusion. 
Their over-expressions all slightly reduced Aβ42 toxicity. In addition to this, lap also rescued 
Amph accumulation at the NMJ which decreased upon Aβ expression. Amph modulated the 
localization of glutamate receptors (GluRII) and so affected disease development. 
 
Figure 6.1 Schematic of lap and Amph in glutamatergic transmission. Lap promotes endocytosis of VGlut and this 
process might be mediated by Rab5. Amph leads to retrival of GluRIIA and GluRIIC in a manner dependent on Dlg.  
 
This work indicated that the neuroprotection of lap could possibly be dependent on its role in 
endocytic recycling. However, my work lacks direct evidence to demonstrate that lap regulated 
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VGlut traffick. Recently Ventimiglia and Bargmann used VGLUT-pHluorin to monitor VGlut 
exocytosis and retrieval in C. elegans. pHluorin is a highly pH-sensitive variant of the green 
fluorescent protein that is minimally fluorescent at the acidic pH conditions, but highly 
fluorescence at neutral pH conditions (Miesenbock et al., 1998). Given that early endosomes 
provide acidic pH conditions, while the plasma membrane creates neutral pH conditions, 
synaptic vesicle exocytosis markedly increases the fluorescence when pHluorin fusion 
proteins target to the plasma membrane, while the subsequent endocytosis and reacidification 
in early endosomes quenches fluorescence, providing distinction at multiple stages of the 
synaptic vesicle cycle ((Di Giovanni and Sheng, 2015; Fernandez-Alfonso and Ryan, 2008; Li 
et al., 2005; Sankaranarayanan and Ryan, 2000). Linking pHluorin to VGLUT, Ventimiglia and 
Bargmann demonstrated that unc-11, a C. elegans homologue of PICALM, accelerated the 
endocytosis-reacidification process (Ventimiglia and Bargmann, 2017). It will be interesting for 
subsequent research to investigate whether the endocytosis process of VGlut is slowed down 
in our AD models using the VGLUT-pHluorin reportor and whether lap overexpression rescues 
this deficit. 
 
In addition to this, although I have identified Rab5 as a suppressor of Aβ42 toxicity, its 
relationship with lap is unclear. In the mammalian model of AD, RAB5 was found to interact 
with PICALM (Zhao et al., 2015b), suggesting that it was a downstream effector of PICALM. 
However, in our Drosophila model, the relationship between Rab5 and lap remained elusive. If 
Rab5 is a downstream effector of lap, it might also regulate VGlut localization. Therefore, a 
quick way to elucidate the relationship between Rab5 and lap is to look at whether the 
blockade of Rab5 expression prevented lap-mediated VGlut recycling at the larval NMJ. 
 
Moreover, this work clearly elucidated the relationship between lap and Amph, namely, lap 
increased Amph intensity at the NMJ upon Aβ expression. Given that this work also showed 
that Amph modulated the localization of GluRII receptors, it will be interesting to understand 
whether lap, via Amph, could possibly modulate the localization of GluRII receptors. In turn, 
GluRII receptors were found to mediate presynaptic glutamate release via retrograde signals. 
(DiAntonio et al., 1999). Based on this observation, it will be not surprising that Amph affects 
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glutamate release. 
 
Finally, it is essential to validate the conserved function of PICALM and BIN1 in mammalian 
models of AD. Given that impacts of PICALM and BIN1 on APP processing are well studied, 
the future work should pay more attention to their contributions to Aβ toxicity. However, Aβ 
expressing mice lack AD phenotypes (Hsiao et al., 1996; Mucke et al., 2000). Therefore, the 
following studies will be dependent on a cell model of AD.  
6.2 Aβ42 expression leads to glutamate excitotoxicity in the short term 
Here I used a genetically encoded glutamate indicator, iGluSnFR, to visualize glutamate 
dynamic and showed that extracellular glutamate is elevated upon Aβ42 expression. My work 
also suggests that an increase in extracellular glutamate might be due to the presynaptic 
accumulation of VGlut. This glutamate excitotoxicity was also observed in mammalian models 
of AD (Abramov et al., 2009; Hynd et al., 2004). It was speculated to be caused by either 
enhancement in glutamate release (Cummings et al., 2015) or impairment in glutamate uptake, 
giving rise to excess extracellular glutamate (Hefendehl et al., 2016; Li et al., 2009; Talantova 
et al., 2013). My work provids further evidence to demonstrate that Aβ42-induced glutamate 
toxicity in vivo. 
 
My work also found that GluRIIA accumulated more on the plasma membrane, while GluRIIB 
accumulated less upon the short-time exposure of Aβ42 (the L3 larvae). This observation 
supported previous in vitro studies. In the past, the long-term Aβ42 exposure was found to lead 
to endocytosis of AMPARs and NMDARs, suggesting that Aβ42 expression gave rise to a 
decrease in glutamate receptors (Hsieh et al., 2006; Shankar et al., 2007; Snyder et al., 2005; 
Zhao et al., 2010). More recent work revealed that although GluN2A was down-regulated upon 
Aβ42 expression, GluN2B was transiently up-regulated (Hu et al., 2009a; Li et al., 2009; Li et al., 
2011; Talantova et al., 2013). This observation correlated with the fact that GluN2A induced 
memory formation, while GluN2B induced memory decay. This different observation might be 
attributed to the time of Aβ42 exposure. Acute exposure of Aβ42 oligomers also conferred an 
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increase in GluA1 on the plasma membrane (Liu et al., 2010; Whitcomb et al., 2015). This 
finding was consistent with the fact that Ca
2+
 influx shortly increased as the primary response 
to Aβ42 exposure (Lauren et al., 2009; Um et al., 2013; Um et al., 2012). Furthermore, knockout 
of a specific AMPAR subunit protected against Aβ42–induced synaptic toxicity (Reinders et al., 
2016). My finding raised the question as to whether Aβ42 expression changed the 
GluRIIA/GluIIB ratio. Also, it remains elusive whether an increase in GluRIIA and a decrease in 
GluRIIB changed synaptic strength. 
 
Apart from this, glutamate excitotoxicity in the short term might finally attenuate glutamatergic 
neurotransmission in the long term through hemostatic scaling. Firstly, Presynaptic glutamate 
negatively modulates the number of GluRII receptors (Featherstone et al., 2002). Secondly, 
GluRII reduces presynaptic glutamate release via retrograde signals (DiAntonio et al., 1999). 
In fact, long-time expression of Aβ42 caused glutamatergic defects in adult flies at 28 days 
(Sofola et al., 2010). This time-dependent toxicity was also observed in the murine model, 
finding that the surface expression of GluN2B elevated at 15 minutes and then returned to 
baseline by 60 minutes after incubation with Aβ42 (Lauren et al., 2009; Um et al., 2013; Um et 
al., 2012).  
 
Given that I have provided an example of using iGluSnFR to visualize glutamate dynamics in 
the larval VNC, it will be interesting to test whether this method allows for detecting 
extracellular glutamate in adults’ brains and therefore detecting the effect of the long-term 
expression of Aβ42 on glutamatergic transmission. 
 
Collectively, my work provided a new insight into the mechanism underlying AD progression, 
namely, Aβ42 resulted in not only excitotoxicity of glutamate receptors but also excess 
glutamate release. As far as I know, one NMDAR antagonist memantine has been used in AD 
treatment (Bormann, 1989; Lipton, 2006; Milnerwood et al., 2010; Okamoto et al., 2009; 
Parsons et al., 1999; Suhs et al., 2014; Talantova et al., 2013; Wang and Zhang, 2005). 
However, it remains elusive whether VGLUT antagonists also attenuate AD phenotypes. 
Riluzole is a glutamate modulator that reduces glutamate release (Martin et al., 1993) and 
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facilitates astrocytic glutamate uptake (Banasr et al., 2010; Frizzo et al., 2004; Fumagalli et al., 
2008). These findings suggest that riluzole will be a potential drug for AD treatment through 
preventing excessive glutamate overflow to the extrasynaptic space (Banasr et al., 2010; 
Brennan et al., 2010; Chowdhury et al., 2008). In fact, riluzole is a FDA (the US food and drug 
administration) approved drug in clinical trials for the treatment of MND (motor neuron disease) 
patients (Bensimon et al., 1994; Gurney, 1997). Therefore, it will be interesting to explore 
whether riluzole will have any therapeutic intervention of AD pathology. 
6.3 Roles of glia in AD pathology 
PICALM is enriched in endothelial cells and microglia. This indicates that PICALM in glial cells 
might contribute to AD progression. In this study, I used a new Drosophila model of AD and 
aimed to understand the role of glial lap in Aβ42 toxicity.  
 
Drosophila glial cells show great similarities with mammalian glial cells and represent a good 
example of the conservation between Drosophila and mammalian nervous systems. This 
highlights that Drosophila glial cells are a good model to elucidate the role of glial cells in AD 
progression. Drosophila nervous system also bears a wide variety of glial subtypes, although 
glial cells only represent 5–10% of the total cells in the Drosophila CNS. Drosophila glial cells 
are mainly constituted in cortex glia, ensheathing glia and astrocytes (Crews, 2010; Jacobs, 
2000). Astrocytes affect neuronal development through FGF and TGF-β (Awasaki et al., 2008; 
Awasaki and Lee, 2011; Bialas and Stevens, 2013; Doherty et al., 2009; Muthukumar et al., 
2014; Stork et al., 2014; Tasdemir-Yilmaz and Freeman, 2014). Moreover, astrocytes 
communicate with the mature neurons through glutamatergic transmission. Similar to 
mammalian astrocytes, Drosophila astrocytes express EAAT1 to promote glutamate clearance. 
In turn, the expression of EAAT1 is modulated by glutamate secreted from neurons 
(Benediktsson et al., 2012; Devaraju et al., 2013; Freeman et al., 2003; Yang et al., 2009). 
Both astrocytes and ensheathing glia are involved in debris clearance. For instance, 
ensheathing glia engulf axonal debris through activating the Draper receptor (Awasaki et al., 
2006; Doherty et al., 2009; Doherty et al., 2014; Lu et al., 2014; MacDonald et al., 2006; 
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Macdonald et al., 2013; Ziegenfuss et al., 2008; Ziegenfuss et al., 2012). Drosophila glial cells 
are also found to facilitate the clearance of toxin proteins (Pearce et al., 2015). Besides that, 
Drosophila glial cells include perineural glia (PG) and subperineural glial cells (SPGs) that 
establish the BBB of flies (Auld et al., 1995; Baumgartner et al., 1996; Carlson et al., 2000; 
Leiserson et al., 2000; Schwabe et al., 2005). In particular, Drosophila PNS has the wrapping 
glia to wrap, support, and modulate the development and function of sensory and motor 
neurons (Beckervordersandforth et al., 2008; Leiserson et al., 2000; Stork et al., 2008). 
Collectively, the contributions of Drosophila glial cells to neurodegenerative diseases are the 
most understudied. Therefore, we should pay more attention to the role of Drosophila glial 
cells in AD progression. 
 
My study has found that overexpression of lap in glial cells showed suppression of Aβ42 toxicity. 
However, as this model confers exogenous toxicity of quinic acid (Riabinina et al., 2015), I 
cannot exclude the possibility that lap specifically reduced toxicity caused by quinic acid. 
Although this model takes this disadvantage, it might be still useful to investigate the 
glia-neuron communications in AD pathology (Pearce et al., 2015) because constitutive 
expression of QF2 is independent of feeding quinic acid. In addition to this, the other possible 
approach to drive gene expression is using the LexA-lexAop system, but this binary 
expression system is not inducible (Aso et al., 2014; Lai and Lee, 2006). 
 
In the mammalian nervous system, approximately 90% of the cells in the brain are glial cells 
that surround neurons. Therefore, mammalian gilal cells are more complicated than 
Drosophila glial cells. Mammalian glial cells are categorized in oligodendrocytes, astrocytes 
and microglia. They are distinguished in morphology, origins, markers and function. 
Oligodendrocytes form the myelin sheath and wrap axons. They ensheath axons to enable 
fast transduction of electrical signals. Oligodendrocytes communicate with neurons through 
glutamatergic transmission, suggesting that oligodendrocytes are crucial to learning and 
memory (Fruhbeis et al., 2013; McKenzie et al., 2014). Oligodendrocytes support energy 
metabolism in the adjacent axons as well. Oligodendrocytes take up glucose from the blood 
and synthesize lactate (Funfschilling et al., 2012; Rinholm et al., 2011). Lactate is then 
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released by the monocarboxylate transporter MCT1 and imported into neurons (Lee et al., 
2012). Furthermore, oligodendroglial glutamate receptors regulate glucose import of 
oligodendrocytes, indicating that glutamatergic transmission is coupled with glial metabolism 
(Saab et al., 2016). Given that PICALM is involved in glutamatergic transmission in my study, it 
is worthy of exploring whether PICALM affects oligodendrocyte-neuron communications and 
therefore AD pathology. As oligodendroglial glutamate receptor regulates glucose metabolism, 
it will be interesting to investigate the link between glutamatergic transmission and glucose 
metabolism in the AD case because glucose metabolism is impaired in the AD case (Carro et 
al., 2006; Carro et al., 2002; Craft et al., 2012; Dudek et al., 1997) Winkler et al., 2015; Niccoli 
et al., 2016). 
 
The function of astrocytes is dependent on their secreted proteins. For example, 
astrocytes-secreted APOE enhances presynaptic function of glutamatergic synapses (Goritz 
et al., 2005; Mauch et al., 2001). As well as the control of synapse formation, astrocytes can 
communicate with neurons in a rapid way. Astrocytes release and take up diverse 
neurotransmitters such as calcium, glutamate and D-serine (Nett et al., 2002; Panatier et al., 
2011; Perea and Araque, 2005; Verbich et al., 2012; Wang et al., 2006). These molecules 
modulate synaptic transmission and affect memory acquisition (Kronschlager et al., 2016). In 
turn, astrocytic activity is regulated by neuron-secreted glutamate (Yang et al., 2009).  
 
In AD frequent dysregulation of glia is observed, for example, reactive astrogliosis is a 
common feature of AD. One prevailing view insists that reactive astrocytes lead to detrimental 
effects because of neurotoxic inflammation. These inflammatory molecules include a number 
of cytokines, chemokines and growth factors (Sofroniew, 2015; Sofroniew and Vinters, 2010). 
However, inhibition of reactive astrogliosis exacerbates disease progression in a mouse model 
of AD, indicating that reactive astrocytes may exert a beneficial function and increase neuronal 
survival (Nagele et al., 2004; Thal et al., 2000). Astrocytes confer benefits via diverse ways. 
Firstly, astrocytes internalize Aβ42 and clear Aβ42 peptides (Wyss-Coray et al., 2003). Secondly, 
astrocytes uptake excess extracellular glutamate and interfere with Aβ42 toxicity without 
affecting Aβ42 levels (Simpson et al., 2010). Although my work cannot conclude that lap in glial 
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cells reduced Aβ42 toxicity, this work showed that lap in glial cells did not change Aβ42 levels. 
As Drosophila glial cells are a counterpart to mammalian astrocytes, mammalian astrocytes 
might be not involved in Aβ42 clearance but glutamate release. In fact, astrocytes are reported 
to release excess glutamate upon Aβ42 exposure (Hu et al., 2009a; Li et al., 2009; Li et al., 
2011; Talantova et al., 2013). An interesting possible future work would be to investigate 
whether PICALM in astrocytes modulates glutamatergic neurotransmission and therefore 
affects disease progression. 
 
Microglial activation is also observed in AD. Microglia are either positive or negative 
modulators of AD. On one hand, microglial activation gives rise to inflammation and ROS 
production to exacerbate neurodegeneration (Block et al., 2007); on the other hand, activated 
microglia phagocytoses Aβ42 peptides via the CCR2 receptor (Kobayashi et al., 1993), beclin 
(Lucin et al., 2013) or AD risk genes, TREM2 (Kleinberger et al., 2014; Ulland et al., 2017; 
Wang et al., 2015; Yeh et al., 2016) and CR1 (Fuhrmann et al., 2010), whereas the other AD 
risk gene, CD33, perturbs this Aβ42 clearance (Griciuc et al., 2013).  
 
Both astrocyte and microglia communicate with the brain endothelial cells and pericytes that 
form the blood-brain barrier (BBB). The BBB transcytoses proteins from the blood and brain. 
For example, a BBB breakdown is found in AD that increases BBB permeability (Zhao et al., 
2015a; Zlokovic, 2008). The BBB breakdown incurs the decreased Aβ42 transport across the 
BBB (loss of toxicity) and the increased entry of neurotoxic products into the brain. (gain of 
toxicity). Aβ42 is effluxed into the BBB and degraded by neprilysin via binding to LRP1 (Deane 
et al., 2004; Winkler et al., 2015). This process is facilitated by PICALM (Zhao et al., 2015b). 
The BBB efflux of Aβ42 is also mediated by an AD risk gene, CLU (Bell et al., 2007). Conversely, 
the other AD risk gene, APOE4, slows the internalized Aβ42 (Bell et al., 2012; Deane et al., 
2008). Efflux of Aβ42 across the BBB is also interfered by RAGE (Deane et al., 2003; Deane et 
al., 2012). RAGE is a transporter on the cell surface of endothelial cells and physically 
interacts with Aβ42. RAGE/ Aβ42 interaction results in the accumulation of Aβ42 in neurons, and 
so as expected intervention of the RAGE/ Aβ42 interaction has been shown to reduce ROS and 
attenuate Aβ42 damage (Yan et al., 1996). Overall, compared to studies on the function of 
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PICALM in the blood-brain barrier, studies on the function of PICALM in microglia are sparse. 
Given that Drosophila does not have a counterpart to mammalian microglia, a following 
possible study could investigate whether PICALM facilitate Aβ42 clearance in microglia in a 
mammalian model of AD.  
6.4 Potential mechanisms underlying identified modifiers of Aβ42 toxicity 
My work in chapter 5 has identified 4 potential gene-knockdown suppressors of Aβ42 toxicity. 
As stated earlier, none of them were linked to AD risk. Given that CG15011 regulated gene 
transcription and reduced Aβ levels, future works should identify whether its downregulation 
reduces Aβ transcription. As Larp mediated mRNA translation and showed a trend to decrease 
Aβ levels, the following work is evitable to investigate whether its downregulation reduces Aβ 
translation. Because Aβ species are produced from APP protein, its expression is independent 
of transcriptional and translational regulation in human brains. If these two genes change Aβ 
transcription or translation, they might not be the actual modifiers. 
 
One potential gene knockdown suppressor is Sodh-2, a Drosophila orthologue of sorbitol 
dehydrogenase (SDH). Inhibition of SDH was reported to suppress neurodysfunction in 
diabetes (Cameron et al., 1997; Ng et al., 1998; Obrosova et al., 1999; Tilton et al., 1995), 
suggesting its downregulation might provide global neuroprotection. Most importantly, AD was 
shown to give rise to progressive impairment of metabolic processes, indicating that metabolic 
interventions might ameliorate the AD phenotype (Niccoli et al., 2016; Tien et al., 2016; 
Winkler et al., 2015; Yoon et al., 2012) 
 
Another promising candidate is Pxn. Although the function of the PXN protein is unclear, it is 
well known that PXN is secreted into the ECM. Given that many secreted proteins such as 
APOE affect clearance of Aβ and formation of amyloid plaques (Bales et al., 2009; Fryer et al., 
2005; Oakley et al., 2006; Youmans et al., 2012), this protein might be involved in formation of 
amyloid plaques. 
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It is important to note that 25% of Drosophila genes are not conserved in humans. Therefore, it 
will be necessary to confirm whether the contributions of these candidate suppressors of Aβ 
toxicity are conserved in mammalian models of AD. Given that these hits are supposed to 
modulate the downstream of Aβ toxicity, they may not affect APP processing. Therefore, future 
works could use APP KI mice or APP iPSCs-derived neurons.  
 
In summary, this work aimed to investigate candidate modifiers of Aβ toxicity from GWAS and 
from a Drosophila screen. This work achieved this purpose by identifying lap, Amph, Rab5, 
EndoA and Snap25 as potential gene-overexpression suppressors of Aβ42 toxicity, and 
CG15011, Larp, Pxn, and Sodh2 as gene-knockdown suppressors of Aβ42 toxicity. This work 
also elucidated the molecular mechanisms underlying the protection of lap and Amph in Aβ 
pathogenesis which modulates glutamate transmission. Subsequent studies should mainly 
focus on validating the functional conservation of these candidate modifiers in a mammalian 
model of AD. Future works should also pay attention to elucidating the molecular mechanisms 
by which down-regulation of CG15011, Larp, Pxn, and Sodh2 attenuates Aβ pathology. 
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Appendix  
List of abbreviations 
Abbreviation Denotation 
α7 nAChR α7 nicotinic acetylcholine receptor 
Aβ Amyloid beta 
Aβarc Arctic Aβ 
AD Alzheimer's disease 
ADAM Metallopeptidase 
ADHD Attention deficit hyperactivity disorder 
AICD Amyloid intracellular domain 
AKT1 Protein kinase B 
ALS Amyotrophic lateral sclerosis 
AMPAR α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid-type glutamate receptor 
Amph Amphiphysin 
AP2 Adaptor protein 2 
APLn Anterior paired lateral neuron 
ApoE Apolipoprotein E 
APP Amyloid precursor protein 
APPL APP-like protein 
APP
SW
 Swedish APP 
ARF ADP ribosylation factor 
ATG Autophagy related protein 
BACE Beta-amyloid cleaving enzyme 
BIN1 Bridging integrator 1 
BIP (GRP78) Glucose-regulated protein 78kDa 
C83 83-residue C-terminal fragments 
C99 99-residue C-terminal fragments 
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CaMKII Calcium/Calmodulin dependent protein kinase 
CDK Cyclin-dependent kinase 
CME Clathrin-mediated endocytosis 
CI Ca
2+
-impermeable 
CLC Clathrin 
CNS Central nervous system 
CP Ca
2+
-permeable 
cpGFP circularly permutated GFP 
CRISPR Clustered regularly interspaced short palindromic repeat 
CTF C-terminal fragment 
d day 
DALn Dorsal anterior lateral DAL neurons 
DLG Discs large MAGUK scaffold protein 
DLM Dorsal longitudinal muscle 
DPMn Dorsal paired medial neuron 
DR6 Death receptor 6 
E Exon 
EAAT Excitatory amino acid transporter 
ECM Extracellular matrix 
eIF1A eukaryotic translation initiation factor 1A 
elF2α eukaryotic translation initiation factor 2 subunit alpha 
ENDOA Endophilin 
EOAD Early-onset AD 
ELISA Enzyme-linked immunosorbent assay 
EphB2 Ephrin type-B receptor 2 
ER Endoplasmic reticulum 
ESCRT Endosomal sorting complex required for transport 
ETC Electron transport chain 
FAD Familial AD 
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FTD Frontotemporal dementia 
FTDP-17 Frontotemporal dementia like Parkinsonism linked to chromosome17 
FYN FYN proto-oncogene 
GAK Cyclin G associated kinase 
GAP GTPase-activating protein 
GDI GDP dissociation inhibitor 
GEF Guanidine exchange factor 
GEI Genetically encoded indicator 
GETI Genetically encoded transmitter indicator 
GEVI Genetically encoded voltage indicator 
GF Giant fiber 
GFP Green fluorescence protein 
GltI Glial glutamate transporter I 
GluA AMPAR subunit 
GluCl Glutamate-gated chloride channel 
GluR  Glutamate receptor 
GMR Glass multiple reporter 
GO Gene ontology 
GS Gene switch 
GSK Glycogen synthase kinase 
GDP Guanosine diphosphate 
GTP Guanosine triphosphate 
GTPase GTP hydrolase 
GWAS Genome-wide association studies 
HD Huntington’s disease 
hNPC human neural progenitor cells 
HSC70 Heat shock 70kDa protein 
iGluSnFR intensity-based glutamate-sensing fluorescent reporter 
IIS Insulin-like substrate 
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iPSC induced pluripotent stem cells 
ITM Intermediate-term memory 
JNK3 C-Jun N-terminal kinase 3 
KC Kenyon cell 
lap Like AP180 protein 
LC3 Microtubule associated protein 1 light chain 3 
LDLR Low density lipoprotein receptor 
LilrB2 Leukocyte immunoglobulin like receptor B2 
LOAD Late-onset AD 
LP-LTM Late-phase long-term memory 
LRP1 LDLR-related protein 1 
LTM Long-term memory 
kDa kilo Dalton 
KI Knock in 
MAPT Microtubule-associated proteins 
Mb Million bp 
MB Mushroom body 
MBN Mushroom body neuron 
MBON Mushroom body output neuron 
mGluR5 metabolic glutamate receptor 5 
min minutes 
miRNA MicroRNA 
MMP5 Matrix metalloproteinase 5 
MT Microtubule 
mTOR Mechanistic target of rapamycin kinase 
MVB Multivesicular body 
N N-terminal 
NAD Nicotinamide adenine dinucleotide 
NFT Neurofibrillary tangle 
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NMDAR N-methyl-D-aspartate receptor 
NMJ Neuromuscular junction 
NR NMDAR subunit 
NSF N-ethylmaleimide-sensitive factor 
NTF N-terminal fragment 
p62 Phosphotyrosine-independent ligand for the Lck SH2 domain of 62kDa 
PCR Polymerase chain reaction 
PD Parkinson's disease 
PHF Paired helical filament 
PICALM Phosphatidylinositol binding clathrin assembly protein 
piRNA PIWI-interacting RNA 
PKA Protein kinase A 
PNS Peripheral nervous system 
PP2A Protein phosphatase 2A 
PP2B Protein phosphatase 2B 
PrP Prion protein 
PSD-95 Postsynaptic density protein 95 
PSEN (PS) Presenilin 
PXN Peroxiredoxin 
QUAS QF binding UAS 
R Repeat sequence 
RAB Ras-related protein 
RAS RAS proto-oncogene 
REP Rough eye phenotype 
RNAi RNA interference 
ROS Reactive oxygen species 
RT-qPCR Reverse transcription quantitative PCR 
RU Mifepristone 
SAD Sporadic AD 
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SDH Sorbitol dehydrogenase 
SCA Spinocerrebellar ataxia 
shRNA short hairpin RNA 
siRNA small interfering RNA 
SIRT Sirtuin 
SM Sec1-Munc18 
SNAP25 Synaptosome associated protein 25 
SNARE Soluble NSF attachment protein receptor 
SNP Single nucleotide polymorphism 
STM Short-term memory 
SYP Synaptophysin 
SYT1 Synaptotagmin 1 
SYX Syntaxin 
TF Transcriptional factor 
TM Transmembrane 
TTM Tergotrochanteral muscle 
UAS Upstream-activating sequence 
UPS Ubiquitin proteasome system 
UPR Unfolded protein response 
VAMP (SYB) Vesicle associated membrane protein (Synaptobrevin) 
VDRC Vienna Drosophila RNAi Center 
VGlut Vesicular glutamate transporter 
VNC Ventral nerve cord 
WAVE1 Wiskott-Aldrich syndrome protein 1 
XBP1 X-box binding protein 1 
 
